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Endometrial adenocarcinoma is the most common gynaecological malignancy in 
Western countries, affecting mainly post-menopausal women with a frequency of 15-
20 per 100 000 women per year. Over-expression of the cyclooxygenase (COX) 
enzymes and prostaglandin receptors has been demonstrated in endometrial 
adenocarcinoma as well as other gynaecological pathologies. Increased expression of 
the prostaglandin F2α (PGF2α) receptor (FP) has been previously demonstrated in 
endometrial adenocarcinoma. A role for the FP receptor in the promotion of 
endometrial adenocarcinoma has been shown, with evidence for elevated PGF2α-FP 
signalling up-regulating angiogenic and tumourigenic genes, and increasing 
proliferation and migration of neoplastic epithelial cells. This thesis examines 
signalling pathways regulated by and interacting with the FP receptor that influence 
chemokine expression and subsequent effects in endometrial adenocarcinoma.     
 
To investigate PGF2α-FP interactions in endometrial adenocarcinoma, an endometrial 
epithelial cell line of adenocarcinoma origin (Ishikawa cells) stably transfected with 
the FP receptor to levels seen in cancer was used (FPS cells). An antibody array 
identified the chemokine C-X-C motif Ligand 1 (CXCL1) as a target gene regulated 
by PGF2α-FP signalling in this cell line. Expression of CXCL1 and its receptor, 
CXCR2, were elevated in cancer tissue as compared to normal endometrium and 
localised to glandular epithelium, endothelium and stroma. The induction of CXCL1 
expression in FPS cells and endometrial adenocarcinoma explants was determined to 
be by a signalling pathway involving Gq, the epidermal growth factor receptor 
(EGFR) and extracellular signal-regulated kinase (ERK). The infiltration of immune 
cells into endometrial adenocarcinoma as compared to normal endometrium was then 
investigated. Increased neutrophils were present in endometrial adenocarcinoma 
compared with normal endometrium, and the expression of CXCR2 was colocalised 
to neutrophils. In vitro chemotaxis assays demonstrated that conditioned media from 
PGF2α-treated FPS cells stimulated human neutrophil chemotaxis which could be 
abolished by CXCL1 protein immunoneutralisation from the conditioned media or 
 
 
antagonism of CXCR2 on neutrophils. Moreover, xenograft tumours in nude mice 
arising from inoculation with FPS cells had higher neutrophil infiltration compared 
to tumours arising from wild-type cells or following treatment of mice bearing FPS 
tumours with CXCL1-neutralising antibody. Therefore, the up-regulation of CXCL1 
by PGF2α promoted neutrophil chemotaxis into endometrial adenocarcinoma. 
 
The expression of a further chemokine, CC motif Ligand 20 (CCL20) was 
determined to be regulated by PGF2α -FP signalling in endometrial adenocarcinoma, 
and expression of CCL20 and its receptor CCR6 was elevated in endometrial 
adenocarcinoma. The induction of CCL20 by PGF2α -FP signalling in FPS cells was 
dependent on the signalling molecules Gq, EGFR, ERK, calcineurin and nuclear 
factor of activated T-cells (NFAT). The treatment of endometrial epithelial cells with 
recombinant CCL20 caused a significant increase in proliferation. 
 
Finally interactions between the signalling pathway of another pro-inflammatory 
lipid, lysophosphatidic acid (LPA), and FP receptor signalling in endometrial 
adenocarcinoma were examined. LPA increased expression of the FP receptor and 
the FP target genes previously discussed in this thesis, CXCL1 and CCL20, in FPS 
cells. Expression of the LPA receptors (LPAR) 1, 2 and 3 was localised in 
endometrial tissue, and LPAR2 and 3 were found to be elevated in endometrial 
adenocarcinoma compared with normal endometrium, suggesting amplification of 
the PGF2α -FP signalling pathway by LPA was possible. 
 
Collectively, these data demonstrate that inflammatory cytokine signalling pathways 
regulated by PGF2α-FP activation can promote immune cell infiltration and 
proliferation of endometrial adenocarcinoma, and that interaction of LPA and PGF2α-
FP signalling in endometrial adenocarcinoma may exacerbate the disease. 
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Chapter 1                                                                                           Literature Review  
2 
1 Literature Review 
1.1 Introduction 
Endometrial adenocarcinoma is the most common gynaecological malignancy in the 
Western world (Doll et al. 2008). A role for the prostaglandins in this cancer has 
been shown, with evidence for the up-regulation of cyclooxygenase enzymes (Tong 
et al. 2000; Kilic et al. 2005) and the prostaglandin receptors (Sales et al. 2004; Sales 
et al. 2004b), and the promotion of a number of tumourigenic genes (Sales et al. 
2005; Genc et al. 2007; Sales et al. 2007; Sales et al. 2008). The focus of this thesis 
is on the contribution of the F-prostanoid receptor to inflammatory signalling 
pathways in endometrial adenocarcinoma, and how these pathways may be amplified 
by other lipid signalling mediators. This chapter gives a brief introduction to the 
normal cycling uterus and a background to endometrial adenocarcinoma, including 
established genetic and hormonal changes which contribute to tumour progression. 
The concept that inflammation may play a key role in tumour progression is then 
introduced, and how the hormonal and genetic changes may contribute to the 
inflammatory microenvironment is discussed. The role that prostaglandins, 
chemokines and the lipid signalling mediator lysophosphatidic acid may play in 
inflammation in endometrial adenocarcinoma is then considered. 
 
1.2 The normal endometrium 
The uterus is a unique organ in the adult female, with a highly specialised 
endometrial lining that undergoes a cycle of proliferation, angiogenesis and shedding 
on a monthly basis in order to prepare for implantation of the embryo. The uterus is 
formed in the developing embryo from the Mullerian ducts, which also give rise to 
the epithelial lining of the cervix, ovaries and upper vagina (Cunha et al. 2002). In 
the adult, the uterus consists of an outer peritoneal wall over a thick myometrial layer 
of smooth muscle, and the internal endometrial layer. Four distinct regions make up 
the uterus: the fundus, corpus, isthmus and cervix, which are displayed in Figure 1.1 
(Johnson et al. 2000).  





Figure 1.1 The adult uterus. The uterus is composed of four distinct regions: the upper 
region of the uterus named the fundus, the main body of the uterus containing the uterine 
cavity named the corpus, the flexible lower region named the isthmus, and the cervix. It is 
comprised of three layers; the outer peritoneal wall, a muscular myometrium and the internal 
endometrium. Adapted from http://www.nlm.nih.gov/medlineplus. 
 
The endometrium is situated directly adjacent to the muscular myometrium with no 
separating tissue. It is composed of a columnar epithelium with epithelial glandular 
extensions throughout the stroma, and is separated into two layers known as the 
functionalis and basalis (Figure 1.2). In the functionalis layer, the epithelial glandular 
protrusions extend through the stroma from the surface epithelium.  The basal 
regions of the glands extend through the denser stroma of the basalis layer. As well 
as luminal and glandular epithelial cells, the microenvironment of the endometrium 
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Figure 1.2 The structure of the endometrium. The endometrium lies adjacent to the 
myometrium and is composed of two distinct layers, the functionalis and basilis. It is 
comprised of an epithelium extending in glandular protrusions throughout the stroma. 
Adapted from (Gargett 2007). 
 
The endometrium has the capacity to shed and completely renew itself within one 
menstrual cycle, a process limited to humans, old world primates including macaques 
and baboons, some new world monkeys (Dempsey 1939; Ortiz et al. 2005), shrews 
and fruit-bats (Zhang et al. 2007). In humans, this lasts an average of 28 days, being 
split into three phases: menses (day 1-4), the proliferative phase (day 5-14) and the 
secretory phase (day 14-28) (McLennan et al. 1965). The menstrual cycle takes place 
in response to hormonal changes which regulate the cycle of proliferation, 
differentiation and tissue breakdown. The human menstrual cycle was first explicitly 
likened to an inflammatory wound healing process in 1986 by Finn, who described 
the similarities of the two processes. These include increased blood flow and vessel 
permeability, the change to decidual tissue which resembles the granulation tissue of 
wound healing, and the infiltration of immune cells (Finn 1986). Subsequent 
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evidence has strengthened this analogy by examining in more detail the tissue 
remodelling, cytokine expression and leukocyte influxes that occur (Jabbour et al. 
2006). In wound healing, a leukocyte influx in response to cytokine production 
occurs before the re-growth of tissue mediated by epidermal growth factor (EGF) 
and platelet-derived growth factor (PDGF). Angiogenesis is mediated by vascular 
endothelial growth factor (VEGF) and fibroblast growth factor (FGF) (Barrientos et 
al. 2008). In the normal endometrial cycle, this is mirrored by the influx of 
leukocytes at the breakdown of tissue at menstruation, and the regrowth of the 
endometrium during the proliferative phase under the control of growth factors and 
angiogenic mediators (Critchley et al. 2001). The contribution of chemokines to the 
inflammatory aspects of the menstrual cycle is further discussed in Section 1.5.1. 
1.2.1 The menstrual cycle 
1.2.1.1 The proliferative phase 
An overview of the menstrual cycle and hormonal changes involved is given in 
Figure 1.3. The proliferative phase of the cycle occurs after menstruation when the 
functionalis layer of the endometrium has been shed, and the growth factors 
mediating this regeneration liken this stage to the healing of a wound (Barrientos et 
al. 2008). At this point, only the base of the endometrial glands remains, and 
therefore the proliferative phase is characterised by the re-growth of epithelial glands 
and the stromal compartment. Under the control of oestrogen, both the epithelial 
cells making up the glands and the surrounding stoma begin to proliferate (Ludwig et 
al. 1976). At this point, the oestrogen receptor (ER) is expressed at its highest level 
in stromal and glandular epithelial cells (Snijders et al. 1992). Progesterone receptor 
(PR) is also expressed in the glandular epithelial cells (Lessey et al. 1988). The 
expression of both is upregulated by oestradiol from the ovary (Chauchereau et al. 
1992). The glandular epithelial cells begin to undergo morphological changes and 
increase in size, and an increase in the mitotic index of stromal cells can be seen 
indicating proliferation (Johannisson et al. 1987).  
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Figure 1.3 The human menstrual cycle. After menstruation and the shedding of the 
functionalis layer of endometrial tissue, the proliferative phase of the cycle occurs under the 
control of the hormone oestrogen. During this phase, cell proliferation is driven by stem cells, 
and increased proliferation gives rise to a thickened endometrium. At ovulation and as 
progesterone levels begin to increase, endometrial cells begin to differentiate and secrete 
proteins in preparation for implantation. This is known as the secretory phase of the cycle. 
Falling progesterone levels then initiate breakdown of endometrial tissue, known as 
menstruation. Adapted from www.iupucanatomy.com. 
 
During the proliferative phase, the endometrium thickens a remarkable amount, from 
1 mm to 3-4 mm (Dockery 2002). Evidence for a population of stem cells being 
primarily responsible for renewing the endometrium has strengthened in recent years 
with the development of a number of assays for stem cells. This concept was 
proposed decades ago due to the recognition of the huge regenerative capability of 
the endometrium (Prianishnikov 1978). It was subsequently supported by studies of 
epigenetic errors in methylation patterns which were consistent with a long lived 
population of stem cells dividing rather than the division of differentiated cells (Kim 
et al. 2005). Additionally common and persistent genetic changes in endometrial 
epithelial cells indicated that the cells making up glands are clonal and therefore 
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likely to be formed from a single cell (Mutter et al. 2001). A population of putative 
stem cells able to form colonies was subsequently isolated from human uterine 
stromal and epithelial cell explants (Gargett 2006; Gargett et al. 2009) and the 
murine uterus (Cervello et al. 2007). The proposed site of the endometrial stem cell 
niche in the endometrium is in the basalis layer and is displayed in Figure 1.4. As the 
proliferative phase of the menstrual cycle depends on oestrogen, it is as yet unknown 
if endometrial stem cells express ER, or if these cells are induced to undergo division 
by oestrogen-mediated signals from the stem cell niche (Gargett 2007).  
 
Figure 1.4 The proposed site of endometrial epithelial and stromal stem cells. The 
stem cell niche is proposed to exist in the basalis layer of the endometrium. Stem cells can 
regenerate the funtionalis layer of the endometrium after menstruation. Adapted from 
(Gargett 2007). 
 
A number of growth factors are produced during the proliferative phase of the cycle, 
under the control of oestrogen, which are similar to those produced in an 
inflammatory environment (Barrientos et al. 2008). These include transforming-
growth factor (TGF; Nelson et al. 1992), EGF (Nelson et al. 1991) and FGF 
(Fujimoto et al. 1996). The epithelial and stromal compartments of the endometrium 
are not the only cells undergoing regeneration, as the uterus is one of the few sites in 
the adult which undergoes regular angiogenesis. Angiogenesis is the generation of 
new vasculature from existing blood vessels, and can occur by four mechanisms: 
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sprouting, intussusception, elongation, or incorporation of endothelial cells from the 
circulation into vessels (Girling et al. 2005). The vascular structure of the 
endometrium is well described, with the main blood supply reaching the uterus 
through the myometrium from the radial arteries. The arteries then begin to split, and 
in the functionalis layer become the coiled spiral arteries characteristic of the 
endometrium. These arteries further split into the capillary plexus at the surface of 
the endometrium (Rogers 1996). It is the vessels in the functionalis layer that are 
primarily remodelled during the menstrual cycle. During the proliferative phase, the 
endometrial vessels proliferate and sprout (Ferenczy et al. 1979) under the control of 
oestrogen-induced angiogenic factors including VEGF (Li et al. 1994), EGF (Nelson 
et al. 1991) and platelet-derived endothelial growth factor (Zhang et al. 1997). The 
wave of vessel proliferation and VEGF expression has also been subsequently 
demonstrated in macaques, in an elegant experiment examining angiogenesis after 
the withdrawal of a progesterone implant (Nayak et al. 2002). Proliferation is not the 
only mechanism contributing to angiogenesis, and during this stage the endometrial 
vessels also elongate as a result of the remodelling of existing vessels (Gambino et 
al. 2002). 
1.2.1.2 The secretory phase 
The secretory phase of the menstrual cycle begins after ovulation, and is 
accompanied by a rise in progesterone levels produced by the corpus luteum (Figure 
1.3). Progesterone receptor expression reaches a maximum at the early secretory 
phase in the glandular epithelial cells, and reduces progressively throughout the mid 
and late secretory phases. Oestrogen receptor expression is at its maximum levels in 
both the glandular epithelium and stroma in the proliferative phase, and declines 
throughout the secretory phase (Snijders et al. 1992).  
 
During the early secretory phase, a small amount of cell proliferation occurs and very 
little secretory material is produced by the epithelial cells. As the early secretory 
phase endometrium develops into mid secretory phase endometrium, epithelial and 
stromal cells are under the control of progesterone rather than oestrogen and cease to 
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proliferate and begin to differentiate. Glandular epithelial cells increase in diameter, 
and begin to produce a number of secretory products and cytokines in preparation for 
implantation. This stage of the cycle is also known as the window of implantation 
(Jansen et al. 1985; Dockery et al. 1988; Dockery 2002).  
 
The mid-secretory phase is characterised by a loss of nuclear ER and PR expression 
in glandular epithelial cells, while an increase in expression is observed in stromal 
cells (Snijders et al. 1992). The glycoproteins secreted at this stage have been well 
characterised and described. These include cytokines which are critical to 
implantation, such as interleukin-11 (Dimitriadis et al. 2000), interleukin-6 
(Tabibzadeh et al. 1995) and leukaemia inhibitory factor (LIF; Cullinan et al. 1996), 
which may support the invasion of the trophoblast at implantation (Dimitriadis et al. 
2005). Several growth factors are also upregulated at this phase of the cycle, 
including EGF, which is strongly expressed by the stromal cells and may play a role 
in trophoblast invasion (Bass et al. 1994). Heparin-binding EGF-like growth factor 
and insulin-like growth factor binding protein-1 are both also upregulated at this 
stage in the cycle (Guzeloglu-Kayisli et al. 2009). 
 
A component of vascular remodelling occurs during this phase of the cycle, which 
takes the form of development of the spiral arteries and subepithelial capillary plexus 
(Girling et al. 2005). This is thought to occur mainly by intussusception or sprouting 
rather than proliferation, as an increase in branching points has been described at the 
secretory phase of the cycle (Gambino et al. 2002). This vascular remodelling was 
demonstrated to be essential to endometrial function, as the administration of an 
angiogenesis inhibitor to mice resulted in failures of numerous reproductive 
processes including decidualisation and placental formation (Klauber et al. 1997). A 
wave of endothelial cell proliferation was shown to occur in the human endometrium 
in the mid-secretory phase (Ferenczy et al. 1979). This was not confirmed in the 
macaque studies described earlier, which showed increased proliferation only in the 
mid-proliferative phase of the cycle (Nayak et al. 2002), and has also not been 
confirmed in subsequent human studies (Girling et al. 2005). However a 
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progesterone-mediated increase in an isoform of VEGF has been demonstrated in the 
mid-late secretory phase of the cycle, which increases vessel permeability and so 
may be involved in the changes in vessel structure required for implantation (Ancelin 
et al. 2002). 
 
As the late secretory phase develops, the major changes in the endometrium involve 
the stroma, as the glandular epithelial cells begin to regress and shrink at this stage. 
The epithelial cells cease to secrete glycoproteins; however the glands remain full of 
secretory products (Dockery et al. 1990). The stromal cells begin to undergo the pre-
decidual reaction, which involves a reorganisation and loosening of the cells 
(Dockery et al. 1990). The stromal compartment is also important in remodelling 
events at this stage of the cycle due to the large influx of immune cells which occurs, 
of which over 50% is composed of an infiltration of uterine natural killer cells 
(uNK). These cells are often found in a cuff around the spiral arteries (Bulmer et al. 
1991). The appearance of uNK cells at this point is likely induced by the stromal 
decidual reaction rather than the implanting blastocyst (Ordi et al. 2006), and uNK 
cells are implicated in both the preparation for pregnancy by the remodelling of 
spiral arteries and in modulation of the maternal immune response to the foetus. The 
importance of uNK cells in these processes has been demonstrated in mouse models 
which lack NK cells. In these mice, the decidual arteries do not undergo remodelling 
prior to implantation (Ashkar et al. 2000). Additionally it is postulated that uNK cells 
may interact with HLA-G present on trophoblast cells, to modify cytotoxic responses 
of uNK cells and other leukocytes to the trophoblast cells (Hunt et al. 2005). Other 
immune cells infiltrating at this stage include T cells, macrophages (Bulmer 1994) 
and neutrophils mediated by IL-8 (Critchley et al. 1994).  
1.2.1.3 Menstruation 
In the absence of implantation, progesterone levels fall in the late secretory phase 
and trigger menstruation. This is supported by experiments in animal models 
demonstrating that prolonged progesterone concentrations inhibit menstruation 
(Brenner et al. 2002). The morphological changes taking place at menstruation were 
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first observed by Markee (Markee 1940) by explanting a piece of endometrium to the 
anterior eye of a rhesus monkey. Tissue regression, vasoconstriction of the spiral 
arteries and degradation of the extracellular matrix was observed. The process of 
menstruation is now known to begin with the upregulation of a number of 
inflammatory mediators, for example macrophage chemoattractant protein-1 
(Akiyama et al. 1999) and IL-8 (Critchley et al. 1999; Milne et al. 1999). 
Accompanying this increase in chemokine expression is a further leukocyte influx 
led by uNK cells, macrophages, neutrophils and eosinophils (Critchley et al. 1999).  
The leukocytes, endometrial stromal cells, or both may provide the proteases and 
MMPs which start the breakdown of tissue at menstruation, and indeed the release of 
MMPs by one cell type may activate the proteases released from the other. In stromal 
cells, the withdrawal of progesterone can up-regulate the expression of urokinase-
type plasminogen activator, MMP-1, MMP-3 and MMP-9 (Bruner et al. 1995; Singer 
et al. 1997; Rigot et al. 2001). MMPs can also be produced by leukocytes, as 
neutrophils are a source of MMP-9 (Ardi et al. 2007) and macrophages and 
eosinophils produce MMP-9 (Jeziorska et al. 1996). The key role of neutrophils in 
menstruation has been demonstrated by the impaired onset of tissue breakdown in a 
mouse model deficient in neutrophils (Kaitu'u-Lino et al. 2007).  The role of uNK 
cells may be more directed toward establishment of pregnancy than menstruation, 
however they do produce MT-MMP-1 (Salamonsen et al. 2000).  
 
An upregulation of the prostaglandin-synthesising enzyme COX-2 is also seen at 
menstruation (Critchley et al. 1999). The subsequent increase in prostaglandin 
expression, particularly PGF2α, is responsible for vasoconstriction of the spiral 
arteries and myometrial contractions (Baird et al. 1996). The vasculature is also 
affected by the up-regulation of VEGF by the stromal cells at this time, which is 
potentially mediated by hypoxia driven by vasoconstriction (Popovici et al. 1999). 
VEGF signalling increases vascular permeability (Popovici et al. 1999), and a loss of 
endothelial cell–cell junctions at this time also causes a loss of vascular integrity 
(Tabibzadeh et al. 1996). Menstruation ends when levels of oestrogen begin to rise to 
regenerate the functionalis layer of the endometrium.  
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1.2.1.4 The post-menopausal endometrium 
The post-menopausal endometrium is atrophic, being thinned and quiescent due to 
the changes in the hypothalamic-pituitary-gonadal axis (Sheth et al. 1993). Oestrogen 
receptor is expressed in all cellular compartments, while progesterone receptor is 
expressed in the glandular epithelium and smooth muscle but weakly in the stroma 
(Snijders et al. 1992). 
 
1.3 Endometrial adenocarcinoma 
1.3.1 Epidemiology and incidence 
If the normal cycling endometrium or quiescent post-menopausal endometrium is 
affected by an imbalance of signals promoting growth or genetic alterations, cancer 
of the endometrium can occur. Endometrial adenocarcinoma, the neoplastic growth 
of endometrial epithelial cells, is the most common gynaecological malignancy in 
western countries (Doll et al. 2008). Incidence is estimated at 15-20 per 100 000 
women per year worldwide, with predicted data for 2009 for the United States 
reaching an estimated 42 160 new cases and 7780 deaths (National Cancer Institute, 
NIH). Endometrial adenocarcinoma most commonly affects post-menopausal 
women, as approximately 85% of patients are over 50 years of age (Ellenson et al. 
2004). Survival rates of endometrial adenocarcinoma are approximately 85% at five 
years, which is relatively high compared to other gynaecological tract cancers 
including ovarian and cervical (Di Cristofano et al. 2007). However this survival rate 
is attributed to the early detection of cancer due to presentation of symptoms 
including abnormal uterine bleeding, and therefore a hysterectomy can be performed 
before spread of disease. If the cancer has metastasised beyond the uterus, 
chemotherapy is rarely successful and prognosis is poor (Fleming et al. 2004). Risk 
factors for endometrial adenocarcinoma include post-menopausal oestrogen use 
(Grady et al. 1995), nulliparity (Albrektsen et al. 1995), late menopause onset 
(Kalandidi et al. 1996) and obesity (Sturgeon et al. 1998; Reeves et al. 2007). 
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1.3.2 Clinical features 
Endometrial tumours are divided into well, moderately or poorly differentiated 
cancers histologically, based on tissue architecture and the amount of solid tumour 
present (Ellenson et al. 2004). A study by Bokhman in 1983 proposed that 
endometrial adenocarcinomas could be broadly divided into two types (Bokhman 
1983). Type I endometrial adenocarcinoma is associated with patients displaying 
increased oestrogen levels and hyperlipidemia, and is often related to obesity. These 
tumours are the most common, making up approximately 85% of patients, and 
generally display low invasion and have a good prognosis. They are usually well or 
moderately differentiated tumours, however can progress to invasive and poorly 
differentiated tumours. Type II endometrial adenocarcinoma is independent of 
oestrogen stimulation, and are more aggressive, poorly differentiated tumours with a 
morphology consisting of cells growing in papillary patterns (Hendrickson et al. 
1982). This dualistic model has been strengthened by more recent studies 
demonstrating that the two types of endometrial adenocarcinoma can be divided by 
morphology and genetic mutations (Tashiro et al. 1997; Lax et al. 2000; Catasus et 
al. 2009). Although there are overlapping features between the two types, this thesis 
concentrates only on Type 1 endometrial adenocarcinoma. 
1.3.3 Common genetic and cellular changes leading to development of 
endometrial adenocarcinoma 
It was proposed in a landmark review by Hanahan and Weinberg that there are six 
underlying principles leading to the development of cancers, which are functional 
abilities acquired by cancerous cells and shared by all types of cancer (Hanahan et al. 
2000). The change from normal to malignant cells is a multistep process, ending in 
tumours displaying all of these “hallmarks of cancer”. This theory is supported in 
endometrial cancer as atypical hyperplasic lesions of the endometrium have been 
shown to develop into endometrial cancer (Kurman et al. 1985), potentially as a 
result of the cells acquiring more of these characteristics. These six acquired 
characteristics are based on genetic changes, and are: a self sufficiency in growth 
signals, evading apoptosis, insensitivity to anti-growth signals, tissue invasion and 
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metastasis, limitless replication potential and sustained angiogenesis (Hanahan et al. 
2000). Endometrial adenocarcinoma displays genetic changes which result in the 
above features and are discussed below. More recently, a seventh hallmark of cancer 
has been proposed: inflammation (Figure 1.5; Colotta et al. 2009).  
 
Figure 1.5 The hallmarks of cancer. A model of cancer development proposing that 
cells acquire six “hallmarks” during progression into cancer was proposed by Hanahan and 
Weinberg in 2000 (Hanahan et al. 2000). On the basis of recent evidence suggesting 
inflammation contributes to cancer, the seventh hallmark of an inflammatory 
microenvironment was recently proposed. Adapted from (Mantovani 2009). 
One genetic alteration  that has been linked to endometrial adenocarcinoma is a 
mutation in the tumour suppressor gene PTEN, leading to its inactivation (Tashiro et 
al. 1997). PTEN encodes the phosphatase and tensin homolog protein, which is a 
lipid phosphatase that downregulates phosphatidylinositol-(3,4,5)-triphosphate (PIP3) 
by converting it into PIP2. PIP3 activates Akt signalling, therefore the common 
inactivation of PTEN found in endometrial adenocarcinoma can upregulate Akt 
signalling and subsequently impact on cellular proliferation, adhesion and migration 
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(Maehama et al. 1998). The mutation of this tumour suppressor gene can be seen in 
atypical endometrial hyperplasia, suggesting that it may occur early on or even lead 
to tumour progression (Levine et al. 1998). Furthermore, the conditional deletion of 
PTEN in the endometrium of a mouse model rapidly induced endometrial cancer 
formation (Daikoku et al. 2008). One of the first studies of PTEN in endometrial 
adenocarcinoma found that PTEN mutation was present in 50% of endometrial 
adenocarcinomas (Tashiro et al. 1997) and this figure is now estimated to be between 
30-50% (Di Cristofano et al. 2007; Catasus et al. 2009). This is the highest reported 
frequency of PTEN mutation in any cancer type (Tashiro et al. 1997). 
 
In endometrial adenocarcinoma, PTEN inactivation has been linked to an increased 
risk of metastasis (Salvesen et al. 2002). An additional hallmark of cancer that loss of 
PTEN may preclude is the evasion of apoptosis. In an in vitro model, the re-
introduction of PTEN into endometrial adenocarcinoma cell lines including Ishikawa 
cells induced apoptosis, and prevented ex vivo tumour formation (Sakurada et al. 
1999). In a mouse model, PTEN loss resulted in the upregulation of growth signals, 
as the increased levels of activated Akt led to an increase in ERα activation and 
therefore transcription of target genes which regulate proliferation (Vilgelm et al. 
2006).   
 
PTEN has been demonstrated to regulate levels of expression of the p53 protein, 
another tumour suppressor, by preventing its degradation. Therefore the loss of 
PTEN in endometrial adenocarcinoma may also disrupt p53 levels (Freeman et al. 
2003). The p53 protein is a transcription factor which regulates a number of genes 
which can induce apoptosis in the event of cell damage. In endometrial 
adenocarcinoma, p53 mutation is present in approximately 15-30% of patients (Lax 
et al. 2000; Sakuragi et al. 2002) and is associated with a poor prognosis (Jeon et al. 
2004; Catasus et al. 2009). This is potentially because p53 is more frequently 
mutated in poorly differentiated adenocarcinomas (Kohler et al. 1992; Lax et al. 
2000). However the exact function of mutated p53 in endometrial adenocarcinoma is 
still unclear.  
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A further genetic mutation in endometrial adenocarcinoma that can lead to 
acquirement of many of the hallmarks of cancer is a mutation in the oncogene K-Ras 
(Enomoto et al. 1990). Mutations in this protein activate the extracellular signal-
regulated kinase 1/2 (ERK1/2) signalling pathway, which is a mitogen-activated 
protein kinase (MAPK) pathway. The ERK-MAPK pathway is usually activated by 
signalling from G protein-coupled receptors, and is described in more detail in 
Section 1.4.1 and Figure 1.6. A mutation in K-Ras occurs in approximately 9-33% of 
endometrial adenocarcinomas (Lax et al. 2000). This mutation is also more 
commonly found in poorly differentiated cancers (Kohler et al. 1992).  K-Ras 
mutations can cause constitutive activation of the ERK pathway in the absence of 
stimuli in endometrial adenocarcinoma, and therefore impact on downstream gene 
expression through the transcription of numerous genes promoting tumour 
progression (Mizumoto et al. 2007).The phenotypic effects of K-Ras mutations in 
endometrial adenocarcinoma are yet to be determined, but are likely to involve the 
activation of multiple pathways regulated by ERK signalling which can promote 
growth, migration and angiogenesis (Lax et al. 2000). Interestingly however, ERK 
phosphorylation has been associated with a good prognosis in endometrial 
adenocarcinoma (Mizumoto et al. 2007). 
 
Other tumour suppressor genes and oncogenes commonly found to be mutated in 
endometrial adenocarcinoma include β-catenin (Fukuchi et al. 1998), Par-4 (Moreno-
Bueno et al. 2007) and bax (Sakuragi et al. 2002).   
1.3.4 Oestrogen and progesterone in endometrial adenocarcinoma 
The normal endometrium undergoes regular morphological and structural changes in 
response to the hormones oestrogen and progesterone. These hormones have also 
been shown to play a role in endometrial adenocarcinoma. As described in section 
1.2, oestrogen induces proliferation of endometrial epithelial cells while progesterone 
is thought to mainly oppose the actions of oestrogen and induce cell differentiation 
(Graham et al. 1997). Risk factors for endometrial adenocarcinoma mostly involve 
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an increase in oestrogen exposure or decrease in progesterone exposure, or both. For 
example, one of the major risk factors for endometrial adenocarcinoma is obesity. 
This is thought to increase oestrogen levels in post-menopausal women due to an 
increase in adipose tissue, which is rich in the enzymes promoting oestrogen 
formation (Akhmedkhanov et al. 2001). Other endometrial adenocarcinoma risk 
factors leading to prolonged oestrogen exposure include late menopause, oestrogen 
only contraceptives and oestrogen only hormone therapy. Factors reducing the risk of 
endometrial adenocarcinoma include combined contraceptive pills containing 
progesterone, and progestin treatments are often successfully used in the treatment of 
endometrial adenocarcinoma (Doll et al. 2008). Recent factors shown to decrease 
risk of endometrial adenocarcinoma, such as smoking, red meat consumption and 
coffee drinking, all promote a mechanism of oestrogen metabolism (Gunter 2009). 
Therefore, it may be that increased proliferation due to prolonged oestrogen exposure 
increases the risk of genetic mutations leading to endometrial adenocarcinoma. This 
has become known as the unopposed oestrogen hypothesis (Akhmedkhanov et al. 
2001). 
 
The oestrogen receptors (ER) and progesterone receptors (PR) belong to the steroid 
hormone nuclear receptor superfamily. There are two main isoforms of both ER and 
PR expressed in the endometrium: ERα, ERβ, PR-A and PR-B. Upon activation of 
ER α or β by ligand, the receptors translocate from the plasma membrane to the 
nucleus and form homo or hetero-dimers, which then bind to oestrogen response 
elements (ERE). This complex can than interact with other transcription factors to 
regulate gene transcription. The progesterone receptors act in a similar way, with 
hormone binding inducing dimerisation of PR-A and B and translocation to the 
nucleus. The progesterone receptor then binds to progesterone response elements 
(PRE) to initiate gene transcription. The expression of PR is also under the control of 
oestrogen, as oestrogen increases PR expression. Progesterone can also downregulate 
its own receptor (Graham et al. 1997). 
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In endometrial adenocarcinoma, a change in the ER α/β ratio has been reported with 
a decrease in ERα expression as compared to normal post-menopausal endometrium 
as well as a decrease from well through to poorly differentiated carcinomas (Saegusa 
et al. 2000; Jazaeri et al. 2001). The expression of ERα in endometrial 
adenocarcinoma has been associated with a less aggressive phenotype and prolonged 
patient survival (Ito et al. 2005), therefore the change in the ratio of receptor 
subtypes may be driving proliferation by altering gene transcription mediated 
through oestrogen. An alteration in PR isoform expression has also been 
demonstrated in endometrial adenocarcinoma.  Most commonly, a loss of PR-A 
expression has been described but a decrease in PR-B expression in endometrial 
adenocarcinoma has also been reported (Jazaeri et al. 2001; Saito et al. 2006). 
However PR-B has also been recently reported to promote epithelial cell 
proliferation (De Vivo et al. 2002), therefore it may be that alterations in the PR-A to 
PR-B ratio may affect the anti-proliferative effect of progesterone. 
 
Additionally, oestrogen signalling can activate a number of mitogenic pathways in 
the endometrium, and therefore potentially in endometrial adenocarcinoma.  
Oestrogen-mediated proliferation has been shown to be partially dependent on EGFR 
signalling, which can activate MAPK signalling and numerous growth pathways 
(Nelson et al. 1991). Oestrogen signalling can also upregulate transforming-growth 
factor (TGF) expression in endometrial epithelial cells, suggesting autocrine 
regulation of growth (Nelson et al. 1992). Oestrogen can also act through the Wnt 
signalling pathway in the normal endometrium, by increasing localisation of β-
catenin to the nucleus and promoting growth (Hou et al. 2004). These therefore may 
be signalling pathways that are deregulated in endometrial adenocarcinoma. 
1.3.5 Stem cells in endometrial adenocarcinoma 
As discussed in section 1.2.1.1, the hypothesis that the regeneration of the 
endometrium after menstruation is driven by stem cells located in the basalis layer 
has gained strength in recent years with the isolation of putative stem cells from the 
endometrium (Gargett 2006; Gargett et al. 2009). The idea that cancers are initially 
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formed from tissue stem cells which due to genetic mutations are no longer under the 
control of local signals from the stem cell niche has also been strengthened with the 
isolation of stem cells from corneal, breast and gastrointestinal cancer (reviewed in 
Miller et al. 2005). Therefore, endometrial adenocarcinoma may arise from the 
uncontrolled growth of endometrial stem cells which have acquired the genetic 
mutations described above. Cells with markers of stem cells have recently been 
described in endometrial adenocarcinoma (Rutella et al. 2009). 
1.3.6 The inflammatory microenvironment in endometrial 
adenocarcinoma 
Recently, a seventh hallmark of cancer has been proposed: inflammation (Colotta et 
al. 2009). Epidemiological and molecular data has strengthened the hypothesis that 
chronic inflammation may initiate and worsen neoplastic transformation. Although 
there has been a recent revival of interest in the link between inflammation and 
cancer, this concept was first proposed in the 19
th
 century by Virchow. After 
observing leukocyte influxes in cancers of tissues that experience chronic 
inflammation, he suggested that they may be the cause of tumour growth (Balkwill et 
al. 2001). Inflammation in cancer has now been proposed to function by two 
pathways – intrinsically and extrinsically. In the former, after the initiation of cancer 
by genetic mutations the expression of inflammatory agents is increased, leading to 
the promotion of tumour growth. In the extrinsic pathway, current inflammatory 
conditions lead to the initiation of cancer (Colotta et al. 2009).  
 
Epidemiological data has strengthened the extrinsic inflammatory hypothesis of 
cancer initiation, as inflammatory diseases have been shown to predispose sufferers 
to certain types of cancer. For example, inflammatory bowel disease is associated 
with an increased risk of colon cancer (Flossmann et al. 2007), prostatitis is 
associated with an increased risk of prostate cancer (Sandhu 2008) and infection with 
certain microbes can lead to increased risk of gastric cancer (Suzuki et al. 2009). 
Additionally, long term intake of non-steroidal anti-inflammatory drugs (NSAIDS) 
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in patients at risk of developing these cancers significantly reduces cancer occurrence 
(Dannenberg et al. 2003; Flossmann et al. 2007).  
 
The intrinsic pathway hypothesis states that after cancer development, several 
features of inflammation promote tumour progression. These include increased 
production of inflammatory mediators such as cytokines and prostaglandins, the 
presence of leukocytes, and extensive tissue remodelling including angiogenesis. 
These features will be discussed at a later point in this introduction. This hypothesis 
is strengthened by trials of antagonists of the pro-inflammatory cytokine tumour 
necrosis factor (TNF) in renal cancer patients. These trials have produced some 
promising prognostic results (Harrison et al. 2007), indicating that inflammatory 
pathways occurring in tumours maybe promoting their progression. 
 
A number of studies have now linked endometrial adenocarcinoma and 
inflammation. Risk factors for endometrial adenocarcinoma including obesity, late 
menopause and reproductive disorders such as menorrhagia promote not only 
prolonged oestrogen exposure, but also inflammation (Modugno et al. 2005). 
Furthermore, the transcription factor nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB) controls expression of a number of genes involved in the 
inflammatory and immune response. Increased localisation of NFκB to the nucleus 
has been detected in endometrial adenocarcinoma, implying an upregulation of 
NFκB signalling and hence inflammation (Pallares et al. 2004). Additionally, the K-
Ras mutation frequently detected in endometrial adenocarcinoma has been 
demonstrated to promote production of inflammatory chemokines and cytokines 
(Sparmann et al. 2004). Finally, as previously mentioned, the menstrual cycle can be 
compared to a chronic inflammatory process. The production of some of the pro-
inflammatory mediators normally produced in the endometrium may be increased in 
endometrial adenocarcinoma, and this is thought to promote inflammation (Jones et 
al. 1997).  
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1.3.7 Hormones and inflammation in the endometrium and endometrial 
adenocarcinoma 
Oestrogen plays a key role in the development of endometrial adenocarcinoma, as 
demonstrated by the increase in oestrogen mediated by many of the risk factors 
(Akhmedkhanov et al. 2001). Oestrogen also plays a complex role in inflammation. 
In some cases, it is thought to act as an anti-inflammatory agent. This is based on 
evidence including the decreased risk of cardiovascular disease in pre-menopausal 
women and the decreased severity of inflammatory disease symptoms during 
pregnancy. However, women also show an increased incidence of autoimmune 
disease, indicating that pro-inflammatory functions of female sex hormones exist 
(Nilsson 2007). In the normal endometrium, oestrogen up-regulates a number of 
inflammatory cytokines. These include interleukin-6 (Jacobs et al. 1992), and 
production of this cytokine in an endometrial adenocarcinoma cell line after 
oestrogen stimulation has recently been demonstrated (He et al. 2009). Other 
inflammatory mediators upregulated by oestrogen include interleukin-1, TNF-α, and 
MMPs (Modugno et al. 2005; He et al. 2009), and it has also been shown to activate 
NFκB signalling, which controls a number of inflammatory pathways (Seo et al. 
2004).  
 
In the normal endometrium, progesterone can also influence production of a number 
of inflammatory mediators, however often with opposing anti-inflammatory actions 
to oestrogen. A number of in vitro studies demonstrate that progesterone can inhibit 
cytokine release from murine and human uterine cells (Ito et al. 1994; Kelly et al. 
1994; Kelly et al. 1997). Many of these cytokines are under the control of NFκB. For 
example in a poorly differentiated endometrial adenocarcinoma cell line 
progesterone inhibits NFκB activation, by inducing accessory proteins which form a 
complex inhibiting NFκB activity (Davies et al. 2004). In vivo data has demonstrated 
that mice lacking PR have increased inflammatory responses in the uterus, with an 
increased infiltration of leukocytes and extensive tissue remodelling (Lydon et al. 
1995). Therefore, as endometrial adenocarcinoma is characterised by increased 
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oestrogen to progesterone signalling, an increase in inflammatory mediators may 
occur which is not inhibited by progesterone, thus promoting tumour growth. 
 
A number of these inflammatory pathways in cancer converge on the signalling 
pathway of the cyclooxygenase (COX) enzymes, and their production of 
inflammatory prostaglandins. 
1.4 The prostaglandins 
1.4.1 G-protein receptor coupled signalling 
Before discussing prostaglandin signalling, a brief description of G-protein receptor 
(GPCR) coupled signalling is required. GPCRS are the largest family of cell 
membrane receptors, and are the target of 50-60% of all current therapeutic agents, 
demonstrating that irregular GPCR function is a major aspect of human disease. 
GPCRS have been implicated in promotion of cell proliferation, angiogenesis and 
inflammation in cancer (Dorsam et al. 2007). The common structure of all GPCRs 
consists of seven-transmembrane α-helices interacting intracellularly with a G-
protein made up of 3 subunits – α, β and γ. The Gα subunit is associated with GDP, 
and upon ligand binding, the resulting conformational change in the receptor 
catalyses the transfer of GDP for GTP, leading to dissociation of Gα from βγ and the 
initiation of downstream signalling (Dorsam et al. 2007). 
 
The Gα subunit is further divided into the Gq, Gs, Gi and G12/13 families, of which 
more than one can couple to the same receptor. Each of these families begins 
signalling cascades in different manners. Gq activates the second messengers inositol 
trisphosphate (IP3) and diacylglycerol (DAG), Gs couples to stimulation of adenylyl 
cyclase and cAMP activation. Gi inhibits adenylyl cyclase and thus decreases cAMP 
production, and G12/13 proteins couple to and activate the guanine-nucleotide 
exchange factors Rho (Pierce et al. 2002). Within these families further subdivision 
of proteins occurs, as does some degree of cross talk between pathways. For example 
Gq has been shown to activate the GTP-binding protein Rho by a different 
mechanism to that of G12/13, leading to changes in the actin cytoskeleton mediating 
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cell migration (Chikumi et al. 2002). As the focus of this thesis is the FP receptor, 
which is Gq coupled, the key signalling pathways regulated by Gq signalling are 
represented in Figure 1.6 and described below. 
  
One of the major signalling pathways deregulated in cancer and mediated by Gq-
coupled receptors is the mitogen activated protein kinase (MAPK) phosphorylation 
cascade. This is often activated by mutated K-Ras, as described in Section 1.3.3. The 
signalling cascade begins with the activation of Ras, a small GTPase, by GPCR 
signalling. GTP-bound Ras can then begin a sequential phosphorylation cascade 
beginning with the serine/threonine kinase Raf, which phosphorylates MAPK ERK 
kinase (MEK), which phosphorylates ERK1/2. ERK translocates to the nucleus 
where it activates gene transcription through the regulation of a range of transcription 
factors including AP-1 and Ets (Roberts et al. 2007). MAPK signalling can also be 
activated by the epidermal growth factor receptor (EGFR). In this situation, GPCR 
signalling trans-activates the EGFR by initiating a tyrosine kinase (c-src) and matrix 
metalloprotease-mediated (Guerrero et al. 2004) cleaving of heparin bound–
epidermal growth factor (HB-EGF). Src is itself activated through SH2 domain 
interactions with either an intracellular domain of the GPCR, the G-protein, or 
GPCR-associated proteins (Luttrell et al. 2004). The EGFR is a tyrosine kinase 
receptor which can phosphorylate the adaptor protein SHC, which forms a complex 
with the protein Grb2 and the nucleotide exchange factor Sos-1. Sos-1 can then 
activate Ras and begin the phosphorylation cascade leading to ERK activation 
(Pierce et al. 2001). These two main MAPK signalling pathways, and inhibitors used 
in this thesis which can block steps of the pathway, are outlined in Figure 1.6. 
 
The nuclear factor of activated T cells (NFAT) family of transcription factors is 
linked to promotion of inflammatory gene expression due to its regulation of 
expression of a number of cytokines, and its functional relationship to the NFκB 
family of transcription factors (Hogan et al. 2003). Upon agonist stimulation of a Gq-
coupled receptor, phopspholipase C mediates hydroysis of phosphatidyl inositol-
bisphosphate to IP3, which then activates IP3 receptors on the endoplasmic reticulum 
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 binds the protein calmodulin which activates 
calcineurin by binding and changing its conformation, therefore releasing it from an 
inactive state (Klee et al. 1998). Calcineurin is a serine / threonine phosphatase 
which dephosphorylates and therefore activates NFAT (Klee et al. 1998). The 
pathway can be inhibited at this point by the actions of the protein regulator of 
calcineurin 1-4 (RCAN1-4), which binds to calcineurin and prevents its interaction 
with NFAT. RCAN1-4 can be directly phosphorylated by MEK, indicating cross talk 
occurs between these pathways (Harris et al. 2005). Five NFAT proteins exist, 
NFAT1-5, and after their dephosphorylation these rapidly translocate to the nucleus 
and bind to NFAT-sites on DNA to activate gene transcription. The gene activity 
regulated by NFAT depends in part on binding partners such as AP-1 (Macian et al. 
2001). 
 
NFκB is related evolutionarily and functionally to NFAT, as they bind to structurally 
highly related DNA binding domains and both activate a number of cytokines 
involved in the immune response (Serfling et al. 2004). The pathway leading from Gq 
to NFκB has been elucidated through chemical inhibitor studies, demonstrating that 
phosphatidylinositol (PI) 3-kinase (PI3K) and Akt signalling pathway is important in 
its regulation (Ye 2001). After generation of PIP3, the pleckstin homology domain of 
Akt binds to this and allows phosphorylation of Akt by phosphoinositide dependent 
kinase-1. Akt then activates the IκB kinases (IKK) which phosphorylates the 
inhibitory IκB, leading to its dissociation from NFκB and the translocation of NFκB 
to the nucleus to initiate gene transcription (Ye 2001). 
 
Interacting with some Gq coupled pathways is the protein kinase A (PKA). It has 
been demonstrated to interact directly with GPCRs, to mediate a down-regulation of 
their signalling by phosphorylation of the receptor to dissociate it from the G protein 
(Pierce et al. 2002). It has also been shown to trans-activate the EGFR by direct 
phophorylation (Barbier et al. 1999), and phosphorylate the IP3 receptor to increase 
Ca
2+
 release (Bugrim 1999). PKA therefore has both inhibitory and stimulatory 
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Figure 1.6 Schematic representation of key signalling pathways activated by Gq-
coupled receptor signalling. Antagonists used in this thesis are indicated in blue 
boxes. Agonist stimulation of Gq coupled receptors can lead to activation of the ERK 1/2, 
NFAT, NFκB or Rho signalling pathways. In the ERK1/2 pathway, Gq can directly activate 
the small GTPase Ras, which begins a phosphorylation cascade of the proteins Raf and 
MEK finally resulting in ERK translocation into the nucleus to initiate gene transcription. 
Alternatively, GPCR activation can lead to the activation of c-src and matrix 
metalloproteases, which cleave heparin-bound EGF to transactivate the EGFR. The 
phosphorylation cascade leading to ERK activation then begins. The NFAT signalling 
pathway begins with PLC mediated hydrolysis of phosphatidyl inositol-bisphosphate to IP3, 





 binds the protein calmodulin which activates calcineurin through release of auto-
inhibition. Calicineurin is a serine / threonine phosphatase which acts to dephosphorylate 
and therefore activate NFAT. The pathway can be inhibited at this point by the actions of 
RCAN1-4, which binds to calcineurin and prevents its interaction with NFAT. 
Dephosphorylation of NFAT results in translocation to the nucleus and activation of gene 
transcription. The gene activity regulated by NFAT depends in part on binding partners such 
as AP-1. NFκB is activated by the PI3K generation of PIP3. The protein Akt binds to this 
which allows its phosphorylation by phosphoinositide dependent kinase-1. Akt then activates 
the IκB kinases (IKK) which phosphorylate IκB, leading to its dissociation from NFκB and the 
translocation of NFκB to the nucleus to initiate gene transcription. PKA can interact with 
numerous proteins in this pathway. It interacts directly with GPCRs to mediate a down-
regulation of their signalling by phosphorylation. It also trans-activates the EGFR and 
phosphorylates the IP3 receptor to increase Ca2+ release. Gq has recently also been shown 
to activate the GTP-binding protein Rho, leading to changes in the actin cytoskeleton 
mediating cell migration. 
 
1.4.2 Prostaglandin formation and signalling 
Prostaglandins are bioactive lipids, formed from COX enzyme mediated metabolism 
of the membrane fatty acid arachidonic acid. The prostaglandins are a member of the 
eicosanoid family, which is also made up of leukotrienes and thromboxanes.  
 
Prostaglandins were originally discovered in 1930 in human semen, and are so 
named due to the belief that they originated in the prostate. It was subsequently 
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demonstrated that prostaglandins could be isolated from nearly all tissues, and in 
1964 their formation from arachidonic acid was reported (Rouzer et al. 2005). 
Arachidonic acid is released from the plasma membrane or dietary fatty acids by the 
action of phospholipase A2 or C. Two sequential reactions are then performed by the 
COX enzymes which take place at two distinct sites on the enzyme.  Arachidonic 
acid is first cyclised and oxygenated to the hydroperoxy endoperoxide prostaglandin 
G2 (PGG2). This is then reduced into the hydro endoperoxide PGH2 (Rouzer et al. 
2005). A series of prostanoid synthase enzymes then produce either PGD2, PGE2, 
PGF2α, prostacyclin or thromboxane, and are named dependent on what prostanoid 
they produce. The synthase enzymes are differentially expressed in different tissues, 
and the balance of these can determine the main prostaglandin type formed 
(Helliwell et al. 2004). Prostaglandins are then transported out of the cell by a 
prostaglandin receptor (Reid et al. 2003), and act in a paracrine or autocrine manner 
on their corresponding G-protein coupled receptors (DP, EP1-4, FP, IP and TP 
respectively). The prostaglandin receptors couple to different G-proteins, as the EP2, 
EP4, IP and DP receptors couple to Gs and signal using cAMP as a second 
messenger. EP1, FP and TP couple to Gq to activate IP3 and calcium signalling. The 
G-protein coupling to EP3 appears to depend on splice variant and cell type (Breyer 
et al. 2001). Figure 1.7 below summarises arachidonic acid metabolism and 
prostaglandin signalling. 














































Figure 1.7 Schematic representation of arachidonic metabolism and prostanoid 
signalling pathways. Arachidonic acid (AA) is released from membrane lipids by the 
enzyme phospholipase A2 (PLA2). The enzymes cyclooxygenase (COX) 1 or 2 and specific 
prostaglandin synthases then catalyse reactions converting AA into prostaglandin (PG) D2, 
PGE2, PGF2α, prostacyclin (PGI2) or thromboxane (TXA). The prostaglandins are transported 
out of the cell by a prostaglandin transporter (PGT) and act in a paracrine or autocrine 
manner on their corresponding G-protein coupled receptors and activate the second 
messengers inositol trisphosphate (IP3), calcium (Ca
2+
) or cAMP and subsequent 
downstream events. Adapted from Jabbour et al. 2004. 
 
 
The COX enzyme exists in two main isoforms, COX-1 and COX-2. COX-1 
expression varies little throughout the body and is considered a constitutive enzyme. 
However, COX-2 can be regulated by growth factors, cytokines, and mechanical 
stress (Morita 2002). COX-2 expression is also increased in many cancer types 
including endometrial adenocarcinoma (Tong et al. 2000; Jabbour et al. 2001) and in 
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inflammation (Morita 2002). COX-1 expression is not altered in endometrial 
adenocarcinoma (Tong et al. 2000), however upregulation has recently been 
demonstrated in other cancer types including cervical cancer (Sales et al. 2002). 
 
In the female reproductive tract, the COX enzymes and prostaglandins play an 
important role. The COX-2 knockout mouse (but not COX-1) displays reproductive 
failures at the stages of ovulation, fertilisation, implantation and decidualisation (Lim 
et al. 1997). Mice lacking the FP and EP receptors have demonstrated that these 
prostaglandins play an important role in reproduction. Knock out of EP2 results in 
mice which are infertile due to defects in ovulation (Kennedy et al. 1999; Tilley et al. 
1999) and fertilisation (Hizaki et al. 1999). The FP receptor also plays a key role in 
reproduction, as demonstrated by the FP knock out mouse. Despite a normal estrous 
cycle and early pregnancy, the FP receptor knock out mouse fails to undergo 
parturition, due to a failure to initiate luteolysis which normally decreases 
progesterone levels (Sugimoto et al. 1997). PGF2α is a smooth muscle contractant, 
and can induce contractions in the uterus and vasculature which may also play a role 
in parturtion (Senior et al. 1992). In the human endometrium, expression of COX-2 
(Jones et al. 1997; Uotila et al. 2002) and FP receptor increases in the proliferative 
phase of the cycle (Milne et al. 2003). As described in section 1.2.1.1, this is 
coincident with a period of angiogenesis, and prostaglandin signalling through these 
receptors has been demonstrated to increase the expression of angiogenic factors in 
endometrial cells including FGF and VEGF (Sales et al. 2004; Sales et al. 2005; 
Sales et al. 2007). 
1.4.3 The FP receptor 
The human FP receptor was originally characterised in tissues such as myometrium 
and corpus luteum by pharmacological and functional assays studying parameters 
including binding affinity (Powell et al. 1976; Senior et al. 1992). It was cloned in 
1994 by Abramovitz et al (Abramovitz et al. 1994), and determined to be made up of 
359 amino acid residues. FP is a Gq-protein coupled receptor activating IP3 and 
calcium as second messengers (Davis et al. 1987; Black et al. 1990). In sheep, a 
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functional splice variant of the FP receptor able to activate IP3 was cloned in 1997 
(Pierce et al. 1997). More recently, six isoforms of the FP receptor have been 
detected in human tissues such as heart and placenta, named altFPs (Vielhauer et al. 
2004; Liang et al. 2008). These splice variants show no detectable activity and do not 
bind PGF2α alone, however can form heterodimers with the FP receptor which result 
in IP3 and calcium accumulation. As yet the signalling implications of this are 
unclear (Liang et al. 2008). Similarly to most GPCRs, continued PGF2α signalling 
can result in FP internalisation (Srinivasan et al. 2002), and FP has been 
demonstrated to localise to plasma membrane, cytoplasm and the nuclear envelope in 
some cell types (Milne et al. 2003; Schlotzer-Schrehardt et al. 2002). PGF2α can also 
bind with low affinity to the EP1 and EP3 receptors (Kiriyama et al. 1997), and 
PGD2 can bind with low affinity to FP (Abramovitz et al. 1994). 
 
Numerous physiological functions have been reported as a result of FP receptor 
signalling. In FP-transfected HEK-293 cell lines, PGF2α signalling leads to re-
organisation of the cell cytoskeleton, indicating FP signalling can lead to changes in 
cell morphology and movement (Pierce et al. 1999). Additionally, FP activation has 
been demonstrated to perturb cell cycle progression by delaying progression into 
mitosis, and extended activation generated aneuploidy (Chen et al. 2006). In this cell 
type, FP receptor signalling activates the ERK signalling cascade (Xu et al. 2008) 
which can then activate cross-talk with β-catenin signalling (Xu et al. 2008; Xu et al. 
2009). 
  
Deregulated PGF2α-FP signalling has been shown to contribute to endometrial 
pathologies including dysmenorrhoea and endometriosis. In dysmenorrhoea, elevated 
PGF2α levels are present in menstrual fluid (Stromberg et al. 1984), which may play a 
role in affecting the vasculature and contractions of the uterus. Women with 
endometriosis, the growth of endometrial tissue outside of the uterine cavity, have 
increased COX-2 (Ota et al. 2001) and PGF2α metabolite expression (Sharma et al. 
2009), which may be resulting in the high levels of angiogenic factors seen in the 
peritoneal fluid (Gazvani et al. 2002). The FP receptor is expressed in prostate cancer 
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(Krishnan et al. 2007) and recent data from our laboratory have demonstrated that  
FP receptor expression is elevated in endometrial adenocarcinoma (Sales et al. 2004; 
Sales et al. 2005). COX-2 is also increased in endometrial adenocarcinoma, and an 
upregulation of COX-2 has been associated with mutated PTEN and NFκB 
expression in endometrial adenocarcinoma cell lines, linking genetic mutations to 
increased inflammation driven by the prostaglandins (St-Germain et al. 2004). One 
of the downstream effects of FP signalling is an increase in COX-2 expression 
(Fujino et al. 2003), therefore this positive feedback loop may amplify PGF2α 
signalling in endometrial adenocarcinoma (Jabbour et al. 2005). 
 
In endometrial adenocarcinoma, the increase in COX-2 and FP receptor expression 
leads to the activation of a number of signalling pathways which results in the 
upregulation of angiogenic genes. For example, the expression of VEGF (Sales et al. 
2005) and FGF2 (Sales et al. 2007) is upregulated in endometrial adenocarcinoma 
cell lines and tissue explants after PGF2α-FP receptor signalling. This was shown to 
be dependent on ERK1/2 trans-activation by the EGFR (Sales et al. 2004; Sales et al. 
2005; Sales et al. 2007). PGF2α activation of its receptor also promotes proliferation, 
adhesion and migration of endometrial adenocarcinoma cells (Milne et al. 2003; 
Sales et al. 2008), demonstrating that it may promote tumourigenesis of endometrial 
adenocarcinoma by a number of mechanisms. A summary of FP receptor signalling 
in endometrial adenocarcinoma is given in Figure 1.8. 
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Figure 1.8 Schematic representation of FP receptor signalling in endometrial 
adenocarcinoma cells. PGF2α signalling activates the FP receptor, which is coupled to Gq 
and activates IP3 and calcium (Ca
2+
) as second mesengers. A c-Src and MMP mediated 
mechanism then cleaves heparin-binding EGF (HB-EGF) which transactivates the EGFR 
and begins the ERK phosphorylation cascade leading to the transcription of genes involved 
in angiogenesis (VEGF and FGF), proliferation and migration (adhesion, invasion and 
metastases). FP receptor signalling can also upregulate expression of COX-2, leading to the 
formation of PGF2α which is transported out of the cell by a prostaglandin transporter (PGT) 
and completes the autocrine signalling pathway. Adapted from Jabbour et al. 2006. 
 
1.4.4 The FP receptor and inflammation  
Prostaglandins are potent inflammatory mediators. The NSAIDs used to inhibit 
inflammation are COX-2 inhibitors, and therefore used to prevent prostaglandin 
formation (Cha et al. 2007). The COX-2 knock out mouse displays an altered 
inflammatory response, with a decreased leukocyte response to areas of necrosis 
(Dinchuk et al. 1995). In endometrial adenocarcinoma the activation of the 
transcription factor NFκB, which is associated with inflammatory pathways, 
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upregulates COX-2 expression and therefore prostaglandin formation in response to 
inflammation (St-Germain et al. 2004). The hormonal change to a low progesterone 
to oestrogen ratio associated with endometrial adenocarcinoma development may 
also promote prostaglandin formation and inflammation, as progesterone is able to 
inhibit inflammatory-induced PGF2α expression (Ishihara et al. 1995). 
 
As well as being activated by inflammation, PGF2α – FP receptor signalling can 
promote an inflammatory environment. Angiogenic factors produced by PGF2α – FP 
signalling can lead to tissue remodelling, which is one aspect comprising an 
inflammatory microenvironment (Colotta et al. 2009). Additionally, the expression 
of cytokines including IL-6 and IL-8 can be regulated by PGF2α – FP signalling 
(Noguchi et al. 2001; Chang et al. 2009). Aspects of cytokine signalling in 
inflammation and cancer including leukocyte recruitment and tissue remodelling will 
be discussed in the next section. 
 
1.5 Cytokines and chemokines 
Cytokines are small peptides (approximately 8 kDa) released by cells that have 
numerous functions including acting as growth signals and chemotactic agents. 
Chemokines are a subfamily of cytokines, so named for their chemoattractant 
properties. The chemokine family is divided into four groups based on the position of 
two cysteine molecules (C) and any other amino acid (X) in the amino terminal of 
the protein. The groups are known as C, C-C, C-X-C and C-X3-C (Murphy et al. 
2000). The C-X-C family is further subdivided into ELR (glutamine-leucine-
arginine) positive or negative chemokines, dependent on the presence or absence of 
this amino acid motif. ELR+ chemokines have angiogenic properties, whilst ELR- 
chemokines are angiostatic (Strieter et al. 1995). Chemokines bind to GPCRs to 
activate signalling, and these receptors are present on immune cells as well as on 
cells making up other tissues of the body (Murphy et al. 2000). A link between 
prostaglandins and chemokines has been previously demonstrated further to the 
expression of chemokines mediated by FP receptor signalling, as COX-2 expression 
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has been colocalised with interleukin-8 and MCP-1 in the normal endometrium 
(Jones et al. 1997). COX-2 has also been colocalised with the expression of 
chemokines promoting leukocyte infiltration in bladder cancer (Chen et al. 2009).  
1.5.1 Cytokines and chemokines in the normal endometrium 
Cytokines and chemokines produced throughout the normal menstrual cycle are 
thought to be involved in tissue remodelling of the endometrium as well as the 
control of leukocyte influx (Kelly et al. 2001). These features mean that menstruation 
resembles an inflammatory process, in which chemokines play a major part 
(Critchley et al. 2001). The endometrial stroma is made up of a mixture of cells, 
including macrophages, neutrophils, natural killer (NK) cells and lymphocytes.  
 
During the proliferative phase, a number of angiogenic chemokines are produced by 
the endometrium which may contribute to the large amount of vascular remodelling 
that occurs at this phase of the cycle. These include ELR+ chemokines such as 
interleukin-8, which is expressed in the epithelial cells (Arici et al. 1998) and in peri-
vascular cells (Critchley et al. 1994). MCP-1 is also produced in the stroma and 
perivascular cells (Jones et al. 1997). CCL-5 (also known as RANTES) is 
chemotactic for monocytes and activated T cells, and is expressed in the proliferative 
endometrial stroma (Hornung et al. 1997). The upregulation of these cytokines 
causes the relatively low infiltration of macrophages and neutrophils seen at this 
stage of the cycle (Kelly et al. 1994). Macrophages secrete a range of angiogenic 
factors (Lin et al. 2006) which includes VEGF in the endometrium (Gargett et al. 
2001), while the neutrophils at this stage of the cycle are observed adjacent to the 
vasculature and produce VEGF, and therefore may be involved in vascular 
remodelling of the endometrium (Gargett et al. 2001). 
 
The early secretory phase is characterised by a rise in progesterone levels, and as 
progesterone is anti-inflammatory it suppresses the production of chemokines in the 
endometrium at this stage. A marked decrease in IL-8 and MCP-1 expression is 
observed (Jones et al. 1997). However during the mid secretory phase, also known as 
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the window of implantation, a number of cytokines are upregulated to aid 
implantation, including IL-11 (Dimitriadis et al. 2000), LIF (Cullinan et al. 1996) 
and IL-6 (Tabibzadeh et al. 1995). These factors are thought to aid adhesion of the 
blastocyst to the endometrium (Marwood et al. 2009). A gene array carried out at the 
mid secretory phase of the menstrual cycle demonstrated the chemokines including 
MCP-3 and MIP-1β that are present in the endometrium at this stage of the cycle 
(Jones et al. 2004). These may also play a role in chemoattraction of the trophoblast 
cells, however as no chemokine or chemokine receptor knock out mouse has yet 
displayed a reproductive phenotype, there may be a high degree of redundancy 
between these chemokines (Power 2003).  
 
 In the late secretory phase, the decrease in progesterone concentrations caused by 
the breakdown of the corpus luteum results in a further rise in chemokine expression 
(Jones et al. 1997). A large population of uNK cells appears in the stroma of the 
endometrium (King et al. 1989). This is coincident with the increase of a number of 
cytokines which may chemoattract uNK cells, including IL-15 (which also promotes 
their proliferation), macrophage inflammatory protein-1α (Kitaya et al. 2003), and 
MCP-1 (Jones et al. 1997). At this stage in the cycle, and during the menstrual phase, 
most chemokine production is driven by leukocytes (Jones et al. 2004). At 
menstruation degradation of the extracellular matrix occurs, mediated partly by 
chemokines and leukocytes. This has been demonstrated by the irregular endometrial 
breakdown and repair in a mouse model deficient in neutrophils (Kaitu'u-Lino et al. 
2007). MIP-1α is released from the glandular epithelium which promotes infiltration 
of macrophages, which may contribute to the tissue destruction and promotion of 
apoptosis seen at menstruation (Akiyama et al. 1999). Therefore chemokine 
expression and leukocyte infiltration is a normal inflammatory process in the 
menstrual cycle, which may become deregulated in endometrial adenocarcinoma.  
1.5.2 Chemokines in cancer 
The upregulation and tumour-promoting effects of chemokines have been 
demonstrated in several types of cancer, including prostate, ovarian and breast 
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(Moore et al. 1999; Yang et al. 2006 ; Yao et al. 2007; Ghadjar et al. 2008). 
Originally, the role of chemokines in cancer was thought to be restricted to the 
chemo-attraction of immune cells, however recent evidence has demonstrated that 
chemokines also promote cell proliferation, cell migration and angiogenesis (Strieter 
et al. 2006). This can lead to extensive tissue remodelling and inflammation, 
contributing to tumour progression (Mantovani et al. 2008). A number of 
chemokines are upregulated in different cancers, however the key chemokines that 
are focused on in this thesis are chemokine (C-X-C) motif ligand 1 (CXCL1) and 
chemokine (C-C) motif ligand 20 (CCL20). 
1.5.2.1 CXCL1 
CXCL1 (also known as growth-regulated oncogene α) is an ELR+ member of the C-
X-C family of chemokines with potent angiogenic, chemoattractant and 
inflammatory activities (Strieter et al. 2006). CXCL1 mRNA expression has 
previously been documented in stromal cells of the normal endometrium (Nasu et al. 
2001) however its expression and localisation in endometrial adenocarcinoma has 
not previously been described. CXCL1 was first identified in the conditioned 
medium of a malignant melanoma cell line and named melanoma growth-stimulatory 
activity (Richmond et al. 1985), and has since been shown to be produced by several 
cancer types. The proteins CXCL2 and CXCL3 were subsequently isolated, and 
demonstrated to have 90% and 86% sequence homology respectively to CXCL1 
(Haskill et al. 1990). CXCL1 binds to the CXCR2 receptor (Addison et al. 2000) to 
promote the recruitment of neutrophils to sites of inflammation (Moser et al. 1990). 
CXCR2 signalling can be inhibited by pertussis toxin, suggesting coupling to Gi/0 
(Hall et al. 1999). CXCL2 and CXCL3 also bind to CXCR2, however whether they 
play a similar role in cancer to CXCL1 is unclear. CXCL2 may have contrasting 
functions as it has been demonstrated to be a negative regulator of epithelial cell 
growth in colon cancer (Li et al. 2004). CXCL3 promotes melanoma growth in a 
nude mouse model (Haghnegahdar et al. 2000) and is correlated with invasiveness in 
prostate cancer (Engl et al. 2006), and therefore may perform a similar function to 
CXCL1.  
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CXCL1 contributes to cancer growth in different ways, and due to the presence of 
the ELR motif one such mechanism is angiogenesis. In prostate cancer, CXCL1 
expression is increased (Moore et al. 1999). In an in vivo model of prostate cancer, 
this increase was shown to contribute to tumour growth by increasing angiogenesis 
(Moore et al. 1999). CXCL1 also promotes angiogenesis in colorectal cancer (Wang 
et al. 2006) and melanoma (Haghnegahdar et al. 2000; Singh et al. 2009). Its 
expression is also upregulated as compared to normal tissue in both of these cancer 
types (Li et al. 2004; Haghnegahdar et al. 2000; Wen et al. 2006; Rubie et al. 2008). 
An increase in expression of CXCR2 can also promote tumour progression, as 
demonstrated by the decreased angiogenesis and tumour growth displayed in lung 
cancer xenografts of cell lines deficient in CXCR2 (Keane et al. 2004). 
 
CXCL1 has also been described to perform other functions in cancer. In bladder 
cancer, CXCL1 expression is increased and associated with greater invasive ability 
(Kawanishi et al. 2008), and the increased expression in colon cancer is also 
associated with metastasis (Li et al. 2004). This may be attributable to its ability to 
downregulate the expression of fibulin-1, an extracellular matrix protein, in a colon 
cancer cell line, thus promoting migration (Wen et al. 2006). CXCL1 can also 
increase proliferation of cancer cells. It is upregulated in oesophageal cancer and acts 
via an autocrine signalling pathway to promote cell proliferation (Wang et al. 2006; 
Wang et al. 2009). In ovarian cancer xenografts, CXCL1 promotes cell proliferation 
via paracrine signalling to stromal fibroblasts (Yang et al. 2006). Interaction between 
CXCL1 and p53 has recently been demonstrated, as mutant p53 can bind to the 
CXCL1 promoter and increase CXCL1 expression in colon cancer cell lines (Yan et 
al. 2009). Several cell signalling pathways are involved in the induction of CXCL1 in 
different cancer types including ERK 1/2 (Wang et al. 2000; Wang et al. 2006; Yang 
et al. 2006) and p38 MAPK- NFκB signalling (Ward et al. 1999).  
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Chemokines are also potent immune cell attractants. CXCR2 is expressed highly on 
neutrophils and at lower levels on monocytes and macrophages (Murphy et al. 2000). 
The functions of immune cells in cancer will be discussed in Section 1.6.  
1.5.2.2 CCL20 
CCL20 (also known as macrophage inflammatory protein-3α) is a member of the 
CC-family of chemokines. CCL20 binds to the CC-receptor 6 (CCR6), a Gq-protein 
coupled receptor (Al-Aoukaty et al. 1998) that is expressed on dendritic cells, B and 
T lymphocytes, and tissues including spleen, lymph nodes, appendix and pancreas. 
CCL20 is the only chemokine known to interact with the CCR6 receptor (Schutyser 
et al. 2003). 
 
Similarly to CXCL1, the expression of CCL20 and CCR6 has been described in 
several different types of cancer. CCL20 is over-expressed in cancers of the colon 
(Brand et al. 2006) liver (Rubie et al. 2006), pancreas (Campbell et al. 2005), 
prostate (Ghadjar et al. 2008) and Hodgkins lymphoma (Baumforth et al. 2008). The 
receptor CCR6 is also upregulated in colon (Brand et al. 2006), liver 
(Dellacasagrande et al. 2003) and prostate cancer (Ghadjar et al. 2008).  
 
Within these cancer types, CCL20-CCR6 signalling has been proposed to influence 
epithelial cell migration or metastasis (Dellacasagrande et al. 2003; Campbell et al. 
2005; Rubie et al. 2006) and proliferation (Brand et al. 2006; Beider et al. 2009). In 
pancreatic cancer tissue, CCL20 and CCR6 were co-localised to the same cells, and 
in a pancreatic cancer cell line this autocrine signalling caused a significant increase 
in cell invasion (Kimsey et al. 2004). This was discovered to be dependent on an 
upregulation of MMP-9 by CCL20-CCR6 signalling (Campbell et al. 2005). 
Increased migration was also demonstrated in colorectal cancer cells after autocrine 
CCL20-CCR6 signalling (Brand et al. 2006). Increased invasiveness and metastasis 
were also associated with CCL20 or CCR6 expression in nasopharyngeal cancer 
(Chang et al. 2008), prostate cancer (Ghadjar et al. 2008) and liver cancer (Rubie et 
al. 2006). 
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CCR6 expression can influence metastasis in some cancer types. Increased CCR6 
expression in plasmacytoma cells in a mouse model led to a higher incidence of liver 
metastasis. This was found to be due to the high levels of CCL20 production by the 
liver causing migration of cancer cells towards this chemokine gradient, in a similar 
mechanism to chemoattraction of immune cells (Dellacasagrande et al. 2003). This 
mechanism has also been proposed as the reason for the high number of patients with 
colorectal cancer presenting with liver metastasis (Ghadjar et al. 2006). 
 
CCL20 has been demonstrated to be regulated by the NFκB (Harant et al. 2001) and 
NFAT family of transcription factors (Pietila et al. 2007). It can also be induced via 
an ERK signalling pathway (Sandri et al. 2008; Kanda et al. 2009). 
 
The expression of CCL20 has been described in an endometrial epithelial cell line 
and more recently primary endometrial epithelial cells (Ghosh et al. 2009), as well as 
primary endometrial stromal cells (Sun et al. 2002). Its expression in endometrial 
adenocarcinoma has previously been identified by a gene array comparing normal 
endometrium with adenocarcinoma samples (Wong et al. 2007). 
1.6 Leukocytes in cancer 
Chemokines control the influx of leukocytes into tumours. Leukocytes are a hallmark 
of inflammation, as well as promoters of inflammation and Virchow‟s original 
observation that cancer and inflammation may be linked was based on the 
observation of leukocytes in tumours (Balkwill et al. 2001). The tumour 
microenvironment is commonly infiltrated by several types of leukocyte including 
macrophages, neutrophils, T and B lymphocytes, natural killer (NK) cells and 
dendritic cells, and these have been shown to play contrasting roles in tumour 
promotion and destruction (de Visser et al. 2006).  
 
The immune system is composed of adaptive immune cells, comprising B and T 
lymphocytes, and innate immune cells including mast cells, dendritic cells, NK cells, 
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macrophages and neutrophils. Immune cells monitor the body for disturbances such 
as tissue injury. The first response at a site is often the release of proteases, reactive 
oxygen species and cytokines by macrophages and mast cells which chemoattract a 
further innate immune response. Dendritic cells then migrate to the lymph nodes to 
present antigen to the adaptive immune system. B cells, CD4+ helper T cells and 
CD8+ cytotoxic T cells respond by expressing antigen-specific receptors and 
clonally expanding to target the disturbance. Inflammation then resolves and the 
tissue recovers, by pathways partly mediated by immune cells (Roitt et al. 2000).  
 
A popular model of immune cell infiltration into tumours is similar to this system. It 
proposes that the first types of immune cell to infiltrate a tumour are those of the 
innate immune system which are chemo-attracted by pro-inflammatory cytokines 
secreted by the cancerous cells. After the initial infiltration of cells of the innate 
immune system, the activation of antigen presenting cells such as dendritic cells may 
result in the recruitment of cells of the adaptive immune system such as T and B 
lymphocytes to the tumour (de Visser et al. 2006). This model of infiltration into 
cancer is depicted in Figure 1.9. 
 
The discovery of cells of the immune system within solid tumours originally led to 
the hypothesis that immune cells were attacking and destroying the tumour, and may 
eventually be used in cancer immunotherapy (Dirkx et al. 2006). This may be true in 
some cases, as some studies have shown that immune-compromised patients, for 
example AIDS and organ transplant patients, have a higher risk of hodgkins 
lymphoma (Clifford et al. 2009) and tobacco and alcohol related cancers of the lung, 
oesophagus, head and neck, and pancreas (Clifford et al. 2005; Herrero et al. 2005). 
Additionally, in some studies an infiltration of immune cells, particularly NK or T 
cells, into cancer is associated with an improved prognosis (Coca et al. 1997; 
Ishigami et al. 2000). There is also good evidence that these lymphocytes can 
contribute to tumour cell destruction by cell-mediated cytotoxicity (Nishimura et al. 
1999), for example transgenic mice predisposed to cervical cancer show a decreased 
risk of development when an enhanced CD4+ T cell response is present (Daniel et al. 
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2005). Additionally, mice lacking cytotoxic T cells have an approximately four fold 
greater risk of skin cancer (Girardi et al. 2001). However, paradoxically tumours are 
often infiltrated by regulator T cells which can suppress these adaptive immune 
responses (Giatromanolaki et al. 2008). 
 
However, a large body of evidence suggests that chronically activated innate immune 
cells can promote tumour growth, angiogenesis and cell migration (Murdoch et al. 
2008). In endometrial cancer, the infiltration of macrophages (Salvesen et al. 1999; 
Ohno et al. 2004), natural killer cells (Hachisuga et al. 1997) and B and T 
lymphocytes (Yamazawa et al. 2001; Chang et al. 2005; Ohno et al. 2005; Ohno et 
al. 2006; Miyatake et al. 2007; Giatromanolaki et al. 2008) has previously been 
reported. The two cytokines discussed in this thesis activate receptors that are 
expressed on different immune cells. CXCL1 binds to CXCR2 which is expressed 
primarily on neutrophils, but also on monocytes (Weber et al. 1999; Traves et al. 
2004; Smith et al. 2005). CCL20 signalling plays an important role in the 
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Figure 1.9 A model of immune cell infiltration into cancer. At cancer initiation, 
cytokines secreted by tumour cells chemoattract cells of the innate immune system. These 
produce a number of tumour promoting factors. Tumour antigens are also taken up by 
dendritic cells which activate adaptive immune responses by T and B lymphocytes, which 
often occur after the initial infiltration of innate immune cells. These mount cytotoxic 
responses against the tumour. Adapted from de Visser et al. 2006. 
1.6.1 Macrophages 
The most common infiltrating immune cell into cancer is often the macrophage 
(Dirkx et al. 2006). Tumour associated macrophages (TAM) are increased in 
endometrial adenocarcinoma (Hachisuga et al. 1997; Salvesen et al. 1999) as well as 
other cancer types including colon (Forssell et al. 2007), breast (Bingle et al. 2006), 
bladder (Chen et al. 2009) and melanoma (Hussein 2006). Macrophages show high 
plasticity, and subpopulations promoting tumour progression in different ways have 
been identified, for example the TIE2 subset expressing the angiopoietin receptor 
(Venneri et al. 2007). This plasticity may also be the reason for contrasting reports of 
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TAM both promoting and reducing tumour growth (Saccani et al. 2006; Forssell et 
al. 2007). However increased TAM are often associated with a poor prognosis 
(Salvesen et al. 1999; Yang et al. 2007), and primarily TAM are thought to 
contribute to angiogenesis within cancers. Macrophages secrete factors such as 
VEGF and angiopoetins which increase angiogenesis (Nesbit et al. 2001; Bingle et 
al. 2006; Venneri et al. 2007) and have been shown to be essential for the initiation 
of angiogenesis in breast cancer (Lin et al. 2007). Macrophages can also promote 
tumour invasion and metastasis, through the secretion of proteases including MMP12 
and MMP-9 (Luo et al. 2006; Yang et al. 2007). 
1.6.2 Neutrophils 
Neutrophil infiltration contributes to tumour promotion in similar ways to 
macrophage infiltration; by the production of a number of angiogenic factors and 
proteases which can impact on tissue remodelling and inflammation. Neutrophils 
produce angiogenic factors including VEGF and FGF (Gargett et al. 2001; Scapini et 
al. 2004; Ai et al. 2007), and promote invasion and metastasis through the production 
of proteases including MMP-9 (Ardi et al. 2007). In a nude mouse model of breast 
cancer, an increased infiltration of neutrophils increased invasiveness of the tumour, 
likely due to protease production (Yao et al. 2007). In addition, the depletion of 
neutrophils in mouse models of fibrosarcoma and colon cancer significantly 
decreased metastasis in these animals (Tazawa et al. 2003; Yamamoto et al. 2008). 
However neutrophils may also promote tumourigenesis through means other than 
tissue remodelling. In an in vitro model of colon cancer, neutrophils promote cellular 
stress by inducing transient errors in DNA replication in epithelial cells (Campregher 
et al. 2008), which could ultimately lead to carcinogenesis. Neutrophils from ovarian 
cancer patients released higher levels of reactive oxygen species which could 
potentially promote cellular changes which support tumour progression (Klink et al. 
2008).   
 
Some evidence suggests that neutrophil secreted products may decrease tumour 
growth in some circumstances. For example, neutrophils produce the protease 
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neutrophil elastase. This has been demonstrated to cleave plasminogen to activate the 
anti-angiogenic factor angiostatin, which inhibited VEGF and FGF induced 
angiogenesis in vitro. However this only occurred at increased concentrations of 
elastase (Scapini et al. 2002). Neutrophil elastase has also been shown to directly 
degrade VEGF and FGF, and the incubation of neutrophil elastase with these factors 
decreased their angiogenic ability in the aortic ring assay in vitro (Ai et al. 2007). 
This action of neutrophil elastase may represent a feedback to the angiogenic factors 
being produced by neutrophils, and it is unclear if this mechanism is occurring in 
cancer.  
1.6.3 B Cells 
B cells are capable of producing antibody against tumour antigens (Roitt et al. 2000). 
However, the serum proteins secreted by B cells can chemoattract innate immune 
cells, and therefore may promote chronic inflammation and tumour progression 
(Hoebe et al. 2004). Indeed, elimination of B and T cells in a mouse model reduced 
innate immune cell infiltration into developing tumours and levels of tumourigenic 
factors including VEGF and MMP9. This caused a decrease in tumour growth. Re-
introduction of B cells restored the infiltration of innate immune cells and 
angiogenesis to control levels (de Visser et al. 2005). As low levels of B cells are 
usually found in tumours (de Visser et al. 2006), their role in these tissues has not 
been extensively studied. 
1.6.4 T cells 
T cells are divided into CD4+ or CD8+ cells, on the basis of the presence or absence 
of these surface antigens. Broadly speaking, CD4+ T cells interact with B cells to 
activate proliferation and antibody production, CD8+ T cells to facilitate 
differentiation, or macrophages to promote inflammatory cytokine production. CD8+ 
T cells are cytotoxic, and can induce the death of cells infected with pathogens, or 
tumour cells by cell to cell interactions or secreted factors (Roitt et al. 2000). In 
cancer, most evidence indicates that T cells are anti-tumourigenic. For example, 
CD4+ and CD8+ T cells have been demonstrated to eradicate tumours from mouse 
Chapter 1                                                                                           Literature Review  
45 
models of cancer though production of cytokines and directly adhering to tumour 
cells (Nishimura et al. 1999). The role played by CD4+ cells however appears to be 
dependent on the environment of the tumour and cancer model used (Ellyard et al. 
2007). For example, subsets of CD4+ T cells can be activated in different cancer 
types. Regulatory FOXP3-expressing CD4+ T cells are one such subset which can 
suppress T cell population expansion and cytotoxicity. These are associated with 
increased microvascular density and angiogenic factors including VEGF in 
endometrial adenocarcinoma (Giatromanolaki et al. 2008). A low infiltration of this 
subset of lymphocytes has also been associated with increased survival in 
endometrial adenocarcinoma (Kondratiev et al. 2004). Different cytokines may also 
be produced by CD4+ T cells dependent on the tumour environment, which can play 
different roles in chemoattraction of innate immune cells such as macrophages 
(Badoual et al. 2006).  
 
A low infiltration of CD8+ T cells has been associated with poor prognosis in 
endometrial adenocarcinoma (Ohno et al. 2005), and similarly a high CD8+ cell 
infiltration has been correlated with an increased survival rate (Kondratiev et al. 
2004; de Jong et al. 2009), demonstrating that CD8+ infiltration may be destructive 
to the tumour. CD8+ T cells can eradicate mouse mammary tumours in the absence 
of CD4+ T cells (Ostrand-Rosenberg et al. 2000). The tumour-destroying properties 
of CD8+ T cells may be inhibited by not only the regulatory T cells described above, 
but also but other innate immune cells, for example the production of indoeamine 
dioxygenase  by innate immune cells decreases T cell proliferation and promotes 
their apoptosis (Bronte et al. 2003). Therefore the plasticity of T cells may be 
modulated by innate immune cells already present within the tumour, to promote a 
pro-tumourigenic environment. 
1.6.5 NK cells 
NK cells are lymphocytes yet are components of the innate immune system. NK cells 
distinguish the loss of antigen, and can recognise tumour cells by the loss of MHC 
class I expression (Zamai et al. 2007). Upon recognition, NK cells secrete a variety 
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of lytic factors from specialised granules, able to lyse and promote apoptosis of 
targeted tumour cells. Therefore presence of NK cells in a tumour is likely to 
decrease tumour growth (Zamai et al. 2007). In a mouse model of fibrosarcoma, low 
NK cell infiltration was observed, which was due to secreted factors including 
granulocyte macrophage colony-stimulating factor (GM-CSF), IL-3 and IL-6 from 
the tumour impairing the maturation of NK cells (Richards et al. 2008). In an 
alternative mouse model of sarcoma, complete depletion of NK cells led to an 
increased rate of tumour initiation (Smyth et al. 2001). Additionally, NK cells can 
contribute to tumour destruction by the production of anti-angiogenic factors, 
including interferon-γ (Hayakawa et al. 2002). 
1.6.6 Dendritic cells 
Dendritic cells are the main antigen presenting cells of the immune system, which 
infiltrate tissues as immature cells. Upon the uptake of antigen and in response to 
inflammatory stimuli they differentiate into mature dendritic cells capable of 
activating lymphocytes (Schutyser et al. 2003). In cancer, increased numbers of 
immature dendritic cells in the tumour has been demonstrated to promote immune 
tolerance to the tumour. Immature dendritic cells taken from the tumour of a mouse 
model of colon cancer induced lower levels of T cell clonal expansion than mature 
dendritic cells (Bonnotte et al. 2004). It is possible that factors derived by the tumour 
promote dendritic cell immaturity or inhibit differentiation. For example VEGF 
(Gabrilovich et al. 1998) and the overexpression of CCL20 by colon cancer cells has 
been demonstrated to preferentially recruit immature dendritic cells in vitro (Wang et 
al. 2008). Similarly to other leukocytes discussed here, dendritic cells can also 
produce a host of angiogenic factors, including VEGF (Fainaru et al. 2008). 
 
1.7 Other lipid mediators and their interactions with prostaglandins: 
Lysophophatidic acid 
In a physiological setting, signalling cascades are unlikely to function alone without 
interaction and cross-talk with other cascades. Other lipid mediators which have been 
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demonstrated to play a role in cancer signalling are those derived from 
lysophospholipids, of which the main ligands are sphingosine-1-phosphate (S1P), 
lysophosphatidic acid (LPA), sphingosylphosphorylcholin, psychosine, sphingosine 
and lysophosphatidylcholine (Graler et al. 2002). The two most extensively studied 
lipid mediators are LPA and S1P. There is evidence that S1P promotes numerous 
functions in cancer including angiogenesis, invasion, proliferation and evasion of 
apoptosis (Visentin et al. 2006). However due to the proven importance of LPA in 
the reproductive system (Ye 2008) and in cancer (Mills et al. 2003) this thesis will 
concentrate on only the role of LPA in endometrial adenocarcinoma. 
 
LPA is a water-soluble phopholipid that acts as an important extracellular signalling 
molecule. Its actions as a bioactive lipid were first discovered 30 years ago when it 
was shown to induce muscle contraction and platelet aggregation (Mills et al. 2003). 
LPA was postulated to signal through a GPCR, however this was not confirmed until 
1996 when the first LPA receptor was cloned form neuroblast cells lines (Hecht et al. 
1996), and renewed interest in this phopholipid began. LPA is formed by two main 
metabolic pathways, and appears to be formed extracellularly as well as 
intracellularly by the action of secreted enzymes. In the first pathway, the choline 
from lysophosphatidylcholine is removed to form lysophospholipids by autotaxin 
(ATX; also known as lysophospholipase D) then LPA is formed by phospholipase 
A1/2 (PLA1/2) (Tokumura et al. 1999; Aoki et al. 2002). In the second pathway, 
LPA is converted from phosphatidic acid by removal of a fatty acid chain by PLA1/2 
(Aoki et al. 2002). Therefore, the availability of these enzymes also determines in 
some part the amount of LPA signalling within a cell. ATX was originally 
discovered as a melanoma-secreted factor (Stracke et al. 1992) and has now been 
shown to be increased in cancers including endometrial and lung (Yang et al. 1999; 
Tokumura et al. 2007). It promotes metastasis, invasion and angiogenesis, although 
whether this is via a direct effect on endothelial cells or on the tumour 
microenvironment is unknown (Nam et al. 2001). 
 
Chapter 1                                                                                           Literature Review  
48 
LPA signalling mediates a diverse range of actions, which may depend on the GPCR 
which is activated. Seven GPCRs have now been identified and named LPAR1-7 
(Murph et al. 2008). LPAR1-3 (which used to be known as endothelial 
differentiation gene 2, EDG4 and EDG7) are widely expressed in the body, while 
LPAR4-7 have limited expression and as yet unknown functions (Murph et al. 2006). 
LPAR 1-3 share high sequence homology with each other (48.8 – 53.7%; (Bandoh et 
al. 1999) but less than 20% homology with LPAR 4-7 (Murph et al. 2008).  
 
LPAR-1 was cloned in 1996 from a neuroblast cell line, and identified as a GPCR for 
LPA by its signalling properties, and ability to be inhibited by pertussis toxin (Hecht 
et al. 1996). LPAR1 has been shown to couple with Gi/o, Gq and G12/13 (Hecht et al. 
1996; Fukushima et al. 1998; Ishii et al. 2000). The coupling G-protein and 
subsequent signalling pathways activated may differ depending on the cell type and 
model used. LPAR1 expression is widespread throughout the body, with the 
exception of the liver (An et al. 1998). LPA-LPAR1 signalling has been shown to 
activate common GPCR-coupled signalling pathways including NFκB (Chen et al. 
2008) and ERK 1/2 (Shin et al. 2009).  
 
LPAR2 was discovered in 1997 by a GenBank search based on the sequence of 
LPAR1 (An et al. 1998). LPAR2 also couples to Gi/o, Gq and G12/13 (Ishii et al. 2000). 
In contrast to the widespread location of LPAR1, LPAR2 is expressed in a smaller 
number of tissues, including leukocytes, testis, prostate thymus and kidney (An et al. 
1998). Due to the promiscuous G-protein coupling, LPAR2 also activates a range of 
signalling pathways including ERK1/2 (Yun et al. 2005). 
 
LPAR3 was similarly identified by sequencing an unknown gene after amplification 
based on the sequences of LPAR1 and 2 (Bandoh et al. 1999). LPAR3 also couples 
to Gi/o and Gq, but not G12/13 (Bandoh et al. 1999; Ishii et al. 2000). This difference in 
coupling results in some functional differences, such as the promotion of cell 
rounding by Rho activation which is shared by LPAR1 and 2 but not 3 (Ishii et al. 
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2000). However, LPAR3 activation does still activate a range of signalling 
molecules, including AP-1 (Hu et al. 2001) and the EGFR (Shah et al. 2005). 
1.7.1 LPA signalling in reproduction  
The LPAR1 knock out mouse shows defective olfactory development which 
manifests as a failure to suckle and therefore neonatal death (Contos et al. 2000). The 
LPAR2 knock out mouse shows no phenotype (Contos et al. 2002), which indicates 
redundancy between LPA receptors. The LPAR3 knock out mouse however is 
infertile, demonstrating the importance of LPA and this receptor in reproduction (Ye 
et al. 2005).   
 
LPA signalling has been shown to play a key role in several reproductive processes, 
including fertilisation, implantation, decidualisation and parturition (Ye 2008). In 
vitro, LPA induces oocyte maturation, through an unknown receptor and an ERK and 
p38 signalling pathway (Komatsu et al. 2006). As the LPAR1 and 2 mice show no 
adverse affects on reproduction, LPAR3 is likely to play the biggest role in the 
female reproductive system. However LPAR1 signalling has been proposed to play a 
role in angiogenesis in the normal endometrium, as endometrial stromal cells 
stimulated with LPA produced the angiogenic chemokine IL-8 via a LPAR1 and 
NFκB pathway (Chen et al. 2008), and increased expression of LPAR1 has also been 
described in the bovine endometrium during the estrous cycle. Here it is thought to 
contribute to PGF2α induced luteolysis (Woclawek-Potocka et al. 2009). Expression 
of LPAR 2 in the human and mouse placenta has been reported (Ye 2008). 
 
The LPAR3 knock out mouse revealed that LPA plays a major role in implantation. 
In response to LPAR3 deficiency, a delay in implantation and altered positioning and 
numbers of blastocysts was observed. This led to increased embryo death. 
Interestingly, this phenotype is very close to the COX-2 knock out mouse, prompting 
the investigators to partially rescue the phenotype with prostaglandin exposure (Ye et 
al. 2005), linking the LPA and COX-2 signalling pathways.   
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1.7.2 LPA signalling in cancer 
The increased levels of LPA and its receptors in many cancer types has indicated that 
it may play a role in tumour progression. LPAR1, 2 and 3 are expressed in different 
cancers, and the main subtype which LPA signalling occurs through may determine 
the outcome. Elevated LPA concentrations have been found in ascites and serum of 
patients with ovarian (Shen et al. 1998) and endometrial (Tokumura et al. 2007) 
cancer, and expression of LPAR1-3 has been documented in numerous cancers 
including breast (Kitayama et al. 2004), colon (Yun et al. 2005), prostate (Guo et al. 
2006), gastrointestinal (Shin et al. 2009), and ovarian (Nakamoto et al. 2005; Jeong 
et al. 2008; Yu et al. 2008).  
 
LPA signalling has been demonstrated to promote cell migration, cell proliferation 
and tissue remodelling through production of proteases and stimulation of 
angiogenesis (Murph et al. 2006). In gastrointestinal cancer, LPA can promote cell 
migration via a LPAR1-ERK 1/2 signalling pathway (Shin et al. 2009), and similarly 
in breast cancer cell lines, LPAR1 activation promotes cell migration (Chen et al. 
2007). Migration of an ovarian cancer cell line was also promoted by LPA, an effect 
that could be abolished with siRNA against LPAR2 (Jeong et al. 2008). The 
promotion of migratory responses is commonly through LPAR1 or 2, potentially as 
LPAR3 does not couple to G12/13, the main G-protein promoting cell migration (Ishii 
et al. 2000). LPA has also been shown to promote cell proliferation in some cancer 
types, including colorectal cancer (Shida et al. 2005) and prostate cancer, where 
overexpression resulted in increased cell proliferation in vitro and increased tumour 
growth in vivo (Guo et al. 2006). The expression of LPAR2 and LPAR3 on ovarian 
cancer cell lines also increased xenograft growth in nude mice (Yu et al. 2008). 
 
Signalling through the LPA receptors commonly promotes expression of chemokines 
involved in angiogenesis and inflammation. For example, LPA promotes expression 
of CXCL1 in ovarian cancer via LPAR2 (Lee et al. 2006). In colon cancer, LPAR2 
signalling also mediates expression of the angiogenic chemokine IL-8 (Yun et al. 
2005). LPA signalling promotes VEGF expression in ovarian cancer cells, and this is 
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likey to be via LPAR2 or LPAR3, as the knockdown of these decreases VEGF 
expression (Hu et al. 2001). Over-expression of these same two receptors increased 
invasiveness of ovarian cancer xenografts in mice and also increased IL8, IL6 and 
VEGF expression (Yu et al. 2008). The expression of LPA receptors has been 
demonstrated in leukocytes, including macrophages (Hornuss et al. 2001), T cells 
(Zheng et al. 2000) and neutrophils (Tou et al. 2005). Whether LPA plays a role in 
the chemoattraction of these cells into cancer beyond the promotion of chemokine 
expression is unclear. However, LPA is known to induce ROS generation and 
activation of macrophages (Hornuss et al. 2001), cytokine secretion by T cells 
(Zheng et al. 2000; Graler et al. 2002) and degranulation by neutrophils (Tou et al. 
2005). 
1.7.3 LPA and COX signalling interactions 
The inflammatory actions of LPA also include interaction with the COX-2 signalling 
pathway. As well as the LPAR3 knock out mouse, the phenotype of which could be 
rescued by prostaglandin administration (Ye et al. 2005), the roles of LPA and COX-
2 in reproduction converge at other signalling mechanisms. In the bovine uterus, 
LPAR1 is the predominant LPA receptor expressed throughout the estrous cycle, and 
signalling through this increases prostaglandin formation (Woclawek-Potocka et al. 
2009; Woclawek-Potocka et al. 2009). Similarly in the ovine uterus where LPAR1 
and LPAR3 are expressed during pregnancy, LPA stimulation of cultured cells also 
increases prostaglandin formation (Liszewska et al. 2009). In porcine endometrium, 
LPAR3 expression is increased, and signalling through this directly upregulated 
expression of prostaglandin synthase enzymes (Seo et al. 2008). Interactions between 
LPA and COX-2 signalling have also been described in cancer, for example in 
ovarian cancer where LPA signalling induced COX-2 expression though LPAR2 
(Jeong et al. 2008), and a similar increase in COX-2 is mediated by LPA in 
colorectal cancer, through phosphorylation of the EGFR (Shida et al. 2005). 
 
In endometrial adenocarcinoma, LPAR2 mRNA has been previously found to be 
increased (Yun et al. 2005), and also expressed in a moderately differentiated 
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endometrial adenocarcinoma cell line (Hope et al. 2009). Here, it has been shown to 
promote invasion of endometrial cancer cells, via the upregulation of MMPs (Hope 
et al. 2009). In endometrial cells, LPA signalling can promote chemokine expression, 
as IL-8 expression was increased in endometrial stromal cells after LPA treatment 
via a Gi-MAPK-NFκB pathway (Chen et al. 2008). Therefore, LPA expression in 
endometrial adenocarcinoma could promote tumour progression in two different 
ways, firstly by directly acting upon cells expressing its receptors to promote 
migration, proliferation or chemokine expression, or by promoting expression of 
COX-2 and prostaglandins which are also upregulated in endometrial 
adenocarcinoma.  
 
1.8 Aims and objectives of this thesis 
This chapter has introduced the concept that chronic inflammation can initiate or 
promote tumour growth. In endometrial adenocarcinoma, inflammation is promoted 
by the oestrogen to progesterone ratio, genetic mutations activating inflammatory 
pathways, and by chemokines acting directly on neoplastic epithelial cells or to 
promote leukocyte infiltration. The increased expression of COX-2 in endometrial 
adenocarcinoma is mediated by some of these mechanisms, and leads to elevated 
prostaglandin signalling, which can result in the expression of angiogenic and 
inflammatory factors. Our laboratory has previously demonstrated that FP receptor 
expression is elevated in endometrial adenocarcinoma. We therefore hypothesised 
that increased PGF2α-FP receptor signalling may promote inflammation, and the 
crosstalk between LPA and the prostaglandins may function in endometrial 
adenocarcinoma to amplify this signalling. 
 
COX-2 inhibitors were trialled in cancer treatment until 2004. However, with long 
term intake of these drugs the risk of cardiovascular side effects was increased, and 
therefore COX-2 inhibitor drugs such as Vioxx (Rofecoxib) were withdrawn from 
the market (Cha et al. 2007). This has led to an interest in targeting prostaglandin 
signalling directly at the prostaglandin receptor, however as yet only the EP receptors 
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have been considered (Rocca 2006). Due to the high expression of the FP receptor in 
endometrial adenocarcinoma, the aims of this thesis are to delineate some of the FP 
receptor signalling pathways which promote inflammation in endometrial 
adenocarcinoma.  Specifically, studies described in this thesis aim to elucidate 
chemokine expression mediated by the FP receptor, the downstream consequences of 





General materials and methods 
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2 General materials and methods 
2.1 Tissue Collection 
2.1.1 Endometrial tissue 
Normal endometrial tissue at different stages of the menstrual cycle was collected 
from woman undergoing minor gynaecological surgery with no underlying 
pathology. An endometrial suction curette (Pipelle, Laboratoire CDD, France) was 
used to collect tissue which was either stored in RNA Later (Ambion) at -70°C for 
RNA extraction, fixed in neutral buffered formalin and wax embedded for 
histological analysis or placed in serum free medium for tissue culture. All women 
had normal menstrual cycles (25-35 days) and endometrial biopsies were staged 
according to last stated menstrual period. Stage of cycle was confirmed histologically 
by a pathologist and biopsies were designated as proliferative, early secretory, mid 
secretory, or late secretory. Ethical approval was obtained from Lothian Research 
Ethics Committee under ethics number LREC/05/S1103/32 and written informed 
consent was obtained prior to collection. 
2.1.2 Carcinoma tissue 
Endometrial adenocarcinoma tissue was obtained from women undergoing 
hysterectomy after diagnosis of adenocarcinoma of the uterus. Diagnosis of 
adenocarcinoma was confirmed histologically.  At collection, tissue was either stored 
in RNA Later (Ambion) at -70°C for RNA extraction, fixed in neutral buffered 
formalin and wax embedded for histological analysis or placed in complete medium 
for tissue culture. Endometrial adenocarcinoma biopsies were assessed by a 
pathologist and designated as well differentiated, moderately differentiated or poorly 
differentiated tumours. Ethical approval was obtained from Lothian Research Ethics 
Committee under ethics number LREC 1999/6/4 and written informed consent was 
obtained prior to collection. 
Chapter 2                                                                                  Materials and Methods  
56 
2.2 Cell Culture 
2.2.1 Culture conditions and passaging 
The Ishikawa cell line consisting of endometrial epithelial cells originally taken from 
endometrial adenocarcinoma (European Collection of Cell Culture, Wiltshire, UK) 
was used throughout this study. Wild type (WT) Ishikawa cells were maintained in 
Dulbecco‟s Modified Eagles Medium (DMEM) nutrient mixture F-12 with 
Glutamax-1 and pyridoxine supplemented with 10% FCS and 1% penicillin-
streptomycin (500 IU/ml penicillin and 500 µg/ml streptomycin; complete medium). 
Ishikawa cells stably transfected with FP cDNA in the sense direction (FPS cells, 
(Sales et al. 2005)) were maintained as above with the addition of 200 µg/ml G418 
antibiotic. 
 
All cells were routinely passaged twice weekly in T162 flasks and maintained in 
humidified conditions at 37°C with 5% carbon dioxide. To passage, cells were 
washed three times with PBS to remove complete medium followed by addition of 4 
ml 0.05% trypsin-EDTA. Cells were incubated at 37°C for approximately 5 minutes 
with regular agitation until detached from the culture flask. The trypsin was then 
neutralised with the addition of 8 ml complete medium and 3mls of this cell 
suspension was added to 30 ml complete medium and reseeded in a new flask. Cells 
used in experiments were counted using a haemocytometer then plated into culture 
dishes at the densities indicated in Table 2.1. 
Culture Vessel Cell Density / Well 
96 well plate 5 x 10
3 
24 well plate 5 x 10
4 
12 well plate 1 x 10
5 
6 well plate 2 x 10
5 
60 mm dish 2.5 x 10
5 
Table 2.1 Cell densities in different culture vessels used. 
Chapter 2                                                                                  Materials and Methods  
57 
2.2.2 Primary tissue culture conditions 
Normal endometrial and endometrial adenocarcinoma tissue was finely chopped in 
DMEM nutrient mixture F-12 with Glutamax-1 and pyridoxine medium (serum free 
medium) and maintained overnight in humidified conditions at 37°C with 5% carbon 
dioxide. For treatments, 3 to 4 pieces of chopped tissue were place in a well of a 24 
well plate and 1 ml serum free medium containing the treatment was added.  
2.2.3 Cell and tissue treatments 
Ishikawa cells were treated with a previously optimised dose of PGF2α of 100 nM 
(Milne et al. 2003). To determine gene expression in response to PGF2α, WT and FPS 
cells were treated for 2, 4, 6, 8, 12, 18, 24, 48 and 72 hours with vehicle or 100 nM 
PGF2α. 
 
To determine signalling pathways regulated by PGF2α, FPS cells or carcinoma tissue 
were treated for 8 or 24 hours with vehicle, 100 nM PGF2α alone, or 100 nM PGF2α 
and a panel of chemical inhibitors (section 2.2.4) or dominant negative constructs 
(section 2.3.2). 
2.2.4 Chemical inhibitors 
Table 2.2 below lists the chemical inhibitors used to determine signalling pathways 
regulated by PGF2α. The optimal concentration of all chemical inhibitors was 
determined empirically by titration using the manufacturer‟s guidelines as described 
in our previous studies (Sales et al. 2008). Cell viability has previously been 
determined for each inhibitor using the CellTitre 96 AQueous One Solution assay 
(Promega, Southampton, UK) as described (Sales et al. 2004; Sales et al. 2008). All 
treatments were carried out with a control of cells treated with inhibitor alone. 
 








YM254890 Gq 1 µM  Dr Jun Takasaki 
(Ibaraki, Japan) 
AL8810 FP 50 µM  Sigma Aldrich 
(Dorset, UK) 
AG1478 EGFR 200 nM  Calbiochem 
(Nottingham, UK) 
PD98059 MEK 50 µM  Calbiochem 
(Nottingham, UK) 
Cyclosporin A Calcineurin 1 µM  Calbiochem 
(Nottingham, UK) 
EGTA Calcuim 1.5 mM Sigma Aldrich 
(Dorset, UK) 
4C3MQ PKA 1 µM  Merck Biosciences 
(Nottingham, UK) 
Table 2.2 Chemical inhibitors and working concentrations used. 
The mechanisms of action of these inhibitors are described below. 
 
YM254890 is a selective Gαq/11 inhibitor which was originally purified from the 
broth of Chromobacterum species. It interferes with the exchange step of GDP for 
GTP rather than a direct interaction with the receptor. The specificity of YM254890 
has been demonstrated by its ability to block Gq-mediated calcium mobilisation in 
several cell lines including an overexpressing Gq cell line. It did not affect second 
messenger activation mediated by Gαi or Gα15-coupled receptors (Takasaki et al. 
2004). 
 
AL8810 is a specific FP antagonist described by Griffin et al (Griffin et al. 1999). It 
is able to dose-dependently reduce IP3 production in response to fluprostenol, a 
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specific FP agonist. It does not inhibit activation of EP2, EP4, IP or DP by specific 
agonists, demonstrating its specificity. It appears to act as a competitive antagonist 
and also displays weak agonist activity for the FP receptor at 261 ± 44 nM. 
 
AG1478 is an EGFR inhibitor which functions by acting as an analogue of ATP. The 
EGFR must bind to both ATP and substrate to cause activation, and the addition of 
AG1478 competitively displaces ATP binding and therefore EGFR activation (Ward 
et al. 1994). 
 
The extracellular-regulated kinases (ERK) 1/2 are activated by the mitogen-activated 
protein kinase kinase MEK. To inhibit this pathway, PD98059 was used. PD98059 
was identified by screening a compound library for inhibition of ERK1/2 
phosphorylation (Dudley et al. 1995). It reversibly inhibits MEK by preventing its 
phosphorylation at a site distinct to the active site (Alessi et al. 1995). 
 
The nuclear factor of activated T-cells (NFAT) transcription factors are activated by 
a signal transduction cascade involving the protein calcineurin. Cyclosporin A forms 
a complex with the intracellular receptor cyclophilin which then binds to calcineurin 
and prevents its phosphorylation of NFAT, and therefore the translocation of NFAT 
to the nucleus to initiate gene transcription (Clipstone et al. 1994). 
 
Ethylene glycol tetraacetic acid (EGTA) is a calcium chelating compound (Sigma 
Alrdich). 4-cyano-3-methylisoquinoline (4C3MQ) is an isoquinoline-derived potent 
PKA inhibitor. It binds PKA at the catalytic subunit competitively to ATP, therefore 
preventing the ability of PKA to phosphorylate proteins (Lu et al. 1996).  
2.2.5 Adenoviral infection 
A short hairpin RNA adenovirus was used to knock down expression of FP and an 
adenovirus was used to over-express RCAN-1-4. Both were kindly prepared by Dr 
Pamela Brown and Mr Stuart Reid (Biomolecular Core Facility, MRC Human 
Reproductive Sciences Unit, Edinburgh, UK). cDNA of RCAN-1-4 was prepared as 
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previously described (Maldonado-Perez et al. 2009) and fused to the pDC316 shuttle 
vector (Microbix Biopharmaceuticals, Toronto, Canada) to create pDC316-RCAN-1-
4. FP cDNA (ORIGENE, Rockville, MD) was excised with EcoRI and Sma1 and 
fused to the pDC316 vector to pDC316-FP.  
 
HEK-293 cells (Invitrogen, Paisley, UK) were seeded in 6-well plates in nutrient 
mixture F-12 with Glutamax-1 and pyridoxine supplemented with 10% FCS and 1% 
penicillin-streptomycin (500 IU/ml penicillin and 500 µg/ml streptomycin). Once at 
50% confluency, cells were co-transfected with 0.75 µg pDC316RCAN-1 or 
pDC316-FP and 2.25 µg pBGH10 ΔE1,3 Cre adenoviral backbone in Optimem 
Reduced Serum Medium (Invitrogen) using Trans-IT-293 transfection reagent 
(Mirus Bio Corp, Madison, WI) as per the manufacturer‟s instructions. Cells were 
incubated for approximately 2 weeks with regular changes of medium until evidence 
of cytopathic effect (CPE) was seen, which was defined as a rounded appearance to 
cells and when approximately 70% of cells had lifted from the plate surface. 
Adenovirus was then harvested and virus released from the cells by 3 freeze-thaw 
cycles. Serial dilutions of the virus were performed and used to re-infect HEK-293 
cells at 75-85% confluence. Wells were overlaid with 0.5% SeaPlaque Agarose 
(FMC Corp, Rockland, ME) to ensure homogenous plaques were obtained. Plaques 
were visible within 4-5 days and were picked using a P1000 tip. Plaques were freeze-
thawed 3 further times and used to re-infect a further T75 flask which was incubated 
until CPE was observed. The virus from this flask was harvested and termed the first 
seed. The adenovirus was then expanded by inoculation of further flasks with the 
first seed. Adenovirus was purified and concentrated using the Vivapure 
AdenoPACK 100 purification kit (Sartorius AG, Goettingen, Germany) as per 
manufacturer‟s instructions. Virus titres were determined using the AdenoX Rapid 
titre kit (Clontech, France) as per manufacturer‟s instructions. 
 
FPS cells were seeded in 6-well plates and incubated for 24 hours. Cells were then 
infected with scrambled sequence adenovirus, shFP or RCAN1-4 adenovirus at 5 
viruses / cell in complete medium. After 24 hour incubation, cells were starved in 
Chapter 2                                                                                  Materials and Methods  
61 
medium containing 3 µg/ml indomethacin for 18 hours before treatment with 100 nM 
PGF2α.  
2.2.6 Lentiviral infection 
A short hairpin RNA lentivirus (the kind gift of Professor Aubrey Thompson, Mayo 
Clinic, Florida, USA) was used to knock down expression of RCAN-1-4 and was 
prepared as previously described (Bush et al. 2007). FPS cells were seeded in 6-well 
plates and incubated for 24 hours. Cells were then infected with control scrambled 
lentivirus or shRCAN1-4 lentivirus at 5 viruses / cell in complete medium. After 24 
hour incubation, cells were starved in medium containing 3 µg/ml indomethacin for 
18 hours before treatment with 100 nM PGF2α.  
2.3 Luciferase reporter assays 
2.3.1 Transient transfection of CXCL1 luciferase promoter construct 
Luciferase reporter assay was used to determine the promoter activity of CXCL1 
after cell treatments. The gene encoding luciferase is inserted under control of the 
CXCL1 promoter, and CXCL1 transcriptional activity can then be measured by 
luminescence after addition of the luciferase substrate. The CXCL1 reporter plasmid 
consisting of the CXCL1 minimal promoter region inserted into the pGL2 Basic 
vector (Promega) fused to the firefly luciferase reporter (as described in Nirodi et al, 
2001) was kindly supplied by Professor Ann Richmond (Department of Cell 
Biology, Vanderbilt University School of Medicine, Nashville, Tennessee). An 
empty vector (pcDNA3.0; Invitrogen) was used as a control. FPS cells were seeded 
in 12 well plates and 1.5 µg of CXCL1 construct transfected using Superfect 
transfection reagent (Qiagen, Crawley, UK) as per the manufacturer‟s instructions. 
This was co-transfected with 0.15 µg pRL-TK (containing the renilla luciferase 
coding sequence; Promega) as an internal control. After 4 hours the transfection 
media was removed and replaced with complete DMEM for at least 24 hours. Cells 
were then serum starved in medium containing 3 µg/ml indomethacin for 18 hours 
before pre-treatment with vehicle, AL8810 or PD98059 at the concentrations 
indicated in Table 2.2 for 1 hour. Cells were then treated with vehicle or 100 nM 
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PGF2α alone, PGF2α and AL8810 or PGF2α and PD98059 for 2, 4, 6, 8 and 24 hours. 
Promoter activity was measured by luciferase assay as described in section 2.3.3. 
2.3.2 Transient transfection of dominant negatives and CXCL1 
luciferase reporter construct 
In order to determine signalling pathways leading to CXCL1 promoter activation, the 
CXCL1 luciferase promoter construct was co-transfected into FPS cells with 
dominant negative constructs. Dominant negative isoforms of Ras, EGFR, NFAT 
and mitogen-activated protein kinase kinase (MEK) were kindly supplied by 
Professor Zvi Naor (Department of Biochemistry, Tel Aviv University, Tel Aviv, 
Israel) and modes of action are described below. FPS cells were transfected with the 
CXCL1 luciferase promoter construct or empty vector as described in section 2.3.1, 
and 1.5 µg of vector encoding either a dominant negative isoform or empty vector 
pcDNA3.0 was co-transfected. Transfection was performed as described in section 
2.3.1 before cells were serum starved for at least 18 hours then treated with vehicle 
or 100 nM PGF2α for 8 hours. Cells were then washed in ice cold PBS and lysed 
using NPS lysis buffer. Promoter activity was measured by luciferase assay as 
described in section 2.3.3. 
 
The mutant ras protein (DN-Ras) was produced by Feig et al (Feig et al. 1988) by 
altering the specificity of ras binding to GTP and therefore its activation. A GTP-
binding assay was used to identify mutants produced by random mutagenesis of the 
bacterial expression vector ras
H
. Sequencing determined that a substitution of 
asparagine (Asn) for serine at position 17 in the highly conserved p21 region 
decreased GDP binding affinity by approximately 40 fold as compared to normal 
cellular ras
H
. The actions of this dominant protein are demonstrated by its growth 
inhibitory phenotype (Feig et al. 1988; Stacey et al. 1991). 
 
Dominant negative EGFR (DN-EGFR) was produced by the deletion of 63 amino 
acids from the C-terminal of the EGFR, removing 2 autophosphorylation sites 
(Livneh et al. 1986). EGFR cDNA was placed into a substitution SV40-based 
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expression vector and cloned. The resultant plasmid pLΔ NA8 construct was used to 
transform E. coli HB101 and the presence of the required deletion was tested by 
digestion with appropriate restriction enzymes. Dominant negative activity of pLΔ 
NA8 has been previously demonstrated (Livneh et al. 1986). 
 
Dominant negative MEK (DN-MEK) was produced by the mutation of a lysine 
residue to an alanine residue at position 97, resulting in an inactive protein (Seger et 
al. 1994). MEK cDNA was inserted into EcoRI and BamH1 sites of the pcDNA3 
vector and transfected into XL-1 cells. Point mutations were made by polymerase 
chain reaction, and mutations were then sequenced to demonstrate the correct 
composition. Dominant negative ability has been demonstrated by decreased MAPK 
activation and cell proliferation (Seger et al. 1994; Harris et al. 2002). 
 
NFAT binds to specific DNA sequences to activate transcription. Dominant negative 
NFAT was produced by Crotti et al by deletion of the DNA binding domain (Crotti 
et al. 2006). After cloning NFATc1 cDNA into the pTAT–HA vector, the domain 
was deleted by restriction digest with PvuII. Dominant negative ability has been 
previously demonstrated by inhibition of target gene expression (Maldonado-Perez et 
al. 2009). 
2.3.3 Dual luciferase assay 
CXCL1 promoter activity was determined by using the Dual-luciferase reporter 
assay system (Promega). Total luciferase activity was determined relative to the 
internal renilla control and fold increase in luciferase activity was determined as 
compared to vehicle treated cells. 
2.4 Polymerase Chain Reaction (PCR) 
2.4.1 RNA extraction 
RNA was extracted from cells using TRI-reagent (Sigma Aldrich, Dorset, UK) 
following manufacturer‟s guidelines. A volume of 1 ml of TRI-reagent was added to 
experimental wells to lyse cells and samples were placed in Phase Lock tubes 
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(Flowgen Bioscience, Nottingham, UK). A volume of 200 µl bromochloropropane 
(Sigma Aldrich) was added and samples were shaken vigorously for 15 seconds. 
Samples were left to stand at room temperature (RT) for approximately 5 minutes 
before centrifugation at 14000 rpm for 15 minutes at 4 °C. After centrifugation the 
RNA remains in the upper aqueous phase above the gel layer of the Phase Lock tube, 
and DNA and proteins remain in the organic phase below. A volume of 500 µl 
isopropanol was added to the aqueous phase and again spun at 14000 rpm for 15 
minutes at 4 °C to precipitate the RNA. The RNA pellet was then washed in 1 ml 
70% ethanol by centrifugation at 14000 rpm for 5 minutes at 4 °C. The remaining 
RNA pellet was then air dried and resuspended in DEPC treated water.  
 
RNA was extracted from tissues using the Qiagen RNeasy Mini kit (Qiagen, 
Crawley, West Sussex, UK). Pieces of tissue, in 2 ml microcentrifuge tubes 
containing a stainless steel ball, were homogenised in 600 µl RLT lysis buffer using 
a tissue lyser (Qiagen) for 2 x 2 minutes at 25 Hz. The lysate was then centrifuged 
for 3 minutes at 14000 rpm and the supernatant removed into a new microcentrifuge 
tube. A volume of 600 µl of 70 % ethanol was added to the supernatant which was 
then transferred to an RNeasy spin column and centrifuged for 15 seconds at 14000 
rpm. A volume of 700 µl of wash buffer RW1 was added to the spin column which 
was centrifuged at 14 000 rpm for 15 seconds. On-column digestion of DNA was 
then performed by addition of DNAse1 (Qiagen) which was incubated at RT for 15 
minutes. DNAse 1 was then removed by a further wash with wash buffer RW1. 
Subsequently 700 µl of buffer RPE containing ethanol, to wash the RNA, was added 
to the column and centrifuged at 14 000 rpm for 2 minutes. This longer centrifuge 
ensured all residual ethanol was removed from the columns. To elute the RNA which 
had remained stuck to the column throughout, 30 µl DEPC treated water was added 
to the columns which were centrifuged for 1 minute at 14 000 and the eluate was 
collected in new microcentrifuge tubes. 
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RNA was quantified using a Nanodrop-1000 spectrophotometer (Labtech 
International, East Sussex, UK) measuring at a wavelength of 260 nm and 280 nm 
and RNA concentration was adjusted to 100 ng / µl with DEPC-treated water. 
2.4.2 Reverse transcriptase PCR 
RNA samples were reverse transcribed for TaqMan quantitative PCR using the 
following reaction (reagents all supplied by PE Applied Biosystems, Warrington, 
UK): 
Water:      1.75 µl 
Reaction buffer   1 µl 
Magnesium Chloride   2.2 µl (5.5 mM) 
Deoxy (d)-NTPs   2 µl (0.5 mM) 
RNAse inhibitor   0.2 µl (0.4 U) 
Random Hexamers    0.25 µl (2.5 µM) 
Oligo dT    0.25 µl (2.5 µM) 
MultiScribe reverse transcriptase 0.25 µl  
 
The mix was aliquoted into individual tubes (8 µl / tube) and template RNA was 
added (2 µl/ tube of 100 ng RNA) or 2 µl water to control for contamination. 
Samples were incubated for 90 min at 25 ºC, 45 min at 48 ºC and 5 min at 95 ºC. 
Thereafter samples were stored at -20 ºC.  A tube with no reverse transcriptase was 
also included to control for any genomic DNA contamination. 
2.4.3 TaqMan quantitative PCR 
2.4.3.1 Principle of reaction 
TaqMan quantitative PCR was used to accurately quantify mRNA of genes of 
interest in a sample. TaqMan probes have the fluorophore FAM attached to the 5‟ 
end and a quencher dye (TAMRA) attached to the 3‟ end. The 18S probe used in this 
thesis used the VIC fluorophore to distinguish from the gene of interest. After 
annealing to the gene of interest between the primers, Taq polymerase extends from 
the primer 5‟ to 3‟ and displaces FAM. This leads to a separation between the 
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fluorophore and the quencher, leading to an increase in fluorescence which can be 
measured. As the PCR reaction is exponential, the original amount of cDNA in the 





Figure 2.1 Principle of Taqman reaction. 1: Specific primers and probe anneal to the 
gene of interest. Taq polymerase begins to extend the primers from 5’ to 3’. 2:  Taq 
polymerase extends the primer to displace the fluorophore FAM (F) from the TAMRA 
quencher (Q). This results in an increase in fluorescence which can be measured, which 
increases as the PCR reaction continues exponentially. 
2.4.3.2 TaqMan reaction 
cDNA expression was measured using an ABI Prism 7900 HT Fast Real Time PCR 
machine (PE Applied Biosystems, Warrington UK). Primers and probes were 
designed using PRIMER express program Version 3.0 (PE Applied Biosystems), and 
were supplied by Eurogentec (Seraing, Belgium). Sequences are given in Table 2.3. 
Primers and probes were designed with the following features: 
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 A guanosine at the 5‟ end of the probe was avoided to prevent quenching 
when cleaved 
 Primer melting temperature was 58-60 °C, and was equal between the 
forward and reverse primers 
 Primers were designed as close together as possible without overlapping the 
probe 
 Primers and probes were designed where possible to run over an exon-exon 
junctions, to avoid genomic DNA contamination 
 Amplicon length was designed to be 50-150 bp 
 
 The following master mix was made up (reagents supplied by PE Applied 
Biosystems, Warrington, UK): 
 
TaqMan buffer (5.5 mM MgCl2, 200 µm dATP, 200 µM dCTP, 200µM dGTPm 200 
µM dUTP) - 25 µl 
Forward primer (300 nM) – 0.6 µl 
Reverse primer (300 nM) – 0.6 µl 
Probe (100 nM) – 2 µl 
18S mix (forward and reverse primers and probe, 50 nM) – 0.75 µl 
Water – 19.05 µl 
cDNA (40 ng) – 2 µl 
 
This mix was added in duplicate to a 96 well MicroAmp fast optical reaction PCR 
plate (PE Applied Biosystems, Warrington UK). Reactions were incubated for 5 min 
at 45°C followed by 5 min at 95C, followed by PCR cycling for 40 cycles of 15 
seconds at 95°C, and 1 minute at 60°C. 
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Gene Sequence of primers and probe 
CXCL1: Forward 
               Reverse 
               Probe 
5‟-GTTTTCAAATGTTCTCCAGTCATTATG-3‟ 
5‟-CCG CCA GCC TCT ATC ACA GT-3‟ 
5‟-TTC TGA GGA GCC TGC AAC ATG CCA-3‟ 
CXCR2: Forward 
               Reverse 
               Probe 
5‟-TGC TCT TCT GGA GGT GTC CTA CA-3‟ 
5‟-AGA TCT TCA CCT TTC CAG AAA TCT T-3‟ 
5‟-CCC AGC GAC CCA GTC AGG ATT TAA-3‟ 
CCL20: Forward 
              Reverse 
              Probe 
5‟-TCC TGG CTG CTT TGA TGT CA-3‟ 
5‟-CCA AGA CAG TCA AAG TTG CT-3‟ 
5‟-TGC TGC TAC TCC ACC TCT GCG GC-3‟ 
CCR6: Forward 
            Reverse 
            Probe 
5‟-TTG GCT ATA CGA AAA CTG TCA CAG A-3‟ 
5‟-AAG CGT AGA GCA CAG GGT TCA-3‟ 
5‟-TCC TGG CTT TCC TGC ACT GCT GC-3‟ 
LPAR1: Forward 
                Reverse 
                Probe 
5‟-CGT CAG GGC CTC ATT GAC A-3‟ 
5‟-GTG CCT CTC GAT TGC AAT AGC-3‟ 
5‟-CCT GAC GGC ATC TGT GGC CAA CTTA-3‟ 
LPAR2: Forward 
               Reverse 
               Probe 
5‟-GTG TAC ACC CCG CAT TTT CTT C-3‟ 
5‟-ACG CCC CCA GGA TGA TG-3‟ 
5‟-AGA GCA TGT CAG CTG CCA CCC CC-3‟ 
LPAR3: Forward 
                Reverse 
                Probe 
5‟-ACG TCT TGT CT CCG CAT ACA A-3‟ 
5‟ACG CCC CTA AGA CAG TCA TCA-3‟ 
5‟TAC ATC AGC CGC CGG AGG A-3‟ 
COX-2: Forward 
              Reverse 
              Probe 
5‟-CCT TCC TCC TGT GCC TGA TG-3‟ 
5‟-ACA ATC TCA TTT GAA TCA GGA AGC T-3‟ 
5‟-TGC CCG ACT CCC TTG GGT GTC A-3‟ 
18S: Forward 
        Reverse 
        Probe  
5‟ -CGG CTA CCA CAT CCA AGG AA- 3‟ 
5‟ -GCT GGA ATT ACC GCG GCT- 3‟ 
5‟ -TGC TGG CAC CAG ACT TGC CCT C- 3‟ 
Table 2.3 Sequences of TaqMan primers and probes. 
 
Results were analysed by the use of the comparative Ct method, where gene 
expression is measured relative to a reference calibrator sample, such as a sample of 
normal endometrium.  Variation due to differing amounts of RNA and pipetting 
errors are taken into account by normalising results relative to an endogenous 
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housekeeping gene (18S). First the expression of gene of interest is normalised to 
that of the housekeeping gene by subtraction of the threshold cycle (Ct; the cycle 
number at which the gene is first detected), which is termed ΔCt. This assumes that 
primers and probes of 18S and the gene of interest are working at similar efficiencies 
(see section 2.4.3.3). The difference between each sample and the calibrator sample, 
the ΔΔCt, is then determined. Finally, the differences in transcript are expressed 
using the equation: 
2^ (- ΔΔCt) 
This is derived from the equation describing the exponential amplification of PCR: 
 
Xn = X0 (1 + Ex) 
Ct,x
 
Where Xn is the number of templates at cycle X, X0 is the number of template copies 
at initiation, EX is the efficiency of target amplification, and n is the number of 
cycles. 
 
As the ΔΔCt of the control sample is subtracted against itself, its final value after 
applying 2^(- ΔΔCt) is 1. Therefore all other samples are expressed as fold difference 
relative to this. 
2.4.3.3 Primer and probe validation 
As genes of interest were normalised to the endogenous gene 18S, primers and 
probes needed to be validated to ensure they worked at similar amplification 
efficiencies. If amplification of the gene of interest and reference gene are similar, 
when plotted against dilutions of RNA (log ng RNA) the ΔCt values should plot a 
straight line. Primer validations were carried out for each TaqMan primer and probe 
set designed. An example of the validation of CXCL1 is given below (Figure 2.2). 
 






















Figure 2.2 CXCL1 primer and probe validation, with log ng RNA plotted against 
ΔCt. 
2.5 Immunohistochemistry 
2.5.1 Tissue fixation and processing 
Tissues were fixed immediately in 4% neutral buffered formaldehyde (NBF) for 24 
hours and transferred to 70% ethanol for a further 24 hours. Tissues were 
subsequently wax embedded using standard protocols. 
 
Tissues were cut into 5 µm sections and adhered to glass slides by flotation in warm 
water. Slides were then incubated at 37 °C for at least 24 hours to ensure complete 
adherence to the slide. 
2.5.2 3’3- Diaminobenzidine tetrahydrochlorine immunohistochemistry 
The localisation of specific proteins in tissue can be detected by the use of 
immunohistochemistry. A primary antibody binds specifically to an epitope of the 
protein of interest. The secondary antibody raised against the species of the primary 
antibody then binds to the primary antibody. The secondary antibody is conjugated to 
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biotin and so is bound by streptavidin horseradish peroxidise (HRP). This can be 
visualised by with the addition of 3,3- diaminobenzidine tetrahydrochlorine (DAB), 
which produces an insoluble brown precipitate in the presence of HRP. 
 
Slides were dewaxed in xylene for 10 minutes followed by rehydration through 
graded ethanol (100%, 95%, 80%, and 70%) for 20 seconds each and a final wash in 
water. Antigen retrieval was performed for antibodies which required epitope 
unmasking. Where this was required, slides were boiled in a pressure cooker in either 
citrate buffer (0.01M, pH 6) or EDTA buffer (1mM, pH 8) for 5 minutes and left to 
stand for a further 20 minutes.  
 
Endogenous peroxidase activity was then blocked by washing sections in 3% 
hydrogen peroxidase in methanol. After a brief wash in tap water slides were washed 
in Tris buffered saline (TBS) twice for 5 minutes each. Sections were then incubated 
in normal serum from the species in which the secondary antibody was raised for at 
least 30 minutes at room temperature. The primary antibody was then applied diluted 
in 2 parts serum: 4 parts TBS: 0.5% BSA at the dilutions indicated in Table 2.4 and 
incubated at 4 °C overnight. Control sections were included with no primary 
antibody, non-immune IgG or primary antibody pre-absorbed with blocking peptide 
(CXCL1: sc-1374-P, CCL20: sc-9775-P, Santa Cruz Biotechnology, Autogen 
Bioclear, UK). Following further washes in TBS, the indicated biotinylated 
secondary antibody was applied diluted in normal serum at 1:200 for 30 minutes at 
room temperature.  Sections were again washed twice in TBS and subsequently 
streptavidin-HRP (DAKO, UK) diluted 1:1000 in TBS was added for 30 minutes at 
room temperature. After more TBS washes, slides were incubated with DAB 
(DAKO, UK) for 1-5 minutes until positive staining was identified by a brown 
colour under x10 magnification. 
 
Slides were then counterstained for 1-5 minutes in haemotoxylin followed by 5-10 
seconds in 1% acid alcohol to remove any non-specific staining. A blue colour was 
developed by a 30 second wash in Scotts Tap Water then slides were dehydrated 
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through graded alcohols for 20 seconds each and xylene for 2 x 5 minutes. Slides 
were coverslipped using Pertex (Cell Path, Hemel Hempstead, UK). 
 







Antigen retrieval Block Secondary 
Antibody and 
supplier 
CXCL1 (Santa Cruz, 
sc-1374) 




Mouse, 1:100 Not required Goat Goat anti-mouse 
(Sigma, B6649)  
CXCR2 (R&D 
Systems, MAB331) 
Mouse, 1:75 Citrate Goat Goat anti-mouse 
(Sigma, B6649) 
CCL20 (Santa Cruz, 
sc-9775) 
Goat, 1:100 Citrate Rabbit Rabbit anti-goat 
(DAKO EO466) 
CCR6 (Santa Cruz, 
sc-9697) 










EDTA Goat Goat anti-mouse 
(Sigma, B6649) 
CD8 (Santa Cruz, 
sc-70791) 
































Rabbit, 1:250 Citrate Goat Goat anti-rabbit 
(DAKO, E0432) 











Rabbit, 1:300 Citrate Goat Goat anti-rabbit 
(DAKO, E0432) 
Table 2.4 List of primary and secondary antibodies used for DAB 
immunohistochemistry. 
 
2.5.3 Dual immunofluorescence microscopy 
Dual immunofluorescence microscopy is used to determine if two or more antigens 
are expressed in the same cell. Specific protocols for antibodies are described in 
individual chapters. Protocols using two antibodies from the same species required a 
microwave blocking step and the use of secondary antibodies with fragment antigen 
binding fragments (Fab fragments). These ensure that there is no open binding site 
on the secondary antibody which can cross react with the next primary antibody 
which is added  (Negoescu et al. 1994; Lan et al. 1995), and are described in detail in 
Section 4.2.6. Generally, slides were treated as for DAB immunohistochemistry until 
the addition of the secondary antibody, with the exception of carrying out washes in 
phosphate-buffered saline (PBS). A biotinylated or peroxidase conjugated antibody 
was then added, diluted in normal serum at 1:200 or 1:500 respectively for 30 
minutes. Streptavidin AlexaFluor 488 or 546 (Molecular Probes) diluted 1:200 in 
PBS was then added to biotyinlated secondary antibodies for 30 minutes at room 
temperature. To peroxidase-incubated sections, tyramide-cy3 (PerkinElmer, 
Massachusetts, USA) diluted 1:50 in tyramide buffer was added for 10 minutes.  
Alternatively, a fluorophore-conjugated antibody was added diluted 1:200 in PBS 
(AlexaFluor 488 or 546, Molecular Probes, UK) for 1 hour. Sections were then re-
blocked in normal serum and the process repeated with the second primary antibody. 
Nuclei were stained using ToPro (Molecular Probes, UK). Slides were coverslipped 
using Permafluor (Immunotech, Marseille, France). 
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2.5.4 Immunohistochemistry imaging 
DAB immunohistochemistry was visualised on a PROVIS microscope (Olympus Optical, 
London, UK) and images obtained using Canon EOS image capture software (Canon, 
Woodhatch, Surrey, UK). Dual immunofluorescence immunohistochemistry was 
visulaised on a LSM 510 Meta-Confocal (Carl Zeiss, Hertfordshire, UK) and images 
obtained using LSM5 Image Browser. 
 
2.6 Enzyme linked immunosorbent assays (ELISAs) 
2.6.1 CXCL1 
CXCL1 protein secretion by Ishikawa FPS cells in the culture medium was measured 
by ELISA. FPS cells were serum starved in medium containing 3 µg/ml 
indomethacin for at least 18 hours prior to one hour pre-incubation with selected 
chemical inhibitors. Cells were then stimulated with fresh serum-free media 
containing indomethacin with vehicle, 100nM PGF2α (n=4) or 100nM PGF2α and 
chemical inhibitors (n=5) for time points indicated by the figure legend. ELISA 
plates were coated with monoclonal mouse anti-human CXCL1 antibody (720 µg/ml, 
clone 20326, R&D systems, Abingdon, UK) and left at 4 ºC overnight. Wells were 
then blocked with Dry Coat solution (2% polyvinyl pyridine, 1% BSA, 0.05% 
sodium azide, 5mM EDTA in Tris-buffered saline) for 1 hour followed by addition 
of CXCL1 standard (recombinant human CXCL1, R&D Systems, Abingdon, UK) 
and culture medium samples in duplicate diluted in ELISA buffer (2mg / ml BSA, 
2mM EDTA and 300µl Phenol Red Solution and Tween-20% in Tris-buffered 
saline). Plates were incubated for 3 hours at room temperature then washed in ELISA 
wash buffer (0.05% Tween in PBS, pH 7.2-7.4) and 50ng/ml biotinylated goat anti-
human CXCL1 antibody (R&D Systems, Abingdon, UK) was added for 1 hour at 
room temperature. After further washing, streptavidin peroxidase (dilution of 1:2000, 
Roche UK) was added for 20 minutes. Colour change was detected by addition of 
substrate solution (1:1 mix in 100mM sodium acetate buffer, pH 6, of: 5mg/ml 
hydrogen peroxide in sodium acetate buffer, pH 6: tetramethylbenzidine 3mg/ml in 
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dimethyl formamide) and the reaction was stopped by addition of 2N sulphuric acid. 
Optical density of wells was read at 450nM. 
2.6.2 CCL20 
CCL20 protein secretion by Ishikawa FPS cells in the culture medium was measured 
by ELISA. FPS cells were serum starved in medium containing 3 µg/ml 
indomethacin for at least 18 hours prior to one hour pre-incubation with selected 
chemical inhibitors. Cells were then stimulated with fresh serum-free media 
containing indomethacin with vehicle, 100nM PGF2α (n=4) or 100nM PGF2α and 
chemical inhibitors (n=5) for time points indicated by the figure legend. CCL20 
ELISA was performed using the Human CCL20/MIP-3 alpha DuoSet (R&D 
Systems, Abingdon, UK). Plates were coated with capture antibody at 2 µg/ml and 
left at room temperature overnight. Wells were then blocked with Dry Coat solution 
for 1 hour followed by addition of CCL20 standard and culture media samples in 
duplicate diluted in ELISA buffer. Plates were incubated for 2 hours at room 
temperature then washed in ELISA wash buffer. The detection antibody was then 
added to wells diluted to 50ng/ml in ELISA buffer and incubated for 2 hours at room 
temperature. Wells were then washed and streptavidin-HRP diluted 1:200 in ELISA 
buffer was added for 20 minutes at room temperature. Colour change was detected 
by addition of substrate solution and the reaction was stopped by addition of 2N 
sulphuric acid. Optical density of wells was read at 450nM. 
2.7 Statistical Analysis 
Where appropriate, statistical analysis was carried out using GraphPad Prism 
(GraphPad Software. San Diego, California, USA). 
2.8 Commonly used solutions 
2.8.1 Tissue Culture 
Complete Medium 
Dulbecco‟s Modified Eagles Medium (DMEM) Glutamax F-12, supplemented with: 
50 mls (10% ) (v/v) heat inactivated foetal bovine serum 
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5 mls (100 U/ml) Penicillin and (100 µg/ml) Streptomycin 
200µg/ml G418 (FPS Ishikawa cells only) 
Starving Medium 
Dulbecco‟s Modified Eagles Medium (DMEM) Glutamax F-12, supplemented with: 
5 mls (100 U/ml) Penicillin and (100 µg/ml) Streptomycin 
200µg/ml G418 (FPS Ishikawa cells only) 
Transfection Medium 
Dulbecco‟s Modified Eagles Medium (DMEM) Glutamax 
 
2.8.2 Luciferase reporter assays 
NPS Lysis Buffer 
4.4g NaCl 
1.86g EDTA 
25 ml 1M Tris pH 7.4 
3 ml NP40 
50 ml Glycerol 




100 ml 40% formaldehyde 
900 ml Distilled water  
4 g Sodium dihydrogen phosphate monohydrate 
6.5 g Disodium hydrogen phosphate anhydrous  
Citrate buffer (0.1M) 
42.02 g Citric acid monohydrate  
900 ml Distilled water 
pH to 5.5 with concentrated NaOH 
Make up to 2L and pH to 6 
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0.5M Tris-HCl stock x10 
121.14 g Tris(Hydroxymethyl)methylamine 
2000 ml distilled water 
pH to 7.4 with HCl 
0.05M TBS 
100 ml 0.5M Tris-HCl 
900 ml distilled water 
8.5 g sodium chloride 
Peroxidase blocking solution  
30 ml of 30% (3% v/v) Hydrogen Peroxide  
270 ml Methanol  
Blocking solution 
2ml non-immune serum 
8 ml PBS 
0.5 g BSA 
 
Chapter 3 
PGF2α-F prostanoid receptor 
regulation of chemokine (C-X-C) 
motif ligand 1 in endometrial 
adenocarcinoma 
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3 PGF2α-F-prostanoid receptor regulation of chemokine 
(C-X-C motif) ligand 1 expression in endometrial 
adenocarcinoma 
3.1 Introduction  
Overexpression of the cyclooxygenase (COX) enzymes and prostaglandins has been 
demonstrated in endometrial adenocarcinoma (Jabbour et al. 2006) as well as a 
number of other cancer types such as breast, bladder and lung (Cha et al. 2007). 
Expression of the prostaglandin F2α (PGF2α) receptor, FP, is elevated in endometrial 
adenocarcinoma (Sales et al. 2004). FP is a Gq coupled receptor which upon 
activation leads to release of inositol-1,4,5-trisphosphate (IP3) and diacylglycerol 
(DAG) (Abramovitz et al. 1994). A role for FP in endometrial adenocarcinoma has 
been demonstrated with evidence for elevated FP activation leading to the 
upregulation of a number of angiogenic and tumourigenic genes including COX-2 
(Jabbour et al. 2005), FGF2 (Sales et al. 2007) and vascular endothelial growth factor 
(VEGF; Sales et al. 2005). FP activation can also increase proliferation and 
migration of neoplastic epithelial cells (Milne et al. 2003; Sales et al. 2004; Sales et 
al. 2008).  
 
 The chemokine family is divided into four groups based on the position of two 
cysteine molecules (C) and any other amino acid (X) in the amino terminal of the 
protein. The groups are known as C, C-C, C-X-C and C-X3-C (Murphy et al. 2000). 
Chemokine (C-X-C motif) ligand 1 (CXCL1, also known as growth-regulated 
oncogene α) is a member of the CXC family, which is further subdivided into 
glutamine-leucine-arginine positive or negative (ELR+ or ELR-) chemokines, 
dependent on the presence or absence of this amino acid motif. ELR+ chemokines 
have angiogenic properties, whilst ELR- chemokines are angiostatic (Strieter et al. 
1995). 
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 CXCL1 is an ELR+ chemokine with angiogenic, chemoattractant and inflammatory 
activities (Strieter et al. 2006).  It binds to the CXCR2 receptor, a GPCR, (Addison et 
al. 2000) to promote the recruitment of neutrophils to sites of inflammation (Moser et 
al. 1990). CXCL1 has also been implicated in tumourigenesis as it is upregulated in a 
number of cancer types including melanoma (Haghnegahdar et al. 2000; Wang et al. 
2000), colorectal (Li et al. 2004; Wen et al. 2006; Rubie et al. 2008), and prostate 
(Moore et al. 1999). CXCL1 has been demonstrated to promote a variety of 
processes important to tumour progression. For example, increased CXCL1 
expression is associated with greater invasive ability in bladder cancer (Kawanishi et 
al. 2008), promotion of proliferation in oesophageal cancer (Wang et al. 2006) and 
angiogenesis in prostate cancer (Moore et al. 1999). 
 
Recent evidence suggests a link between prostaglandin receptor signalling and 
CXCL1 expression as PGE2 signalling via the EP4 receptor induces CXCL1 
expression in a colorectal cancer cell line (Wang et al. 2006). Although localisation 
of CXCL1 and CXCR2 has previously been described in the normal endometrium 
(Nasu et al. 2001; Mulayim et al. 2003), expression of CXCL1 and CXCR2 in 
endometrial adenocarcinoma and the potential role of FP in the regulation of CXCL1 
have not been examined. This chapter therefore sought to investigate the regulation 
of CXCL1 by PGF2α in an endometrial adenocarcinoma cell model expressing the FP 
receptor, and the expression and localisation of CXCL1 and CXCR2 in endometrial 
adenocarcinoma tissue. 
 
3.2 Materials and Methods 
3.2.1 Tissue collection 
Normal endometrium and endometrial adenocarcinoma tissue was collected as 
described in sections 2.1.1 and 2.1.2. Normal endometrial tissue was collected from 
women undergoing surgery for minor gynaecological procedures with no underlying 
endometrial pathology, and endometrial adenocarcinoma tissue was obtained from 
women undergoing hysterectomy after diagnosis of adenocarcinoma of the uterus. 
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Stage of cycle and grade of cancer was assessed by a pathologist. Written informed 
consent was collected from all patients before surgery and ethical approval was 
obtained from Lothian Research Ethics Committee. 
3.2.2 Cell culture 
Ishikawa FPS cells were maintained as described in section 2.2.1. Primary tissue 
explants were maintained as described in section 2.2.2. 
3.2.2.1 Cell and tissue treatments 
To determine the pattern of CXCL1 expression in response to PGF2α, FPS cells were 
serum starved in media containing 3 µg/ml indomethacin for at least 18 hours prior 
to stimulation for 2, 4, 6, 8, 12, 18, 24, 48 and 72 hours with fresh serum-free media 
containing indomethacin and vehicle or 100 nM PGF2α (n=5). Carcinoma tissue was 
serum starved in media containing 3 µg/ml indomethacin for at least 18 hours prior 
to treatment for 2, 4, 6, 8, and 24 hours with fresh serum-free media containing 
indomethacin and vehicle or 100 nM PGF2α (n=4). 
 
To determine signalling pathways leading to CXCL1 expression regulated by PGF2α, 
FPS cells or carcinoma tissue were serum starved in media containing 3 µg/ml  
indomethacin for at least 18 hours and treated for 8 or 24 hours respectively with 
vehicle, inhibitor alone, 100 nM PGF2α alone or 100 nM PGF2α and a panel of 
chemical inhibitors (n=7) or dominant negative constructs (n=5) as indicated in the 
figure legends. 
3.2.3 Chemokine antibody array 
Cytokine expression by Ishikawa FPS cells was examined using the Raybio Human 
Cytokine Antibody Array 3 (Raybiotech Inc, Middlesex, UK), performed according 
to manufacturer‟s instructions. FPS cells were plated in 60mm petri dishes and 
stimulated for 24 hours with vehicle or 100 nM PGF2α (n=3 each treatment). 
Condtioned media was collected from each treatment and pooled. Antibody array 
membranes were blocked for 30 minutes with 2 ml blocking buffer before addition of 
2 ml of conditioned medium for 2 hours at room temperature (RT) to allow binding 
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of the proteins in the conditioned media to the impregnated antibodies on the 
membrane. Membranes were then washed with wash buffer 1 for 3 x 5 minutes and 
wash buffer 2 for 2 x 5 minutes. The biotin-conjugated primary antibodies were 
diluted in 2 ml blocking buffer and added to the membranes and incubated for 2 
hours at RT.  Membranes were then washed as above and incubated with the HRP-
conjugated streptavidin (diluted 1:1000 in blocking buffer) at 4 °C overnight. 
Membranes were again washed as above and incubated with the detection buffers 
(1:1 mix of detection buffer C and D) for 2 minutes at RT. Cytokine production was 
visualised by detection of the streptavidin-HRP reaction on x-ray film after a 20 
second exposure.  
3.2.4 Polymerase chain reaction 
3.2.4.1 RNA extraction and reverse transcriptase PCR 
RNA from cells was extracted as described in section 2.4.1. Briefly, 1 ml TRI-
reagent was added to experimental wells and RNA extracted using the phenol 
method.  
 
RNA from tissue was extracted as described in section 2.4.1 using the Qiagen minikit 
protocol. Pieces of tissue, in 2 ml microcentrifuge tubes containing a stainless steel 
ball, were homogenised in 600 µl RLT lysis buffer using a tissue lyser (Qiagen 
Crawley, West Sussex, UK) for 2 x 3 minutes at 25 Hz. RNA was then extracted 
following manufacturers guidelines (Qiagen). cDNA was prepared as described in 
section 2.4.2. 
3.2.4.2 Taqman quantitative RT- PCR 
CXCL1 and CXCR2 mRNA expression in cells and tissues was examined using 
Taqman quantitative PCR as described in section 2.4.3.2. Briefly, primer and probe 
sequences were designed to amplify CXCL1 and CXCR2 (sequences given in Table 
2.2). A master mix was made up containing 18S primers and probes and 200ng 
cDNA added to each sample. Samples were added in duplicate to a 96 well 
MicroAmp fast optical reaction PCR plate and analysed using an ABI Prism 7900 
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HT Fast Real Time PCR machine. Expression of analyzed genes was normalised to 
RNA loading for each sample using the 18S ribosomal RNA as an internal standard. 
Results are expressed as fold increase above vehicle treated cells. 
3.2.5 FP adenovirus 
A short hairpin adenovirus to knock down expression of FP was kindly prepared by 
Dr Pamela Brown (Biomolecular Core Facility, MRC Human Reproductive Sciences 
Unit, Edinburgh, UK) as described in section 2.2.5. FP cDNA (ORIGENE, 
Rockville, MD) was excised with EcoRI and Sma1 and fused to the pDC316 vector 
to create pDC316-FP. HEK-293 cells were seeded in 6-well plates in nutrient 
mixture F-12 with Glutamax-1 and pyridoxine supplemented with 10% FCS and 1% 
penicillin-streptomycin (500 IU/ml penicillin and 500 µg/ml streptomycin). Once at 
50% confluency, cells were co-transfected with 0.75 µg pDC316-FP and 2.25 µg 
pBGH10 ΔE1,3 Cre adenoviral backbone in Optimem Reduced Serum Media 
(Invitrogen) using Trans-IT-293 transfection reagent (Mirus Bio Corp, Madison, WI) 
as per the manufacturer‟s instructions. Cells were incubated for approximately 2 
weeks with regular changes of media until evidence of cytopathic effect (CPE) was 
seen, which was defined as a rounded appearance to cells and when approximately 
70% of cells had lifted from the plate surface. Adenovirus was then harvested and 
virus released from the cells by 3 freeze-thaw cycles. Serial dilutions of the virus 
were performed and used to re-infect HEK-293 cells at 75-85% confluence. Wells 
were overlaid with 0.5% SeaPlaque Agarose (FMC Corp, Rockland, ME) to ensure 
homogenous plaques were obtained. Plaques were visible within 4-5 days and were 
picked using a P1000 tip. Plaques were freeze-thawed 3 further times and used to re-
infect a further T75 flask which was incubated until CPE was observed. The virus 
from this flask was harvested and termed the first seed. The adenovirus was then 
expanded by inoculation of further flasks with the first seed. Adenovirus was purified 
and concentrated using the Vivapure AdenoPACK 100 purification kit (Sartorius 
AG, Goettingen, Germany) as per manufacturer‟s instructions. Virus titres were 
determined using the AdenoX Rapid titre kit (Clontech, France) as per 
manufacturer‟s instructions. 
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FPS cells were seeded in 6-well plates and incubated for 24 hours. Cells were then 
infected with 5 viruses / cell in complete medium. After 24 hour incubation, cells 
were starved in media containing 3 µg/ml indomethacin for 18 hours before 
treatment with 100 nM PGF2α or vehicle for 8 hours (n=4). 
3.2.6 Immunohistochemistry 
3,3- diaminobenzidine tetrahydrochlorine (DAB) immunohistochemistry to localise 
CXCL1 and CXCR2 in endometrial tissue was performed as described in section 
2.5.2 (for immunolocalisation of CXCL1: proliferative stage endometrium n=7, early 
secretory stage endometrium n=3, mid secretory stage endometrium n=4, late 
secretory stage endometrium n=5, well differentiated adenocarcinoma n=7, 
moderately differentiated adenocarcinoma n=5, poorly differentiated 
adenocarcinoma n=3. For immunolocalisation of CXCR2: proliferative stage 
endometrium n=4, early secretory stage endometrium n=2, mid secretory stage 
endometrium n=3, late secretory stage endometrium n=4, well differentiated 
adenocarcinoma n=5, moderately differentiated adenocarcinoma n=5, poorly 
differentiated adenocarcinoma n=5). Tissue sections (5 µm) were dewaxed in xylene 
then rehydrated through graded ethanols and water. Antigen retrieval in citrate buffer 
(0.01M, pH 6) was performed, followed by blocking for endogenous peroxidase 
activity by washing sections in 3% hydrogen peroxidase in methanol. Sections were 
then blocked in normal serum of rabbit (for immunolocalisation of CXCL1) or goat 
(for immunolocalisation of CXCR2) followed by overnight incubation with primary 
antibody at the concentrations indicated in Table 2.4. Control sections were included 
with non-immune IgG for both antibodies and primary antibody pre-absorbed with 
blocking peptide (performed for immunolocalisation of CXCL1). Sections were then 
incubated in rabbit anti-goat (for immunolocalisation of CXCL1) or goat anti-mouse 
(for immunolocalisation of CXCR2) biotinylated secondary antibody and 
subsequently streptavidin-HRP. Sections were then incubated with DAB for 1-5 
minutes until positive staining was identified by a brown colour under x10 
magnification. 
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3.2.7 CXCL1 enzyme linked immunosorbent assay (ELISA) 
CXCL1 protein released into the culture medium from treatments described in 
section 3.2.2.1 was measured by ELISA (n=5; R&D Systems, Abingdon, UK) as 
described in section 2.6.1. 
3.2.8 Transient transfection of CXCL1 luciferase promoter construct 
CXCL1 promoter activity was measured in FPS cells by transient transfection of the 
CXCL1 reporter plasmid consisting of the CXCL1 minimal promoter region inserted 
into the pGL2 Basic vector (Promega, Southhampton, UK) fused to the firefly 
luciferase reporter, as described in section 2.4.1. FPS cells were seeded in 12 well 
plates and 1.5 µg of CXCL1 construct co-transfected with 0.15 µg pRL-TK 
(containing the renilla luciferase coding sequence; Promega) as an internal control 
using Superfect transfection reagent (Qiagen) as per the manufacturer‟s instructions. 
After 4 hours the transfection media was removed and replaced with complete 
DMEM for at least 24 hours before cell treatments were carried out as described in 
section 3.2.2.1 (n=7). Cells were then washed in ice cold PBS and lysed in NPS lysis 
buffer. Promoter activity was measured by luciferase assay as described in section 
3.2.10. 
3.2.9 Transient transfection of dominant negatives and CXCL1 
luciferase reporter construct 
CXCL1 promoter activity in response to PGF2α was examined in the presence of 
dominant negative isoforms of signalling molecules, as described in section 2.3.2. 
FPS cell transfection was performed as in section 3.2.8 with the addition of 1.5 µg of 
vector encoding a dominant negative isoform of EGFR, Ras, MEK, NFAT or empty 
vector (pcDNA3.0). Cells were then treated with vehicle control or 100 nM PGF2α, 
and washed in ice cold PBS and lysed in NPS lysis buffer (n=5). Promoter activity 
was measured by luciferase assay as described in section 3.2.10. 
3.2.10 Luciferase reporter assay 
CXCL1 promoter activity was determined by using the Dual-luciferase reporter 
assay system (Promega). Total luciferase activity was determined relative to the 
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internal renilla control and fold increase in luciferase activity was determined as 
compared to vehicle treated cells. 
3.2.11 Statistical analysis 
Where appropriate, data were analysed by Students t-test and one way ANOVA 
using GraphPad Prism (GraphPad Software. San Diego, California, USA). Data are 
presented as mean ± SEM. 
 
3.3 Results  
3.3.1 PGF2α – FP receptor interaction induces CXCL1 protein secretion 
In order to determine cytokines regulated by PGF2α – FP signalling in Ishikawa FPS 
cells, a cytokine antibody array was used to examine protein changes in conditioned 
medium taken from FPS cells stimulated with vehicle or 100 nM PGF2α (Figure 3.1). 
An increase in expression of the cytokines IL-6, IL-7, IL-8 and leptin was observed 
following PGF2α treatment of FPS cells. Additionally, increased expression of 
members of the CXCL family of proteins (CXCL1, 2 and 3) was identified, as well 
as increased expression of CXCL1 alone. 






Figure 3.1 Cytokine expression in FPS cell conditioned media. A Human Cytokine 
Antibody Array was used to determine differences in cytokine production in the conditioned 
medium of (A) vehicle treated and (B) 100 nM PGF2α treated FPS cells. An increase in the 
cytokines of the CXCL family, IL-6, IL-7, IL-8 and leptin was observed, and are indicated by 
arrowheads. 
 
3.3.2 Expression and localisation of CXCL1 and CXCR2 in normal 
endometrium across the menstrual cycle and in endometrial 
adenocarcinoma 
3.3.2.1 Expression of CXCL1 mRNA in normal endometrium and 
endometrial adenocarcinoma 
Normal endometrium (n=45) and endometrial adenocarcinoma tissue (n=58) samples 
were analysed for CXCL1 mRNA expression by quantitative RT-PCR (Figure 3.2). 
CXCL1 expression was increased in the mid-secretory phase of the cycle however 
this increase was not statistically significant (Figure 3.2A). There was no significant 
difference in CXCL1 mRNA expression between grades of cancer examined (Figure 
3.2B), however CXCL1 mRNA was found to be significantly increased by 5.9 ± 2.9 
fold in pooled carcinoma samples as compared to pooled normal endometrium 
samples (p<0.001, Figure 3.2C). 
 
CXCL1,2,3   CXCL1 CXCL1,2,3   CXCL1 
Leptin Leptin 
IL-6 IL-7 IL-8 
IL-6 IL-7 IL-8 
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Figure 3.2 Expression of CXCL1 mRNA in normal endometrium and endometrial 
adenocarcinoma. A: CXCL1 mRNA was examined by quantitative RT-PCR in endometrium 
from the proliferative phase (n=17), early secretory phase (n=11), mid secretory phase 
(n=12) and late secretory phase (n=5) of the menstrual cycle. Differences in expression 
between different stages of the cycle were not statistically significant. B: CXCL1 mRNA was 
examined by quantitative RT-PCR in well (n=18), moderately (n=20) and poorly (n=20) 
differentiated endometrial adenocarcinoma. No significant difference was demonstrated 
between different grades of cancer. C: CXCL1 mRNA expression was examined by 
quantitative RT-PCR in pooled normal endometrial samples (n=45) and pooled 
adenocarcinoma samples (n=58), and demonstrated to be significantly increased in 
carcinoma tissue. *** denotes p<0.001, data are expressed relative to a normal endometrium 
control sample and are presented as mean ± SEM. 
 
Chapter 3                                                        PGF2α regulation of CXCL1 expression  
90 
3.3.2.2 Expression of CXCR2 mRNA in normal endometrium and 
endometrial adenocarcinoma 
Expression of CXCR2, the receptor for CXCL1, was also examined by quantitative 
RT-PCR in normal endometrium (n=45) and endometrial adenocarcinoma tissue (n= 
57; Figure 3.3). CXCR2 mRNA expression was significantly increased in the late 
secretory phase of the cycle as compared to all other menstrual stages (p<0.01, 
Figure 3.3A). CXCR2 mRNA expression was not significantly different between 
different grades of cancer (Figure 3.3B) however expression was found to be 
significantly increased by 4.2 ± 1.04 fold in pooled cancer samples as compared to 
pooled normal endometrium samples (p<0.001, Figure 3.3C). 
 
 
Figure 3.3 Expression of CXCR2 in normal endometrium and endometrial 
adenocarcinoma. A: CXCR2 expression was examined by quantitative RT-PCR in 
endometrium from the proliferative phase (n=18), early secretory phase (n=13), mid 
secretory phase (n=10) and late secretory phase (n=4) of the menstrual cycle. CXCR2 
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mRNA was significantly increased in the late secretory stage of the cycle. B: CXCR2 mRNA 
was examined by quantitative RT-PCR in well (n=18), moderately (n=20) and poorly (n=19) 
differentiated endometrial adenocarcinoma tissue, and did not significantly differ between 
grades of cancer. C: CXCR2 mRNA expression was examined by quantitative RT-PCR in 
pooled normal endometrium samples (n=45) and pooled adenocarcinoma samples (n=57), 
and was significantly increased in carcinoma tissue. **denotes p<0.01, *** denotes p<0.001, 
data are expressed relative to a normal endometrium control sample and are presented as 
mean ± SEM. 
 
3.3.2.3 Localisation of CXCL1 in normal endometrium and 
endometrial adenocarcinoma 
CXCL1 protein in the normal endometrium has been previously examined and 
localised to stromal cells in secretory endometrium (Nasu et al. 2001). In another 
study, CXCL1 was localised to glandular epithelium in secretory and proliferative 
phase endometrium (Hess et al. 2007). In this chapter, endometrial tissue from all 
stages of the cycle (proliferative n=7, early secretory n=3, mid secretory n=4, late 
secretory n=5) was examined by immunohistochemistry for CXCL1 expression. In 
the proliferative phase, CXCL1 staining can be seen in the cytoplasm of the 
glandular epithelium and immunoreactivity is rarely seen in stromal cells (Figure 
3.4A).  CXCL1 was also expressed in vascular endothelial cells throughout the cycle, 
and this is shown in the early secretory phase of the cycle (Figure 3.4B). CXCL1 was 
also localised to glandular epithelium and stroma at this stage of the cycle. In the mid 
and late secretory phases, CXCL1 expression can be seen in the stroma and is also 
localised to glandular epithelium (Figure 3.4C, D). Negative controls were incubated 
with non-immune IgG (inset; Figure 3.4A) and with primary antibody which had 
been pre-absorbed with CXCL1 blocking peptide (inset; Figure 3.4C). Both 
demonstrated no immunoreactivity. 
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Figure 3.4 Localisation of CXCL1 protein in normal endometrium by 
immunohistochemistry. Representative images demonstrating that CXCL1 localises to the 
glandular epithelium, stroma and vascular endothelium in normal endometrium. A: CXCL1 
localises to the glandular epithelium (GE) in proliferative phase endometrium. Negative 
control (inset) is incubated with non-immune IgG (left image is x200 magnification, right 
image is x400). B: In early secretory phase endometrium, CXCL1 immunoreactivity can be 
seen in the glandular epithelium and vascular endothelial cells (VE; left image is x200 
magnification, right image is x400). C: In mid secretory phase endometrium, CXCL1 can be 
localised to glandular epithelium and stroma (S; left image is x200 magnification, right image 
is x400). Negative control (inset) is incubated with primary antibody pre-absorbed with 
CXCL1 blocking peptide. D: CXCL1 also localises to glandular epithelium and stroma in late 
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CXCL1 expression was then examined in all grades of endometrial adenocarcinoma 
by immunohistochemistry (well differentiated n=7, moderately differentiated n=5, 
poorly differentiated n=3). Similarly to normal endometrium, CXCL1 could be 
localised to epithelium (E), vascular endothelium (VE) and stromal cells (S) in all 
grades of cancer studied (Figure 3.5). Negative controls were incubated with primary 
antibody pre-absorbed with blocking peptide (inset; Figure 3.5A) and with non-
immune IgG in place of primary antibody (inset; Figure 3.5B). 
 
 
Figure 3.5 Localisation of CXCL1 protein in endometrial adenocarcinoma by 
immunohistochemistry. Representative images demonstrating that CXCL1 localises to the 
neoplastic epithelium (E), vascular endothelium (VE) and stroma (S) in A: Well differentiated 
carcinoma (left image is x200 magnification, right image is x400). Negative control (inset) is 
incubated with primary antibody pre-absorbed with blocking peptide. B: Moderately 
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control (inset) is incubated with non-immune IgG in place of primary antibody. C: Poorly 
differentiated carcinoma (left image is x200 magnification, right image is x400). All scale bars 
represent 100 µm. 
To further support a role for the FP receptor in the regulation of CXCL1, 
immunohistochemistry for both proteins was carried out on serial sections of 
endometrial adenocarcinoma. For all grades of cancer, FP protein could be localised 
to a number of the same cells as CXCL1. Shown in Figure 3.6 are representative 
images from moderately differentiated (Figure 3.6A) and well differentiated cancers 
(Figure 3.6B), where localisation of FP receptor and CXCL1 can be demonstrated in 
the same neoplastic epithelial cells, vascular endothelial cells and many of the same 
stromal cells. Co-localisation is indicated by arrowheads. FP negative controls were 
incubated with non-immune IgG and are inset in Figure 3.6A; CXCL1 negative 
controls incubated with non-immune IgG and antibody pre-absorbed with blocking 
peptide are shown in Figure 3.5.  
 
Figure 3.6 CXCL1 can be localised to the same cells as the FP receptor by 
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CXCL1 and FP can be colocalised to neoplastic epithelium (E), vascular endothelium (VE) 
and stroma (S; indicated by arrowheads) in A: moderately differentiated endometrial 
adenocarcinoma (x 200 magnification) and B: well differentiated endometrial 
adenocarcinoma (x 400 magnification). All scale bars represent 100 µm. 
3.3.2.4 Localisation of CXCR2 in normal endometrium and 
endometrial adenocarcinoma 
The localisation of the receptor for CXCL1, CXCR2, was then investigated in 
normal endometrium and endometrial adenocarcinoma. CXCR2 expression has been 
previously examined in normal endometrial tissue (Mulayim et al. 2003; Ulukus et 
al. 2005). However discrepancies exist in the literature about the site of expression of 
CXCR2, with no stromal expression observed in one study (Ulukus et al. 2005). 
Therefore we examined CXCR2 expression in all phases of the menstrual cycle 
(proliferative n=4, early secretory n=2, mid secretory n=3, late secretory n=4).  
 
CXCR2 immunoreactivity can be seen in the cytoplasm of the glandular epithelium 
of proliferative phase endometrium; however stromal CXCR2 expression was rarely 
observed (Figure 3.7A). In endometrium from the early secretory phase, CXCR2 was 
also localised to glandular epithelium (Figure 3.7B). In endometrium from the mid 
and late secretory stages, CXCR2 remained localised to the glandular epithelium and 
increasingly was expressed focally in the stroma (S; representative image is shown 
from late secretory phase endometrium in Figure 3.7D). In some tissues from the 
secretory phase CXCR2 could be weakly localised to the vasculature, demonstrated 
in Figure 3.7C. Negative controls were incubated with non immune IgG and 
displayed no immunoreactivity (Figure 3.7C, inset). 
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Figure 3.7 Localisation of CXCR2 protein in normal endometrium by 
immunohistochemistry. Representative images demonstrating that A: CXCR2 localises to 
the glandular epithelium (GE) in proliferative phase endometrium (left image is x200 
magnification, right image is x400). B: In early-secretory endometrium, CXCR2 localised to 
the glandular epithelium (left image is x200 magnification, right image is x400). C: In mid-
secretory phase endometrium, CXCR2 immunoreactivity can be seen in the glandular 
epithelium and vascular endothelium (left image is x200 magnification, right image is x400). 
Negative control (inset) is incubated with non-immune IgG in place of primary antibody. D: In 
late secretory phase endometrium, CXCR2 can be localised to glandular epithelium and is 
seen more frequently in the stroma (S; left image is x200 magnification, right image is x400). 
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CXCR2 localisation was then examined in all grades of cancer (well differentiated 
n=5, moderately differentiated n=5, poorly differentiated n=5). As in normal 
endometrium, CXCR2 could be localised to neoplastic epithelial cells, and also to the 
stroma. CXCR2 immunoreactivity could also be seen in vascular endothelial cells in 
all grades of cancer, and representative images of moderately and poorly 
differentiated cancers demonstrate this (Figure 3.8). Negative controls were 




Figure 3.8 Localisation of CXCR2 protein in endometrial adenocarcinoma by 
immunohistochemistry.  Representative images demonstrating that CXCR2 localises to 
the glandular epithelium (GE), vascular endothelium (VE) and stroma (S) in A: Well 
differentiated carcinoma (left image is x200 magnification, right image is x400). Negative 
control (inset) is incubated with non-immune IgG in place of primary antibody. B: Moderately 
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differentiated carcinoma (left image is x200 magnification, right image is x400). All scale bars 
represent 100 µm. 
3.3.3 CXCL1 mRNA expression is regulated by PGF2α in FPS cells 
CXCL1 protein expression by FPS cells after 24 hours of PGF2α stimulation was 
demonstrated by cytokine antibody array (Figure 3.1). The regulation of CXCL1 by 
PGF2α in FPS cells was therefore next examined by luciferase assay, quantitative RT-
PCR and ELISA.  
 
To examine CXCL1 promoter activity, FPS cells were transfected with a luciferase-
conjugated CXCL1 promoter. Cells were treated for 2-24 hours with vehicle or 100 
nM PGF2α (n=4) and promoter activity was determined by luciferase assay. After 8 
hours of PGF2α treatment CXCL1 promoter activity was significantly elevated as 
compared to the earliest time point and remained elevated to 33.3 ± 2.3 fold above 
vehicle treated control after 24 hours treatment (p<0.05, Figure 3.9A).  
 
CXCL1 mRNA expression was then determined by quantitative RT-PCR. FPS cells 
were treated for 2-72 hours with vehicle or 100 nM PGF2α (n=5). After 4 hours 
PGF2α treatment, CXCL1 mRNA expression was elevated above vehicle treated 
control and this induction was sustained to a maximum of 159.3 ± 62.6 at 12 hours, 
followed by a decrease in mRNA expression (p<0.05, Figure 3.9B).  
 
CXCL1 protein concentration was then measured in medium of FPS cells treated for 
2-72 hours with either vehicle or 100nM PGF2α (n=5). As compared to vehicle 
treated cells, PGF2α treatment resulted in CXCL1 protein production which was 
significantly elevated at 24 hours (p<0.05, Figure 3.9C) and remained significantly 
elevated after up to 72 hours of stimulation.  
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Figure 3.9 Regulation of CXCL1 expression by PGF2α treatment in FPS cells. A: 
CXCL1 promoter activity was measured in FPS cells stimulated with vehicle or 100 nM 
PGF2α over a period of 4 to 24 hours. PGF2α stimulation time-dependently increased CXCL1 
promoter activity. Data are expressed as fold increase in luciferase activity as compared to 
vehicle treated cells. B: CXCL1 mRNA expression in FPS cells was measured by 
quantitative RT-PCR after stimulation with vehicle or 100 nM PGF2α over a period of 2 to 72 
hours. Data are expressed as fold increase over vehicle treated control. C: CXCL1 protein 
secreted into media by FPS cells after stimulation with vehicle treated control or 100 nM 
PGF2α over a period of 2 to 72 hours was measured by ELISA. CXCL1 protein was elevated 
between 24-72 hours after treatment with PGF2α. Data are presented in pg / ml. All data are 
presented as mean ± SEM. * denotes p<0.05, ** denotes p< 0.01. 
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3.3.4 Intracellular signalling pathways mediating PGF2α regulation of 
CXCL1 expression in FPS cells 
3.3.5 Signalling pathways mediating CXCL1 expression in FPS cells 
PGF2α binding to FP activates a range of signalling molecules via Gq-coupled 
pathways (Sales et al. 2005; Sales et al. 2008). To elaborate the pathway leading to 
CXCL1 production, FPS cells were treated with vehicle, 100 nM PGF2α alone or 100 
nM PGF2α and a panel of chemical inhibitors (n=7; Figure 3.10). Treatment of FPS 
cells with PGF2α for 8 and 24 hours induced a 91.5±8.4 and 22.3±4.7 fold increase in 
CXCL1 mRNA (Figure 3.10A) and protein (Figure 3.10B) expression respectively 
compared to vehicle treated cells. This increase was abolished by treatment of cells 
with a selective inhibitor of Gq (YM254890, p<0.01) and significantly inhibited with 
the FP receptor antagonist AL8810 (p<0.05) and inhibitors of epidermal growth 
factor receptor (EGFR; AG1478, p<0.05) and mitogen activated protein kinase 
kinase (MEK; PD98059, p<0.01). However, inhibitors of calcium (ethylene glycol 
tetraacetic acid, EGTA), calcineurin (cyclosporine A, CsA) and protein kinase A 
(PKA; 43CMQ) did not significantly alter CXCL1 mRNA or protein production. 
This indicates that in FPS cells PGF2α regulates CXCL1 expression via the FP 
receptor and a Gq coupled signalling pathway involving components of the mitogen 
activated protein kinase (MAPK) pathway and the EGFR, which has been shown in 
our lab to mediate ERK phosphorylation following FP receptor activation by PGF2α 
(Sales et al. 2005).  
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Figure 3.10 PGF2α regulated CXCL1 expression is decreased by selected chemical 
inhibitors. A: FPS cells were treated for 8 hours in the presence or absence of vehicle or 
PGF2α and chemical inhibitors of Gq, FP, EGFR, MEK, calcium, calcineurin and PKA. PGF2α 
regulated CXCL1 mRNA expression was examined by quantitative RT-PCR and found to be 
significantly inhibited by inhibitors of Gq, FP, EGFR and MEK. Data are expressed as fold 
over vehicle treated control B: FPS cells were treated for 24 hours in the presence or 
absence of vehicle or PGF2α and chemical inhibitors of Gq, FP, EGFR, MEK, calcium, 
calcineurin and PKA. CXCL1 protein was measured by ELISA and found to be significantly 
decreased after treatment with chemical inhibitors of Gq, FP, EGFR and MEK. Data are 
expressed as fold over vehicle treated control and are presented as mean ± SEM. * denotes 
p<0.05, ** denotes p<0.01, *** denotes p<0.001. 
 
To further confirm a role for the FP receptor in PGF2α mediated CXCL1 production, 
short hairpin RNA specifically targeted against the FP receptor (sh FP) or with a 
scrambled sequence as a control (sh scrambled) was transfected into FPS cells using 
adenoviral delivery. After transfection, FPS cells were treated for 8 hours with 100 
nM PGF2α or vehicle (n=4). In FPS cells transfected with the scrambled sequence 
control, CXCL1 mRNA expression after PGF2α treatment was increased 117.5 ± 62.3 
fold over vehicle treated cells at 8 hours (Figure 3.11). This was comparable to non-
adenoviral infected cells (Figure 3.9B). This PGF2α-induced increase in CXCL1 
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mRNA expression was reduced with the addition of shRNA directed against the FP 
receptor to 29.7± 13.2 fold (Figure 3.11). 
 
 
Figure 3.11 PGF2α regulated CXCL1 mRNA expression is inhibited with shRNA 
directed against the FP receptor. FPS cells were transfected with adenovirus containing 
scrambled sequence shRNA (sh scrambled) or shRNA against the FP receptor (sh FP). 
Cells were treated for 8 hours with vehicle or 100 nM PGF2α. CXCL1 expression was 
decreased in cells infected with FP shRNA as compared to scrambled sequence shRNA. 
Data are expressed as fold over vehicle treated control and are presented as mean ± SEM. 
 
In order to confirm the involvement of components of the signalling pathway 
identified by chemical inhibitor experiments, and particularly the involvement of the 
classical mitogen activated protein kinase (MAPK) pathway, cDNA encoding 
dominant negative (DN) mutants of signalling molecules or an empty vector were 
co-transfected into FPS cells with the luciferase-conjugated CXCL1 promoter. DN-
EGFR, Ras and MEK were used to confirm the activation of extracellular signal-
related kinases 1/2 (ERK1/2). Ras is a small heterotrimeric G protein upstream of 
MEK in the MAPK phosphorylation cascade. After transfection, FPS cells were 
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treated for 8 hours with vehicle or 100 nM PGF2α and CXCL1 promoter activity 
measured by luciferase assay (n=5; Figure 3.12). In cells transfected with the empty 
vector, 8 hours PGF2α treatment induced an 18.95 ± 3.6 fold increase in CXCL1 
promoter activity as compared to vehicle treated control cells. This increase was 
significantly decreased when cells were transfected with DN-EGFR (p<0.05), DN-
Ras (p<0.01) or DN-MEK (p<0.01). Transfection of DN-NFAT did not significantly 
affect CXCL1 promoter activity. 
 
Figure 3.12 Inhibition of CXCL1 promoter activity by co-transfection of cDNA 
encoding dominant negative mutant forms of EGFR, Ras and MEK. FPS cells were co-
transfected with cDNA encoding luciferase-conjugated CXCL1 promoter and either empty 
vector, DN-EGFR, DN-Ras, DN-MEK or DN-NFAT. Cells were treated for 8 hours with 
vehicle or PGF2α and CXCL1 promoter activity measured by luciferase assay. CXCL1 
promoter activity was increased by PGF2α treatment. This effect could be significantly 
decreased by transfection of DN-EGFR, DN-Ras and DN-MEK, but not DN-NFAT. Data are 
expressed as fold over vehicle treated control and are presented as mean ± SEM. * denotes 
p<0.05, ** denotes p<0.01. 
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3.3.6 Signalling pathways mediating CXCL1 expression in carcinoma 
tissue 
To confirm results obtained on the FPS cell line in human tissue, human endometrial 
adenocarcinoma explants were treated for 2, 4, 6, 8, and 24 hours with vehicle or 
PGF2α and CXCL1 mRNA expression measured by quantitative RT-PCR. After 
treatment with PGF2α for 24 hours, CXCL1 mRNA expression was significantly 
increased in carcinoma explants by 2.8 ± 1.2 fold as compared to vehicle treated 
control cells (p<0.01; Figure 3.13A). In another set of experiments endometrial 
adenocarcinoma explants were treated for 24 hours with PGF2α alone, PGF2α and the 
FP receptor antagonist AL8810 or PGF2α and the MEK inhibitor PD98059. PGF2α 
treatment increased CXCL1 mRNA expression by 5.3 ± 0.7 fold as compared to 
vehicle treated explants (p<0.01; Figure 3.13B). Co-treatment with PGF2α and 
AL8810 or PD98059 significantly reduced CXCL1 mRNA expression to 2.6 ± 0.2 
and 1.8 ± 0.2 fold respectively (p<0.001; Figure 3.13B), confirming the role of FP 
and MEK in PGF2α–regulated CXCL1 expression in carcinoma tissue. 
 
 
Figure 3.13 PGF2α regulated CXCL1 expression is decreased in carcinoma explants 
by selected chemical inhibitors. A: Endometrial adenocarcinoma explants were treated for 
2 - 24 hours with vehicle or PGF2α and CXCL1 mRNA was measured by quantitative RT-
PCR. CXCL1 mRNA was significantly increased after 24 hours of PGF2α treatment. B: 
Endometrial adenocarcinoma explants were treated for 24 hours with vehicle, PGF2α alone, 
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or PGF2α and chemical inhibitors. Co- treatment with PGF2α and AL8810 or PD98059 
significantly reduced CXCL1 mRNA expression. Data are expressed as fold over vehicle 
treated tissue and are presented as mean ± SEM.  ** denotes p<0.01, *** denotes p<0.001. 
 
3.4 Discussion 
The over-expression of chemokines in cancer has been implicated in the remodelling 
of the tumour microenvironment and promotion of tumour progression (Mantovani et 
al. 2008). This study identified the increased expression of CXCL1 in endometrial 
adenocarcinoma, and characterised the localisation of CXCL1 and its receptor 
CXCR2 in endometrial adenocarcinoma tissue. A role for PGF2α in the regulation of 
CXCL1 was demonstrated in an endometrial adenocarcinoma cell line in vitro and ex 
vivo in endometrial adenocarcinoma tissue explants. 
 
Prostaglandins have previously been demonstrated to regulate chemokine expression 
in vitro. Prostaglandin E2 (PGE2) secretion is elevated in many cancer types and 
recently has been shown to induce CXCL1 production in colon cancer cells. This can 
then promote network formation and migration of endothelial cells; crucial steps in 
the initiation of angiogenesis (Wang et al. 2006). Our laboratory has previously 
ascertained a role for the FP receptor and PGF2α signalling in endometrial 
adenocarcinoma, as PGF2α-FP signalling was shown to regulate a number of pro-
tumourigenic genes (Sales et al. 2004; Sales et al. 2005; Sales et al. 2007; Sales et al. 
2008). In the present study, a chemokine antibody array identified CXCL1 as a 
chemokine regulated by PGF2α-FP signalling in an in vitro model system of the 
Ishikawa cell line stably expressing the human FP receptor (FPS cells).  
 
To confirm the physiological significance of CXCL1 expression demonstrated in our 
cell line model, the expression of CXCL1 and its receptor CXCR2 was examined in 
endometrial tissue. CXCL1 mRNA expression has previously been documented in 
the normal endometrium (Nasu et al. 2001) and in agreement with this study our data 
demonstrate a possible increase in CXCL1 expression in the mid-secretory phase of 
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the menstrual cycle as compared all other phases. The mid-secretory phase of the 
menstrual cycle corresponds to the window of implantation, during which the 
endometrium is receptive to embryo implantation. A previous study examining 
proteins expressed in the mid-secretory phase by use of experimentally induced 
progesterone withdrawal also concluded from the resulting decrease in CXCL1 
expression that this chemokine is expressed at this stage of the menstrual cycle 
(Catalano et al. 2007). This indicates that CXCL1 may play a role in preparation for 
implantation in the normal endometrium, potentially by signalling to the CXCR2 
receptor expressed on trophoblast cells (Red-Horse et al. 2004), or may play a role in 
angiogenesis if implantation occurs (Hess et al. 2007).   
 
Our data demonstrate that CXCR2 mRNA is present across the menstrual cycle and 
is significantly higher in endometrium from the late secretory phase. The elevated 
CXCR2 mRNA expression seen in the late secretory phase of the menstrual cycle 
may be due to the increased number of infiltrating leukocytes present at this stage of 
the cycle, as a number of leukocytes found in endometrial stroma express the 
CXCR2 receptor (Murphy et al. 2000; Salamonsen et al. 2000). Immunoreactivity for 
CXCR2 was demonstrated in glandular epithelium and stroma, and weak CXCR2 
expression was also seen in some vascular endothelial cells. Expression of CXCR2 in 
both epithelial and stromal cells of the normal endometrium has been previously 
demonstrated by immunohistochemistry (Mulayim et al. 2003).  
 
Over-expression of CXCL1 has been shown in a number of cancer types including 
melanoma, colorectal and prostate cancer (Haghnegahdar et al. 2000; Wang et al. 
2006; Wen et al. 2006; Kawanishi et al. 2008; Rubie et al. 2008). Data presented in 
this chapter show increased CXCL1 and CXCR2 mRNA expression in endometrial 
cancer tissue as compared to normal endometrium. CXCL1 immunoreactivity was 
localised to neoplastic epithelial cells, vascular endothelium and stromal cells. 
CXCR2 could also be localised to neoplastic epithelial cells, and this indicates the 
potential for autocrine signalling in endometrial adenocarcinoma. In melanoma and 
colon cancer cell lines, inhibition of CXCR2 signalling on cancer cells inhibits cell 
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proliferation thus indicating that an autocrine signalling pathway is occurring (Li et 
al. 2004; Singh et al. 2009). Furthermore, cell migration may be promoted by 
CXCR2 signalling on neoplastic cells, as shown by the increased metastatic potential 
of colon cancer cell lines expressing high levels of CXCR2 and CXCL1 (Li et al. 
2004). A similar CXCL1-CXCR2 autocrine signalling mechanism may promote 
proliferation and cell migration in endometrial adenocarcinoma. 
 
To investigate a role for PGF2α-FP signalling in CXCL1 regulation as indicated by 
the chemokine antibody array, CXCL1 could be co-localised to the same epithelial 
cells and vascular endothelial cells as the FP receptor, further implicating PGF2α 
signalling in its regulation.  CXCL1 promoter activity, mRNA expression and protein 
secretion was also examined in FPS cells. All were found to be increased after PGF2α 
treatment. The signalling pathways mediating the effect of PGF2α-FP receptor 
signalling on CXCL1 expression were then elaborated by the use of small molecule 
inhibitors of cell signalling pathways. A key effector pathway which has been 
previously shown to regulate signalling in response to GPCR activation is the 
mitogen-activated protein kinase (MAPK) pathway. The signalling components of 
this pathway in FPS cells have been identified in our laboratory, where the 
phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in response to 
PGF2α was demonstrated to be mediated by cross talk with the epidermal growth 
factor receptor (EGFR) after its trans-activation by c-Src phosphorylation (Pierce et 
al. 2001; Sales et al. 2005). This study found that chemical inhibitors of Gq, FP, 
EGFR and the upstream kinase of ERK, MEK, could inhibit CXCL1 mRNA and 
protein production. Nuclear factor of activated T-cells (NFAT), a common regulator 
of cytokine expression (Boyd et al. 2006), has been previously shown in our 
laboratory to be regulated by PGF2α-FP signalling. However, a chemical inhibitor of 
NFAT signalling did not significantly inhibit CXCL1 mRNA or protein production. 
Additionally, inhibition of protein kinase A (PKA) did not significantly alter CXCL1 
production in response to PGF2α – FP receptor signalling, despite evidence that PKA 
can trans-activate the EGFR (Barbier et al. 1999). These data highlight that CXCL1 
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expression in response to PGF2α – FP interaction is mediated via a Gq-EGFR-MEK-
ERK1/2 pathway.  
 
In agreement with the data generated using chemical inhibitors, short hairpin RNA 
against the FP receptor and dominant negative mutants of EGFR, Ras and MEK 
significantly decreased CXCL1 promoter activity and mRNA expression in response 
to PGF2α. These signalling data are supported by previously published evidence in 
colorectal adenocarcinoma cell lines where the ERK pathway was also crucial in the 
regulation of CXCL1 expression after stimulation with PGE2 (Wang et al. 2006). In 
addition, treatment of endometrial adenocarcinoma explants with PGF2α caused an 
increase in CXCL1 expression which was mediated via the FP receptor and ERK1/2 
signalling pathways. This confirms the importance of this signalling cascade in 
regulating CXCL1 expression in endometrial adenocarcinoma tissue ex vivo. The 
signalling pathway leading from FP receptor activation to CXCL1 expression is 
summarised in Figure 3.14, with components of the signalling pathway examined in 
this chapter highlighted in red. 
 
 













Figure 3.14 PGF2α stimulates CXCL1 production in FPS cells and endometrial 
adenocarinoma via a FP-Gq-EGFR-Ras-MEK dependent pathway. Use of dominant 
negative mutants and chemical inhibitors of cell signalling (highlighted in red) demonstrated 
that CXCL1 production by PGF2α-FP signalling is dependent on a FP-Gq-EGFR-Ras-MEK 
signalling pathway. 
 
Deregulation of the MAPK signalling pathway is common in many cancer types, and 
this has previously been shown to lead to upregulation of CXCL1 and other 
chemokines in cancer. CXCL1 is expressed following Ras activation in ovarian 
cancer epithelial cells, and stimulated growth of ovarian cancer xenografts by 
signalling to tumour-associated fibroblasts and altering the tumour 
microenvironment (Yang et al. 2006). IL-8 was expressed via this pathway in a nude 
mouse cervical cancer xenograft model (Sparmann et al. 2004) and IL-6 and IL-10 
were elevated via the MAPK pathway in an in vitro model of breast cancer 
(Sumimoto et al. 2006). 
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The aspects of tumour progression associated with CXCL1 and CXCR2 expression 
in cancer are cell proliferation, invasion, angiogenesis and infiltration of immune 
cells (Keane et al. 2004; Li et al. 2004; Singh et al. 2009; Singh et al. 2009). For 
example, in esophogeal and prostate cancer cell lines, knockdown of constitutive 
production of CXCL1 decreased cell proliferation (Li et al. 2004; Wang et al. 2006). 
A decrease in tumour growth was also demonstrated by inhibition of CXCR2 activity 
in a mouse model of melanoma (Singh et al. 2009) and neutralisation of CXCL1 in a 
mouse model of prostate cancer (Moore et al. 1999). A role for CXCL1 in tumour 
cell invasion has also been demonstrated in other published literature. Increased 
secretion of CXCL1 is associated with increased invasive potential in bladder cancer 
(Kawanishi et al. 2008) and prostate cancer (Li et al. 2004). CXCL1 over-expression 
also decreased expression of fibulin-1, an extracellular matrix protein, in a colon 
cancer cell line. The breakdown of the extracellular matrix is one of the first steps in 
initiation of metastasis (Wen et al. 2006).  
 
CXCR2 was also localised to vascular endothelial cells in endometrial 
adenocarcinoma and the presence of the ELR motif in CXCL1 indicates that it is an 
angiogenic chemokine (Strieter et al. 1995). The angiogenic capabilities of CXCL1 
have been demonstrated in a number of cancer models. In mouse models of 
melanoma and prostate cancer (Moore et al. 1999; Singh et al. 2009), CXCR2 
signalling increased microvascular density in xenografts and a corneal angiogenesis 
assay. Vascular density and tumour growth was also decreased in CXCR2-knockout 
mice xenografted with Lewis-lung carcinoma cells (Keane et al. 2004). In another 
mouse model, CXCL1 neutralisation of melanoma cells taken from tumours 
decreased angiogenic capability in the corneal pocket model (Haghnegahdar et al. 
2000). These studies indicate that in vivo, CXCL1 signalling can induce angiogenesis 
to increase tumour growth. The expression of both CXCL1 and CXCR2 in 
endometrial adenocarcinoma indicates a potential angiogenic role in this cancer type. 
 
An additional role of CXCL1-CXCR2 signalling is in the chemoattraction of immune 
cells.  Strong CXCR2 expression was observed in a number of cells throughout the 
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stroma of endometrial adenocarcinomas which morphologically appeared to be 
immune cells. CXCR2 is highly expressed on neutrophils and on some macrophages 
(Murphy et al. 2000). Neutrophils in cancer have been demonstrated to contribute to 
tissue remodelling impacting on tumour growth (Ardi et al. 2007; Yamamoto et al. 
2008) and a similar role has been shown for macrophages, particularly in the 
promotion of angiogenesis (Bingle et al. 2006; Lin et al. 2007). CXCL1 induced by 
PGF2α in endometrial adenocarcinoma may therefore be signalling to CXCR2 
positive cells in the stroma of endometrial adenocarcinoma. 
 
Wang et al demonstrated an increase in CXCL1 expression after PGE2 treatment in 
colorectal cancer cells, which was shown to promote angiogenesis in vitro (Wang et 
al. 2006). Similarly linking prostaglandins and CXCL1, data presented in this chapter 
show that PGF2α can induce CXCL1 expression in our endometrial adenocarcinoma 
cell line and endometrial adenocarcinoma tissue. Expression of CXCL1 and its 
receptor CXCR2 was increased in cancer as compared to normal endometrial tissue 
and localised to neoplastic epithelium, vascular endothelium and stroma. Evidence 
presented in this chapter therefore indicates that the CXCL1 produced by PGF2α –FP 
interactions in our endometrial adenocarcinoma cell model may promote 
angiogenesis and immune cell infiltration into tumours in vivo. Therefore the next 
chapter in this thesis concentrates on the potential role of CXCL1 in immune cell 
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4 Chemokine (C-X-C motif) ligand 1 expression in 
endometrial adenocarcinoma: Effects on immune cell 
infiltration and angiogenesis 
4.1 Introduction 
In the previous chapter, the regulation of the chemokine CXCL1 by PGF2α in an 
endometrial adenocarcinoma cell line and in endometrial adenocarcinoma explants 
was demonstrated. CXCR2 was localised by immunohistochemistry to a number of 
stromal and vascular endothelial cells within endometrial adenocarcinoma, and 
therefore the potential role of CXCL1 signalling to these cells in endometrial 
adenocarcinoma is further examined in this chapter.  
 
The hypothesis that inflammation may drive tumour progression has received much 
attention, due to studies showing that long term intake of specific COX-2 inhibitors 
(NSAIDS) can significantly reduce cancer occurrence in pre-disposed patients 
(Dannenberg et al. 2003). Of the multiple cell types which make up the tumour 
microenvironment, several types of leukocyte commonly infiltrate and the role that 
these cells play in tumourigenesis is still unclear. In addition to epithelial and 
endothelial cells, expression of CXCR2 has been previously documented on various 
immune cells including neutrophils, eosinophils, monocytes, macrophages, T cells 
and dendritic cells (Murphy et al. 2000). Only the role of CXCL1 as a neutrophil 
chemoattractant is well defined, however there is some evidence that it may promote 
monocyte/macrophage migration into tissues (Weber et al. 1999; Traves et al. 2004; 
Smith et al. 2005). The function of all of these immune cells in cancer has been 
intensely studied, and there is contrasting evidence for a role in both tumour 
promotion and eradication (de Visser et al. 2006). 
 
A popular model of immune cell infiltration into tumours suggests that the first types 
of immune cell to infiltrate are those of the innate immune system including 
macrophages, neutrophils and dendritic cells. These are chemo-attracted by pro-
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inflammatory cytokines secreted by the tumour. The discovery of these cells within 
solid tumours originally led to the hypothesis that immune cells were attacking and 
destroying tumour cells, and may eventually be used in cancer immunotherapy 
(Dirkx et al. 2006). However, new evidence suggests cells of the innate immune 
system promote tumour growth, angiogenesis and cell migration (Murdoch et al. 
2008). After the initial infiltration of cells of the innate immune system, the 
activation of antigen presenting cells such as dendritic cells may result in the 
recruitment of cells of the adaptive immune system such as T and B lymphocytes to 
the tumour. There is some evidence that these lymphocytes can contribute to tumour 
cell destruction by cell-mediated cytotoxicity (de Visser et al. 2006). However, 
paradoxically tumours are often infiltrated by regulator T cells which can suppress 
adaptive immune responses (Giatromanolaki et al. 2008).  
 
In endometrial cancer, the number of infiltrating immune cells has previously been 
examined and compared to normal endometrium. The numbers of macrophages 
(Salvesen et al. 1999; Ohno et al. 2004) and B and T lymphocytes (Yamazawa et al. 
2001; Chang et al. 2005; Ohno et al. 2005; Ohno et al. 2006; Miyatake et al. 2007; 
Giatromanolaki et al. 2008) were found to be increased in cancer, while the number 
of natural killer cells was similar to that of the normal endometrium (Hachisuga et al. 
1997). However the infiltration of neutrophils, the main cell type known to be 
recruited by CXCL1 (Moser et al. 1990), has not previously been quantified in 
endometrial adenocarcinoma.  
 
As discussed in Chapter 3, CXCL1 binding to CXCR2 on endothelial cells can 
promote angiogenesis in a variety of in vitro and in vivo models of cancer. The 
angiogenic properties of CXCL1 have been displayed in vitro by its ability to 
promote several functions of endothelial cells crucial to angiogenesis, including 
network formation (Wang et al. 2006) and endothelial cell migration (Strieter et al. 
1995; Wang et al. 2006). In vivo, mouse models of melanoma (Haghnegahdar et al. 
2000; Singh et al. 2009), lung (Keane et al. 2004) and prostate cancer (Moore et al. 
1999) have decreased tumour angiogenesis after prevention of CXCL1-CXCR2 
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signalling. Therefore in this chapter the dual role of PGF2α-regulated CXCL1 as a 
chemoattractant for immune cells and a stimulator of angiogenesis is investigated.  
 
 
4.2 Materials and Methods 
4.2.1 Tissue collection 
Normal endometrial and endometrial adenocarcinoma tissue was collected for RT-
PCR analysis and immunohistochemistry as described in sections 2.1.1 and 2.1.2. 
Normal endometrial tissue was collected from women undergoing surgery for minor 
gynaecological procedures with no underlying endometrial pathology, and 
endometrial adenocarcinoma tissue was obtained from women undergoing 
hysterectomy after diagnosis of adenocarcinoma of the uterus. Stage of cycle and 
grade of cancer was assessed by a pathologist. Tissue collected for RT-PCR analysis 
was stored in RNA Later (Ambion) at -70°C for RNA extraction and tissue for 
immunohistochemical analysis was fixed in neutral buffered formalin and wax 
embedded. Written informed consent was collected from all patients before surgery 
and ethical approval was obtained from Lothian Research Ethics Committee. 
4.2.2 Cell culture 
Ishikawa FPS cells were maintained as described in section 2.2.1. 
4.2.3 Cell and tissue treatments 
To obtain conditioned media for the neutrophil chemotaxis experiment, FPS cells 
were serum starved in media containing 3 µg/ml indomethacin for at least 18 hours 
prior to stimulation for 48 hours with fresh serum-free media containing 
indomethacin and vehicle or 100 nM PGF2α. Medium from 3 experiments was 
pooled to use in each chemotaxis assay. 
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4.2.4 Immunohistochemistry 
3,3- diaminobenzidine tetrahydrochlorine (DAB) immunohistochemistry was used to 
localise neutrophil elastase, CD68, CD4, CD8, CD20, CD56, and CD11c in human 
endometrial tissue (normal proliferative phase endometrium n=7, well differentiated 
endometrial adenocarcinoma n=10, moderately differentiated endometrial 
adenocarcinoma n=10, poorly differentiated endometrial adenocarcinoma n=10), and 
Gr-1 and CD31 in mouse xenograft tissue (wildtype xenografts n=10, FPS xenografts 
n=10, CXCL1 neutralised FPS xenografts n=10). Immunohistochemistry was 
performed as described in section 2.5.2. Tissue sections (5 µm) were dewaxed in 
xylene then rehydrated through graded ethanols and water. Antigen retrieval in 
citrate buffer (0.01M, pH 6) was performed for CD68, CD8, CD20, CD56, CD31 and 
CD11c. Antigen retrieval in EDTA buffer (1mM, pH 8) was performed for CD4. No 
retrieval step was required for neutrophil elastase or Gr-1. Sections were then 
blocked for endogenous peroxidase activity by washing in 3% hydrogen peroxidase 
in methanol. Blocking in normal serum of rabbit (for immunolocalisation of Gr-1) or 
goat (for immunolocalisation of neutrophil elastase, CD68, CD4, CD8, CD20, CD56, 
CD11c, CD31) was then performed followed by overnight incubation with primary 
antibody at the concentrations indicated in Table 2.4. Control sections were included 
with non-immune rabbit or goat IgG. Sections were then incubated in rabbit anti-rat 
(for immunolocalisation of Gr-1), goat anti-mouse (for immunolocalisation of 
neutrophil elastase, CD68, CD4, CD8, CD20, CD56,) or goat anti-rabbit (for 
immunolocalisation of CD11c, CD31) biotinylated secondary antibody and 
subsequently streptavidin-HRP. Sections were then incubated with DAB for 1-5 
minutes until positive staining was identified by a brown colour under x10 
magnification. Slides were coverslipped and visualised as described in Section 2.5.2 
and 2.5.4. 
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4.2.5 Stereological analyses 
4.2.5.1 Immune cells 
The number of immune cells in endometrial tissue was quantified using 
immunohistochemical staining and standard stereological techniques. Each section 
was examined using x40 plan apo objective from a BH2 microscope (Olympus, 
Tokyo, Japan) fitted with an automatic stage (Prior Scientific Instruments Ltd., 
Cambridge, UK) using a video camera (HV-C20; Hitachi, Tokyo, Japan) and were 
analyzed with Image-Pro Plus 4.5.1 software with a Stereology 5.0 plug-in (Media 
Cybernetics, Wokingham, Berkshire, UK). A total of 40 randomised fields of view 
were examined and counted (proliferative phase endometrium n=7, well 
differentiated endometrial adenocarcinoma n=10, moderately differentiated 
endometrial adenocarcinoma n=10, poorly differentiated endometrial 
adenocarcinoma n=10) and data are expressed as mean ± SEM number of cells per 
mm
2
 of tumour examined.  
4.2.5.2 Microvascular density 
Microvascular density was quantified in mouse xenograft tissue, using 
immunohistochemistry for the vascular marker CD31. A modified intra-tumour 
microvessel density protocol of Weidner (Weidner et al. 1993; Weidner 1995) was 
used. Briefly, each section (n=10 each group, as described in section 4.2.4) was  
examined under low power magnification using x50 plan apo objective from a BH2 
microscope (Olympus, Tokyo, Japan) fitted with an automatic stage (Prior Scientific 
Instruments Ltd., Cambridge, UK) using a video camera (HV-C20; Hitachi, Tokyo, 
Japan). Sections were analyzed with Image-Pro Plus 4.5.1 software with a Stereology 
5.0 plug-in (Media Cybernetics, Wokingham, Berkshire, UK). Section identities 
were blinded, and areas containing neovascular „hotspots‟ were identified by CD31 
staining. Three hotspots were then examined under higher power magnification 
(x200 plan apo objective, 0.9 mm
2
 field). As defined by Weidner, any distinct CD31-
positive endothelial cell or cells separate from other endothelial cells or connective 
tissue was counted as a microvessel. Results were then calculated as the average 
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number of the highest number of microvessels in any single x200 field from the three 
separate hotspots, and are expressed as average highest microvessel count per field.  
4.2.6 Dual immunofluorescence microscopy 
For colocalisation studies, the expression of CXCR2 and neutrophil elastase, CD45, 
CD68, CD3, CD20, CD56, CD11c, CXCL1 or CD31 was examined by dual 
immunofluorescence microscopy in all grades of endometrial adenocarcinoma (well 
differentiated n=3, moderately differentiated n=3, poorly differentiated n=3). 
Protocols differed depending on the species the primary antibodies were raised in, 
and are detailed below. 
4.2.6.1 Dual immunofluorescence microscopy using two primary 
antibodies raised in the same species 
CXCR2 and CD45, CD68, CD3, CD20 and CD56 were all raised in mouse and 
therefore dual immunofluorescence required a microwave blocking step and the use 
of secondary antibodies with fragment antigen binding fragments (Fab fragments). 
These ensure that there are no open binding sites on the secondary antibody which 
can subsequently cross react with the next primary antibody which is added. Sections 
(5 µm) were dewaxed in xylene then rehydrated through graded ethanols and water. 
Antigen retrieval in citrate buffer (0.01M, pH 6) was performed for CD45, CD68, 
CD3, CD20, and CD56. No retrieval step was required for neutrophil elastase. 
Sections were blocked in 5% normal goat serum diluted in PBS with 5% BSA before 
incubation with mouse anti-CD45 (1:1000), neutrophil elastase (1:500), CD68 
(1:1000), CD3 (1:400), CD20 (1:500), and CD56 (1:1500). Following an overnight 
incubation at 4ºC sections were incubated with goat-anti mouse biotinylated Fab, 
then tyramide signal amplification kit (TSA Fluorescein System, 1:50 dilution, 
Perkin Elmer, MA). Sections were then microwaved in 0.01M citrate buffer for 30 
minutes and endogenous peroxidase blocked using hydrogen peroxide. Non-specific 
binding was blocked with 5% normal goat serum and sections were incubated with 
mouse anti-CXCR2 (1:500) at 4ºC overnight. The sections were again incubated with 
goat-anti mouse biotinylated Fab and tyramide signal amplification kit. Nuclei were 
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counterstained in To Pro (Molecular Probes, UK) and sections were then 
coverslipped and visualised as described in Section 2.5.3 and 2.5.4. 
4.2.6.2 Dual immunofluorescence microscopy using two primary 
antibodies raised in different species 
To colocalise CXCR2 with CXCL1, CD11c and CD31, sections (5 µm) were 
dewaxed in xylene then rehydrated through graded ethanols and water. Antigen 
retrieval in citrate buffer (0.01M, pH 6) was performed and sections were blocked in 
5% normal goat serum (CD11c and CD31) or rabbit serum (CXCL1) diluted in PBS 
with 5% BSA. Sections were then incubated with rabbit anti-CD11c (1:100) or CD31 
(1:100), or goat anti-CXCL1 (1:100) overnight at 4ºC. Goat anti-rabbit (CD11c and 
CD31) or rabbit anti-goat (CXCL1) biotinylated antibody was then added, diluted in 
PBS at 1:200 for 30 minutes. Streptavidin AlexaFluor 546 (Molecular Probes) 
diluted 1:200 in PBS was then added to biotyinlated secondary antibodies for 30 
minutes at room temperature. Sections were then re-blocked in normal serum and the 
process repeated with mouse anti-CXCR2 (1:25). Tissues were then incubated with a 
fluorophore-conjugated antibody diluted 1:200 in PBS (AlexaFluor 488, Molecular 
Probes, UK) for 1 hour. Nuclei were counterstained in To Pro (Molecular Probes, 
UK) and then coverslipped and visualised as described in Section 2.5.3 and 2.5.4. 
 
To colocalise CXCL1 with CD31, sections (5 µm) were dewaxed in xylene then 
rehydrated through graded ethanols and water. Antigen retrieval in citrate buffer 
(0.01M, pH 6) was performed and sections were blocked in 5% normal donkey 
serum diluted in PBS with 5% BSA. Sections were then incubated with goat anti-
CXCL1 (1:20) overnight at 4ºC. Donkey anti-goat AlexaFluor 488 antibody was then 
added, diluted in PBS at 1:200 for 1 hour. Sections were then re-blocked in normal 
goat serum and rabbit anti-CD31 added (1:100). Tissues were then incubated with 
goat anti-rabbit biotinylated antibody diluted in PBS at 1:200 for 30 minutes. 
Streptavidin AlexaFluor 546 (Molecular Probes) diluted 1:200 in PBS was then 
added to biotyinlated secondary antibodies for 30 minutes at room temperature for 1 
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hour. Nuclei were counterstained in To Pro (Molecular Probes, UK) and sections 
were then coverslipped and visualised as described in Section 2.5.3 and 2.5.4. 
4.2.7 Neutrophil migration assay 
Neutrophil chemotaxis was analyzed using transwell inserts (5-µm pore size; 
Corning Life Sciences, Leicestershire, UK). Neutrophils were kindly purified as 
previously described (Ward et al. 1999) by Dr A Leitch (Centre for Inflammation 
Research, University of Edinburgh) and resuspended in serum free media. Cells (7.5 
x 10
5
) were added to the top chamber of the transwell insert and 600 µl of 
conditioned media from FPS cells treated with vehicle or 100 nM PGF2α (Section 
5.2.3; V-CM or PGF2α-CM) was added to the bottom chamber. Serum-free media 
alone or with 50 ng/ml recombinant CXCL1 was added as negative and positive 
controls, respectively. Cells were incubated at 37 °C in a 5% CO2 atmosphere for 1 
hour and the plate was gently tapped to dislodge cells adhered to the underside of the 
membrane. Cells in the bottom chamber were collected and counted at least six times 
using a haemocytometer (n=4). 
4.2.8 Animal xenograft model 
The animal model experiments were kindly performed by Dr R Catalano and Dr M 
Wilson. A suspension of 5 x 10
5
 Ishikawa wild-type (WT) or FPS cells in a total 
volume of 0.2 ml DMEM was injected subcutaneously into each dorsal flank of 
CD1-Foxn1
nu
 mice (Charles River) giving rise to two tumours per mouse. The mice 
bearing FPS tumours (n = 20) were divided into two groups of equal tumour size one 
week after engraftment. The mice were then treated twice weekly with 100 µg IgG 
(n=10) or CXCL1 neutralizing antibody (n=10) via intraperitoneal injection for 4 
weeks. Animals bearing WT tumours (n=10) were also treated twice weekly with 
100 µg IgG via intraperitoneal injection for 4 weeks. The animals were maintained 
under sterile conditions in individually vented cages. At the end of the experiment, 
animals were sacrificed and the tumours were excised. One tumour from 5 mice from 
each treatment group was placed in PBS for flow cytometry analysis, and RNA was 
extracted from one tumour of the remaining 5 mice. The second tumour from each 
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mouse was fixed in neutral buffered formalin and wax embedded for histological 
analysis.  
4.2.9 RNA extraction and polymerase chain reaction  
RNA from xenograft tissue was extracted as described in section 2.4.1 using the 
Qiagen minikit protocol. Briefly, pieces of tissue, in 2 ml microcentrifuge tubes 
containing a stainless steel ball, were homogenised in 600 µl RLT lysis buffer using 
a tissue lyser (Qiagen Crawley, West Sussex, UK) for 2 x 3 minutes at 25 Hz. RNA 
was then extracted following manufacturers guidelines (Qiagen). cDNA was 
prepared as described in section 2.4.2. 
4.2.10 Taqman quantitative PCR 
CXCL1 mRNA expression in xenograft tissue was examined using Taqman 
quantitative PCR as described in section 2.4.3.2. Briefly, primer and probe sequences 
were designed to amplify CXCL1 (sequence given in Table 2.2). A master mix was 
made up containing 18s primers and probes and 200 ng cDNA added to each sample. 
Samples were added in duplicate to a 96 well MicroAmp fast optical reaction PCR 
plate and analysed using an ABI Prism 7900 HT Fast Real Time PCR machine. 
Expression of CXCL1 was normalised to RNA loading for each sample using the 
18S ribosomal RNA as an internal standard. Results are expressed compared to 
normal endometrium calibration sample. 
4.2.11 Flow cytometry of xenograft tissue  
Xenografts from nude mice (n=5 each group) were assessed for neutrophil infiltrate 
using flow cytometry. Briefly, tumours were digested by collagenase treatment at 37 
°C for 45 minutes. Tissue was then mechanically disrupted into a single cell solution 
using a syringe and 40 µm mesh and resuspended in FACS wash (PBS + 1%BSA + 
2% formalin). Cells were incubated at 4 °C for 30 minutes in FACS wash containing 
the following monoclonal antibodies and appropriate isotype controls: CD11b-FITC, 
Gr-1-PE and CD11c-APC. All antibodies were obtained from eBioscience (Hatfield, 
UK) and used at a dilution of 1:200. Red blood cells were lysed using BD FACS 
lysing solution according to manufacturer‟s instructions (BD Biosciences, Oxford, 
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UK). Samples were analysed using a FACScalibur cytometer (BD biosystems) using 
BD CellQuest software. In xenograft tissue, neutrophils were defined by expression 
of Gr-1 and CD11b epitope, absence of CD11c and scatter profile. 
4.2.12 Statistical analysis 
Where appropriate, data were analysed by Students t-test and one way ANOVA 
using GraphPad Prism (GraphPad Software. San Diego, California, USA). Data are 
presented as mean ± SEM. 
 
4.3 Results 
4.3.1 Identification of CXCR2 expressing cells in endometrial 
adenocarcinoma 
As described in Chapter 3, a number of stromal cells were seen in all grades of 
endometrial adenocarcinoma expressing CXCR2. The identity of these cells was then 
investigated in all grades of endometrial adenocarcinoma (well differentiated n=3, 
moderately differentiated n=3, poorly differentiated n=3) using dual 
immunofluorescence microscopy to examine the expression of CXCR2 and a number 
of markers of immune cells. Immune cell markers were chosen based on the 
morphological appearance of these cells and previous evidence of CXCR2 
expression on immune cells (Murphy et al. 2000). 
4.3.1.1 CXCR2 and CD45 (Leukocyte common antigen) 
CD45 (also known as protein tyrosine phosphatase receptor type C) is a membrane 
protein tyrosine phosphatase specifically expressed in leukocytes and therefore used 
as a pan-leukocyte marker (NCBI 2009). Dual immunofluorescence microscopy 
revealed high numbers of CD45 positive cells in all grades of endometrial 
adenocarcinoma sections examined. A moderately differentiated cancer is shown in 
Figure 4.1. The expression of CD45 (Figure 4.1A) colocalised to a large number of 
CXCR2 (Figure 4.1B) expressing cells (Figure 4.1C), identifying the majority of 
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CXCR2-positive cells as leukocytes. An enlarged image of the inset box in Figure 




Figure 4.1 Colocalisation of CXCR2 and CD45 protein in a moderately 
differentiated endometrial adenocarcinoma by dual immunofluorescence microscopy. 
CD45 (A) and CXCR2 (B) were colocalised (C) to a large number of cells within the stroma 
of endometrial adenocarcinoma, identifying them as leukocytes. Negative control (inset) was 
incubated with non-immune IgG in place of primary antibody. Scale bar represents 50 µm. D: 
Magnification of the area within the white box inset in 4.1C, colocalisation is indicated by 
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4.3.1.2 CXCR2 and neutrophil elastase 
The expression of CXCR2 on neutrophils is well characterised (Murphy et al. 2000).  
To determine if CXCR2-expressing cells in endometrial adenocarcinoma were 
neutrophils, expression of neutrophil elastase, an enzyme specific to neutrophils used 
to hydrolyse proteins within neutrophil granules (NCBI 2009), was examined by dual 
immunofluorescence microscopy. Neutrophil elastase (Figure 4.2A) and CXCR2 
(Figure 4.2B) colocalised within a large number of cells in all grades of endometrial 
adenocarcinoma, however a number of larger CXCR2-positive cells were not 
neutrophil elastase positive (Figure 4.2C and magnification, Figure 4.2D). 
Colocalisation is indicated by arrowheads. A representative image of a well 
differentiated adenocarcinoma is shown in Figure 4.2. 
 
 
Figure 4.2 Colocalisation of CXCR2 and neutrophil elastase protein in a well 
differentiated endometrial adenocarcinoma by dual immunofluorescence microscopy. 
Neutrophil elastase (A) and CXCR2 (B) were colocalised (C) to neutrophils within the stroma 
of a well differentiated endometrial adenocarcinoma. Negative control (inset) was incubated 
with non-immune IgG in place of primary antibody. Scale bar represents 50 µm. D: 
Magnification of the area within the white box, inset in C. Scale bar represents 10 µm. 
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4.3.1.3 CXCR2 and CD68 
CD68 is a membrane glycoprotein specifically expressed by macrophages and 
monocytes (NCBI 2009). A high number of CD68-positive cells were seen 
throughout the stroma of all grades of endometrial adenocarcinoma (Figure 4.3A), 
however colocalised to only a small number of CXCR2-positive cells (Figure 4.3B 
and merge, 4.3C) within endometrial adenocarcinoma using dual 
immunofluorescence microscopy. Colocalisation is indicated by arrowheads. A 





Figure 4.3 Colocalisation of CXCR2 and CD68 protein in a poorly differentiated 
endometrial adenocarcinoma by dual immunofluorescence microscopy. CD68 (A) and 
CXCR2 (B) were colocalised (C) to a small number of macrophages within the stroma of a 
poorly differentiated endometrial adenocarcinoma. Negative control (inset) was incubated 
with non-immune IgG in place of primary antibody, scale bar represents 50 µm. D: 
Magnification of the area within the white box, inset in C. Colocalisation is indicated by 
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4.3.1.4 CXCR2 and CD3 
The specific T-cell marker CD3 is a protein which forms a complex with the T cell 
receptor to enable antigen recognition (NCBI 2009). CD3 expression (Figure 4.4A) 
could be seen throughout all grades of endometrial adenocarcinoma but did not 
colocalise with CXCR2 expression (Figure 4.4B, C). A magnification is presented in 
Figure 4.4D. A representative image of a well differentiated adenocarcinoma is 




Figure 4.4 Expression of CXCR2 and CD3 protein in a well differentiated 
endometrial adenocarcinoma by dual immunofluorescence microscopy. CD3 (A), a 
specific T-cell marker, and CXCR2 (B) were expressed in a well differentiated endometrial 
adenocarcinoma but did not colocalise (C). Negative control (inset) was incubated with non-
immune IgG in place of primary antibody, scale bar represents 50 µm. D: Magnification of 
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4.3.1.5 CXCR2 and CD20 
CD20 is a membrane protein specifically expressed on B cells (NCBI 2009). 
Similarly to T-cells, B cells were found throughout all grades of endometrial 
adenocarcinoma tissue in clusters (Figure 4.5A) but CD20-positive cells did not 
colocalise with CXCR2 expression (Figure 4.5B, C). This can be clearly seen in the 
magnification in Figure 4.5D. A representative image of a well differentiated 




Figure 4.5 Expression of CXCR2 and CD20 protein in a well differentiated 
endometrial adenocarcinoma by dual immunofluorescence microscopy. CD20 (A), a 
specific B-cell marker, and CXCR2 (B) were expressed in a well differentiated endometrial 
adenocarcinoma but did not colocalise (C). Negative control (inset) was incubated with non-
immune IgG in place of primary antibody, scale bar represents 50 µm. D: Magnification of 
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4.3.1.6 CXCR2 and CD56 
Uterine natural killer (NK) cells can be identified by expression of the adhesion 
molecule CD56 (also known as NCAM1) (NCBI 2009). These cells were sparsely 
distributed throughout all grades of endometrial adenocarcinoma sections examined 
(Figure 4.6A) and did not colocalise with CXCR2 expression (Figure 4.6C, D) in all 
grades of endometrial adenocarcinoma sections examined. A representative image of 




Figure 4.6 Expression of CXCR2 and CD56 protein in a well differentiated 
endometrial adenocarcinoma by dual immunofluorescence microscopy. CD56 (A), a 
specific NK cell marker, and CXCR2 (B) were expressed in a well differentiated endometrial 
adenocarcinoma but did not colocalise (C). Negative control (inset) was incubated with non-
immune IgG in place of primary antibody, scale bar represents 50 µm. D: Magnification of 
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4.3.1.7 CXCR2 and CD11c 
CD11c (also known as integrin alpha-x) is an integrin expressed on immature 
dendritic cells and during differentiation into mature dendritic cells, so despite its 
expression on a small number of other leukocytes is an adequate dendritic cell 
marker (Coukos et al. 2005). In all grades of endometrial adenocarcinoma, CD11c-
positive cells (Figure 4.7A) were seen in clusters within the stroma. CD11c 
expression did not colocalise with CXCR2 expression (Figure 4.7B) in endometrial 
adenocarcinoma sections examined (Figure 4.7C, D). A representative image of a 




Figure 4.7 Expression of CXCR2 and CD11c protein in a moderately differentiated 
endometrial adenocarcinoma by dual immunofluorescence microscopy. CD11c (A), a 
dendritic cell marker, and CXCR2 (B) were expressed in a moderately differentiated 
endometrial adenocarcinoma but did not colocalise (C). Negative control (inset) was 
incubated with non-immune IgG in place of primary antibody, scale bar represents 50 µm. D: 
Magnification of the area within the white box, inset. Scale bar represents 10 µm. 
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4.3.2 Colocalisation of CXCR2 and CXCL1 expression in endometrial 
adenocarcinoma 
The expression of CXCL1 by a number of stromal cells in endometrial 
adenocarcinoma was also noted in Section 4.2.3.3. To identify if these cells also 
expressed CXCR2, dual immunofluorescence microscopy was performed and 
revealed that CXCL1 (Figure 4.8A) colocalised with CXCR2 (Figure 4.8B) to a high 
number of cells within all grades of endometrial adenocarcinoma, as indicated by 
arrowheads (Figure 4.8 C, D). A representative image of a well differentiated 
adenocarcinoma is shown in Figure 4.8. 
 
 
Figure 4.8 Expression of CXCR2 and CXCL1 protein in a well differentiated 
endometrial adenocarcinoma by dual immunofluorescence microscopy. CXCL1 (A) 
and CXCR2 (B) colocalised in a number of cells in a well differentiated endometrial 
adenocarcinoma (C). Negative control (inset) was incubated with non-immune IgG in place 
of primary antibody, scale bar represents 50 µm. D: Magnification of the area within the 
white box, inset in C. Colocalisation is indicated by arrowheads. Scale bar represents 10 µm. 
 
4.3.3 Localisation and quantification of immune cells in endometrial 
adenocarcinoma by immunohistochemistry 
As the majority of CXCR2 positive cells in the stroma of endometrial 
adenocarcinoma were immune cells, notably neutrophils, the infiltration of immune 
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cells into endometrial adenocarcinoma as compared to normal endometrium from the 
proliferative stage of the menstrual cycle was localised and quantified. Immune cells 
were identified and localised by immunohistochemistry of specific markers and then 
quantified using standard stereological techniques (normal proliferative endometrium 
n=7, well differentiated endometrial adenocarcinoma n=10, moderately differentiated 
endometrial adenocarcinoma n=10, poorly differentiated endometrial 
adenocarcinoma n=10). Immune cells were identified by expression of the following 
markers: neutrophil elastase (neutrophils), CD68 (macrophages), CD4 (CD4+ T 
cells), CD8 (CD8+ T cells), CD20 (B cells), CD56 (uterine natural killer (uNK) 
cells) and CD11c (dendritic cells). 
4.3.3.1 Neutrophil infiltration into endometrial adenocarcinoma as 
compared to normal endometrium 
Neutrophils in normal endometrium from the proliferative phase of the menstrual 
cycle and in all grades of endometrial adenocarcinoma were measured by expression 
of neutrophil elastase (representative images shown in Figure 4.9). Neutrophils were 
seen scattered throughout the stroma, and were rarely present in normal endometrium 
from the proliferative phase of the menstrual cycle (Figure 4.9A). Neutrophils were 
more frequently distributed in all grades of endometrial adenocarcinoma (Figure 
4.9B). No significant difference in neutrophil infiltration was seen between different 
grades of endometrial adenocarcinoma. Therefore the data was pooled, and the 
number of neutrophils in endometrial cancer was significantly increased as compared 
to normal proliferative endometrium (p<0.01; Figure 4.9C), by an average of 13.9 ± 
2.3 fold. 
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Figure 4.9 Localisation and quantification of neutrophils in normal endometrium 
and endometrial adenocarcinoma. A: Representative image demonstrating the localisation 
of neutrophil elastase expression, a neutrophil marker, in normal proliferative phase 
endometrium (n=7). Neutrophils are found rarely throughout the stroma. Scale bar 
represents 100 µM. B: Representative image demonstrating the localisation of neutrophils in 
well differentiated endometrial adenocarcinoma. Neutrophils are present throughout the 
stroma (well differentiated adenocarcinoma n=10, moderately differentiated adenocarcinoma 
n=10, poorly differentiated adenocarcinoma n=10). Negative control (inset) was incubated 
with non-immune IgG in place of primary antibody, Scale bar represents 100 µM. C: 
Neutrophils were significantly increased in endometrial adenocarcinoma as compared to 
normal endometrium from the proliferative stage of the menstrual cycle (n= as above). No 
significant difference was found between different grades of cancer. Data are expressed as 
number of neutrophil elastase positive cells/mm
2
 and are presented as mean ± SEM. ** 
denotes p<0.01. 
4.3.3.2 Macrophage infiltration into endometrial adenocarcinoma as 
compared to normal endometrium 
 Macrophages in normal endometrium from the proliferative phase of the menstrual 
cycle and in all grades of endometrial adenocarcinoma were measured by expression 
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of CD68 (representative images shown in Figure 4.10). Macrophages were present 
throughout the stroma of endometrial tissue from the proliferative phase of the 
menstrual cycle (Figure 4.10A) and in all grades of endometrial adenocarcinoma 
(Figure 4.10B). Macrophage numbers did not significantly vary between grades of 
endometrial adenocarcinoma examined, and hence data were pooled. Macrophages 
were significantly increased an average of 2.48 ± 0.73 fold in all grades of 
endometrial adenocarcinoma pooled as compared to normal endometrium from the 
proliferative phase of the menstrual cycle (p<0.05; Figure 4.10C). 
 
Figure 4.10 Localisation and quantification of macrophages in normal 
endometrium and endometrial adenocarcinoma. A: Representative image demonstrating 
the localisation of CD68 expression, a macrophage marker, in normal proliferative phase 
endometrium (n=7). Macrophages are found throughout the stroma. Scale bar represents 
100 µM. B: Representative image demonstrating the localisation of macrophages in a 
moderately differentiated endometrial adenocarcinoma. Macrophages are present 
throughout the stroma (well differentiated adenocarcinoma n=10, moderately differentiated 
adenocarcinoma n=10, poorly differentiated adenocarcinoma n=10). Negative control (inset) 
was incubated with non-immune IgG in place of primary antibody, Scale bar represents 100 
µM. C: Macrophages were significantly increased in endometrial adenocarcinoma as 
compared to normal proliferative phase endometrium (n= as above). No significant 
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difference was found between different grades of cancer. Data are expressed as number of 
CD68 positive cells/mm
2
 and are presented as mean ± SEM. *denotes p<0.05. 
4.3.3.3 CD4+ T cell infiltration into endometrial adenocarcinoma as 
compared to normal endometrium 
CD4+ T cells in normal endometrium from the proliferative phase of the menstrual 
cycle and in all grades of endometrial adenocarcinoma were measured by expression 
of CD4 (representative images shown in Figure 4.11). CD4+ T cells were present 
throughout the stroma in normal proliferative phase endometrium (Figure 4.11A) and 
in all grades of endometrial adenocarcinoma, often in small clusters (Figure 4.11B). 
There was no significant difference in CD4+ T cell numbers between different 
grades of endometrial adenocarcinoma, and therefore data were pooled. No 
significant difference was found between infiltrations of CD4+ T cells in pooled 
endometrial adenocarcinoma as compared to normal endometrium from the 
proliferative phase of the cycle, however a trend towards increased numbers in 




Chapter 4                     Effects of CXCL1 expression in endometrial adenocarcinoma  
135 
Figure 4.11 Localisation and quantification of CD4+ T cells in normal endometrium 
and endometrial adenocarcinoma. A: Representative image demonstrating the localisation 
of CD4+ T cells in normal endometrium from the proliferative phase of the menstrual cycle 
(n=7). CD4+ T cells are found throughout the stroma. Scale bar represents 100 µM. B: 
Representative image demonstrating the localisation of CD4+ T cells in a moderately 
differentiated endometrial adenocarcinoma. T cells are present throughout the stroma, often 
found in clusters (well differentiated adenocarcinoma n=10, moderately differentiated 
adenocarcinoma n=10, poorly differentiated adenocarcinoma n=10). Negative control (inset) 
was incubated with non-immune IgG in place of primary antibody, Scale bar represents 100 
µM. C: CD4+ T cell numbers  did not significantly differ in endometrial adenocarcinoma as 
compared to normal endometrium from the proliferative phase of the menstrual cycle (n= as 
above). No significant difference was found between different grades of cancer. Data are 
expressed as number of CD4+ T cells cells/mm
2
 and are presented as mean ± SEM.  
 
4.3.3.4 CD8+ T cell infiltration into endometrial adenocarcinoma as 
compared to normal endometrium 
CD8+ T cells in normal endometrium from the proliferative phase of the menstrual 
cycle and in all grades of endometrial adenocarcinoma were measured by expression 
of CD8 (representative images shown in Figure 4.12). In normal proliferative phase 
endometrium, CD8+ T cells were found sparsely throughout the stroma (Figure 
5.12A). CD8+ T cells were also found throughout the stroma of all grades of 
endometrial adenocarcinoma, and a representative image of a well differentiated 
adenocarcinoma is presented below (Figure 5.12B). There was no significant 
difference in numbers of CD8+ T cells between the different grades of cancer. 
Moreover, CD8+ T cells did not differ between normal endometrium and 
endometrial adenocarcinoma (Figure 5.12C).  
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Figure 4.12 Localisation and quantification of CD8+ T cells in normal endometrium 
and endometrial adenocarcinoma. A: Representative image demonstrating the localisation 
of CD8+ T cells in normal endometrium from the proliferative phase of the menstrual cycle 
(n=7). T cells are found scattered throughout the stroma. Scale bar represents 100 µM. B: 
Representative image demonstrating the localisation of CD8+ T cells in a well differentiated 
endometrial adenocarcinoma. T cells are present throughout the stroma (well differentiated 
adenocarcinoma n=10, moderately differentiated adenocarcinoma n=10, poorly differentiated 
adenocarcinoma n=10). Negative control (inset) was incubated with non-immune IgG in 
place of primary antibody, Scale bar represents 100 µM. C: CD8+ T cell numbers did not 
significantly differ in endometrial adenocarcinoma as compared to normal endometrium from 
the proliferative phase of the menstrual cycle. No significant difference was found between 
different grades of cancer (n= as above). Data are expressed as number of CD8+ T cells 
cells/mm
2
 and are presented as mean ± SEM.  
 
4.3.3.5 B cell infiltration into endometrial adenocarcinoma as 
compared to normal endometrium 
B cells in normal endometrium from the proliferative phase of the menstrual cycle 
and all grades of endometrial adenocarcinoma were measured by expression of CD20 
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(representative images shown in Figure 4.13). CD20+ B cells were present in small 
numbers in the stroma of normal proliferative phase endometrium (Figure 4.13A). In 
all grades of endometrial adenocarcinoma, B cells were present throughout the 
stroma, often in small clusters. A representative image of a well differentiated 
adenocarcinoma is presented in Figure 4.13B. No significant difference was found 
between infiltrations of B cells in normal endometrium from the proliferative phase 
of the menstrual cycle as compared to endometrial adenocarcinoma, or between 
different grades of cancer (Figure 4.13C). 
 
 
Figure 4.13 Localisation and quantification of B cells in normal endometrium and 
endometrial adenocarcinoma. A: Representative image demonstrating the localisation of 
CD20, a B cell marker, in normal endometrium from the proliferative phase of the menstrual 
cycle (n=7). B cells are found scattered throughout the stroma. Scale bar represents 100 µM. 
B: Representative image demonstrating the localisation of B cells in a well differentiated 
endometrial adenocarcinoma. B cells are present in small clusters throughout the stroma 
(well differentiated adenocarcinoma n=10, moderately differentiated adenocarcinoma n=10, 
poorly differentiated adenocarcinoma n=10). Negative control (inset) was incubated with 
non-immune IgG in place of primary antibody, Scale bar represents 100 µM. C: B cell 
numbers did not significantly differ in endometrial adenocarcinoma as compared to normal 
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endometrium from the proliferative phase of the menstrual cycle. No significant difference 
was found between different grades of cancer (n= as above). Data are expressed as number 
of CD20 positive cells/mm
2
 and are presented as mean ± SEM.  
  
4.3.3.6 NK cell infiltration into endometrial adenocarcinoma as 
compared to normal endometrium 
NK cells in normal endometrium from the proliferative phase of the menstrual cycle 
and in all grades of endometrial adenocarcinoma were measured by expression of 
CD56 (representative images shown in Figure 4.14). CD56+ NK cells were localised 
to the stroma in normal proliferative phase endometrium and were present in high 
numbers (Figure 4.14A). NK cells were present sparsely in all grades of endometrial 
adenocarcinoma studied. A representative image of a moderately differentiated 
adenocarcinoma is shown in Figure 4.14B. No difference in numbers of NK cells 
between different grades of endometrial adenocarcinoma was found. Hence data 
were pooled and NK cells were significantly decreased in endometrial 
adenocarcinoma as compared to normal endometrium from the proliferative phase of 
the menstrual cycle (p<0.001; Figure 4.14C) by 9.5 ± 2.8 fold.  
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Figure 4.14 Localisation and quantification of NK cells in normal endometrium and 
endometrial adenocarcinoma. A: Representative image demonstrating the localisation of 
CD56 expression, a NK cell marker, in normal endometrium from the proliferative phase of 
the menstrual cycle (n=7). NK cells were observed in high numbers throughout the stroma. 
Scale bar represents 100 µM. B: Representative image demonstrating the localisation of NK 
cells in a moderately differentiated endometrial adenocarcinoma. NK cells were present 
rarely throughout the stroma (well differentiated adenocarcinoma n=10, moderately 
differentiated adenocarcinoma n=10, poorly differentiated adenocarcinoma n=10). Negative 
control (inset) was incubated with non-immune IgG in place of primary antibody, Scale bar 
represents 100 µM. C: NK cells were significantly decreased in endometrial adenocarcinoma 
as compared to normal endometrium from the proliferative phase of the menstrual cycle. No 
significant difference was found between different grades of cancer (n= as above). Data are 
expressed as number of neutrophil elastase positive cells/mm
2
 and are presented as mean ± 
SEM. *** denotes p<0.001. 
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4.3.3.7 Dendritic cell infiltration into endometrial adenocarcinoma as 
compared to normal endometrium 
Dendritic cells in normal endometrium from the proliferative phase of the menstrual 
cycle and in all grades of endometrial adenocarcinoma were localised by CD11c 
expression (representative images shown in Figure 4.15). Dendritic cells were 
sparsely localised within the stroma of normal endometrium from the proliferative 
phase of the menstrual cycle (Figure 4.15A) and were seen more frequently in all 
grades of endometrial adenocarcinoma (Figure 4.15B). There was no significant 
difference in dendritic cell number between different grades of endometrial 
adenocarcinoma, and hence the data were pooled. Dendritic cells were significantly 
increased in endometrial adenocarcinoma as compared to normal endometrium 
(p<0.05; Figure 4.15C) by 6.8 ± 0.9 fold. 
 
 
Figure 4.15 Localisation and quantification of dendritic cells in normal 
endometrium and endometrial adenocarcinoma. A: Representative image demonstrating 
the localisation of CD11c expression, a dendritic cell marker, in normal endometrium from 
the proliferative phase of the menstrual cycle (n=7). Dendritic cells were found in low 
numbers throughout the stroma. Scale bar represents 100 µM. B: Representative image 
demonstrating the localisation of dendritic cells in a poorly differentiated endometrial 
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adenocarcinoma. Dendrtitic cells were present throughout the stroma (well differentiated 
adenocarcinoma n=10, moderately differentiated adenocarcinoma n=10, poorly differentiated 
adenocarcinoma n=10). Negative control (inset) was incubated with non-immune IgG in 
place of primary antibody, Scale bar represents 100 µM. C: Dendritic cells were significantly 
increased in endometrial adenocarcinoma as compared to normal endometrium from the 
proliferative phase of the menstrual cycle. No significant difference was found between 
different grades of cancer (n = as above). Data are expressed as number of CD11c positive 
cells/mm
2
 and are presented as mean ± SEM. * denotes p<0.05. 
 
4.3.4 PGF2α-induced CXCL1 expression by FPS cells induces 
neutrophil migration in vitro 
As CXCR2 expression was colocalised with neutrophil elastase (Figure 4.2) and 
neutrophils were present at increased levels in endometrial adenocarcinoma as 
compared to normal endometrium from the proliferative phase of the menstrual cycle 
(Figure 4.9), it was next determined whether the CXCL1 induced in FPS cells via 
PGF2α-FP receptor interaction (as described in Chapter 3) could induce neutrophil 
chemotaxis in vitro. Human neutrophils were purified from peripheral blood and 
used in a transwell chemotaxis assay (Figure 4.16). A significant increase in 
neutrophil chemotaxis in response to conditioned media from FPS cells treated with 
100 nM PGF2α for 48 hours (PGF2α-CM) was demonstrated as compared with media 
from vehicle-treated cells (V-CM; p<0.001). Chemotaxis was significantly inhibited 
with immunoneutralisation of CXCL1 from the conditioned media before incubation 
with neutrophils, or with the addition of the CXCR2 antagonist SB225002 to PGF2α-
CM (p<0.001). Incubation of PGF2α-CM with goat IgG as a control for antibody 
absorption did not significantly affect chemotaxis induced by PGF2α-CM. Serum free 
media was used as a negative control for random migration, and data are presented 
relative to this. Recombinant CXCL1 was used as a positive control for directed 
migration (data not shown). 
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Figure 4.16 PGF2α-induced CXCL1 can induce neutrophil chemotaxis in vitro. A 
transwell assay was used to measure neutrophil chemotaxis (n=4) in response to 
conditioned media from FPS cells treated with PGF2α for 48 h (PGF2α-CM) compared with 
vehicle-treated cells (V-CM). Chemotaxis was increased by PGF2α–CM, and this was 
significantly reduced with immunoneutralisation of CXCL1 protein from the medium or the 
addition of 60 nM SB-225002. Control goat IgG immunoneutralisation showed no significant 
effect. Data shown are mean ± SEM *** denotes p<0.001. 
4.3.5 PGF2α-stimulated CXCL1 induces neutrophil migration in vivo  
To explore whether FP receptor signalling could promote neutrophil migration in 
vivo, a mouse xenograft model was used. Ishikawa wild-type (WT) cells with low 
level of FP expression or FPS cells were injected subcutaneously into nude mice 
(experiment performed by Dr. R Catalano). Mice were then regularly injected with 
control IgG (WT and FPS xenografts) or CXCL1 antibody (FPS xenografts only), as 
described in section 4.2.8. Tumours formed from FPS cells demonstrated 
significantly higher CXCL1 mRNA expression compared with WT tumours (p<0.05; 
Figure 4.17). 
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Figure 4.17 CXCL1 mRNA is significantly increased in FPS xenografts. CXCL1 
mRNA expression is significantly increased in nude mice xenografts (n=10 each group) 
formed from FPS cells compared with WT cell xenografts. Injection of CXCL antibody did not 
significantly alter CXCL1 mRNA expression in FPS tumours as compared to FPS tumours 
injected with control IgG antibody. Data are presented as mean ± SEM, * denotes p<0.05. 
 
Neutrophil infiltration into the xenografts (n=5 tumours from each treatment group) 
was then analysed by flow cytometry (Figure 4.18A). FPS xenografts displayed 
increased neutrophil infiltration as compared to WT xenografts (p<0.001; Figure 
4.18B). This infiltration was significantly decreased in FPS xenografts from mice 
injected with CXCL1 neutralizing antibody compared to FPS xenografts from mice 




Chapter 4                     Effects of CXCL1 expression in endometrial adenocarcinoma  
144 
 
Figure 4.18 Neutrophil infiltration is significantly increased in FPS xenografts. A: 
Representative image of scatter profile of neutrophils identified in mouse xenografts (inset 
box) by flow cytometry. B: Percentage of neutrophils in total tumour cells from WT and FPS 
xenografts (n = 5 per treatment group), measured by flow cytometry. Increased neutrophil 
infiltration is seen in FPS xenografts, which is significantly reduced by injection of CXCL1-
neutralising antibody. Data are presented as mean ± SEM, *** denotes p<0.001. 
 
To further confirm this analysis, immunohistochemistry of the specific murine 
neutrophil marker granulocyte receptor -1 (Gr-1) was performed on xenograft tissue 
(Figure 4.19, neutrophils indicated by arrowheads). Higher numbers of neutrophils 
were seen distributed throughout FPS xenografts (Figure 4.19B) as compared to WT 
(Figure 4.19A) or CXCL1 immunoneutralised FPS (Figure 4.19C) xenografts. 
Neutrophils were commonly localised to the leading edge of the xenografts, but 
could be seen scattered throughout the tissue in some samples.  
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Figure 4.19 Localisation of neutrophils in mouse xenografts by Gr-1 
immunohistochemistry. Representative images showing localisation of neutrophils by Gr-1 
expression (as indicated by arrowheads) in xenografts. A: Xenografts arising from WT cells 
treated with IgG. B: Xenografts arising from FPS cells treated with IgG. C: Xenografts arising 
from FPS cells treated with CXCL1 antibody. Left image is x200 magnification, right image is 
x400. Negative control (inset) is incubated with non-immune IgG in place of primary 
antibody. All scale bars represent 100 µm. 
 
4.3.6 Localisation of CXCL1 and CXCR2 to endothelial cells in 
endometrial adenocarcinoma 
CXCL1 binding to CXCR2 has been demonstrated to promote angiogenesis in a 
number of mouse models (Moore et al. 1999; Haghnegahdar et al. 2000; Barcelos et 
al. 2004; Wang et al. 2006). As described in Chapter 3, expression of CXCL1 and 
CXCR2 could be localised to endothelial cells in all grades of endometrial 
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adenocarcinoma. This localisation was further confirmed using dual 
immunofluorescence microscopy. Expression of CXCL1 (Figure 4.20A, green 
channel) and the specific endothelial cell marker CD31 (red channel) was colocalised 
in all grades of endometrial adenocarcinoma (yellow channel, merge).  CXCR2 
expression (Figure 4.20B, green channel) also colocalised to that of CD31 (red 
channel; yellow channel, merge) localising its expression to endothelial cells in all 
grades of endometrial adenocarcinoma. Representative images of a well 
differentiated carcinoma (Figure 4.20A) and moderately differentiated 
adenocarcinoma (Figure 4.20B) are shown. 
 
 
Figure 4.20 Expression of CXCL1 and CXCR2 by CD31 positive vascular 
endothelial cells. A: Expression of CXCL1 (green channel) and CD31 (red channel) were 
colocalised (yellow channel, merge), demonstrating the expression of CXCL1 by endothelial 
cells in a well differentiated endometrial adenocarcinoma. Negative control (inset) was 
incubated with non-immune IgG in place of primary antibody, scale bar represents 10 µm. B: 
Expression of CXCR2 (green channel) and CD31 (red channel) was colocalised (yellow 
channel, merge), demonstrating the expression of CXCR2 by endothelial cells in a 
moderately differentiated endometrial adenocarcinoma. Negative control (inset) was 
incubated with non-immune IgG in place of primary antibody, scale bar represents 100 µm. 
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4.3.7 PGF2α-stimulated CXCL1 does not alter microvascular density in 
vivo 
As CXCR2 was expressed on endothelial cells in endometrial adenocarcinoma 
(Figure 4.20B) and its expression has been previously demonstrated on mouse 
endothelial cells (Devalaraja et al. 2000), angiogenesis in WT, FPS and CXCL1-
immunoneutralised FPS xenografts was examined (n=10 each group). The 
expression of CD31, a vascular marker, was identified by immunohistochemistry and 
CD31+ cells were counted. There was no significant difference in microvascular 
density between the three groups examined (Figure 4.21). 
 
Figure 4.21 Microvascular densities in WT, FPS and FPS xenografts neutralised for 
CXCL1. CD31 immunohistochemistry was used to examine microvascular density in nude 
mice xenografts (n=10 each group) arising from injection of WT cells treated with IgG, FPS 
cells treated with IgG and FPS cells treated with CXCL1 antibody. No significant difference 
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4.4 Discussion 
Expression of chemokines in cancer contributes to a tumour microenvironment 
displaying classic features of inflammation, including the recruitment of immune 
cells and tissue remodelling by angiogenesis. In Chapter 3, the expression of CXCR2 
on cells throughout the stroma of endometrial adenocarcinoma and on vascular 
endothelium was demonstrated. This chapter therefore sought to investigate the 
identity of the CXCR2 expressing stromal cells, and the potential consequences of 
PGF2α-regulated CXCL1 signalling to CXCR2 on immune cell infiltration and 
angiogenesis.  
 
CXCR2 is expressed on a number of leukocytes (Murphy et al. 2000). Dual 
immunofluorescent immunohistochemistry of the pan-leukocyte marker CD45 and 
CXCR2 in endometrial adenocarcinoma demonstrated both the large number of 
leukocytes infiltrating the tumours and the expression of CXCR2 on a proportion of 
these. However, a number of leukocytes did not express CXCR2, and conversely a 
number of CXCR2-positive cells did not express this leukocyte marker. The identity 
of these latter cells is still unknown. Cells which were CD45+/CXCR2+ were then 
further investigated by the use of a number of specific immune cell markers. The 
majority of CXCR2 expression in the stroma was colocalised to cells expressing 
neutrophil elastase and to a lesser extent CD68, which are neutrophil and 
monocyte/macrophage markers respectively. No colocalisation was seen with 
markers of T or B lymphocytes, NK cells or dendritic cells. Interestingly, CXCR2 
expression in some stromal cells also colocalised to CXCL1 expression, indicating 
that their infiltration could further chemoattract other CXCR2-expressing immune 
cells. 
 
CXCR2 localization in neutrophils in endometrial adenocarcinoma suggested that 
CXCL1 signalling via CXCR2 could play a role in immune cell function. A role for 
CXCL1 in neutrophil influx has been previously shown in an angiogenic sponge 
model in the mouse, as endogenous CXCL1 expression increased immediately 
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preceding a neutrophil influx (Barcelos et al. 2004). As neutrophil infiltration has not 
previously been quantified in endometrial adenocarcinoma, the number of 
neutrophils and other immune cells in endometrial adenocarcinoma was investigated 
by immunohistochemistry. 
 
Macrophage infiltration into cancer has been intensely studied in recent years, as 
tumour associated-macrophages (TAM) are increased in a number of cancer types 
including breast, colon, bladder and melanoma (Bingle et al. 2006; Hussein 2006; 
Forssell et al. 2007; Chen et al. 2009). Immunohistochemistry demonstrated 
increased macrophage infiltration into all grades of endometrial adenocarcinoma as 
compared to normal endometrium from the proliferative phase of the menstrual 
cycle, in agreement with a number of studies where macrophages are increased in 
cancer as compared to normal tissue (Miyatake et al. 2007). This has been associated 
with a poor prognosis in cancer patients (Salvesen et al. 1999; Yang et al. 2007). 
Macrophages are heterogeneous cells, with the ability to alter their phenotype 
dependent on the environment. This may explain the contrasting reports of roles in 
tumour progression and destruction (Saccani et al. 2006; Forssell et al. 2007). 
Typically, the phenotype adopted by TAM is similar to a polarised M2 response, 
which involves low cytotoxic and antigen presenting functions and the secretion of 
growth factors promoting metastasis and angiogenesis (Luo et al. 2006). 
 
In other cancer types, macrophages may play a key role in tumour progression. This 
is demonstrated by a mouse model of breast cancer lacking macrophage infiltration 
which has a greatly decreased tumour progression and metastasis rate. When 
macrophages were re-introduced, tumour progression rapidly caught up with control 
counterparts (Lin et al. 2001). A number of other studies have shown similar results, 
suggesting macrophages secrete factors such as VEGF and angiopoetins which 
increase angiogenesis (Bingle et al. 2006; Venneri et al. 2007) and are essential for 
the angiogenic switch (Lin et al. 2007). Macrophages also secrete proteases which 
influence metastasis and invasion (Dirkx et al. 2006; Yang et al. 2007). In 
endometrial cancer, expression of platelet-derived endothelial cell growth factor 
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(thymidine phosphorylase) by macrophages is correlated with increased 
microvascular density (Tanaka et al. 2002). Therefore, increased macrophage 
numbers found in endometrial adenocarcinoma described in this chapter may play a 
role in cancer progression through one or more of these mechanisms. CXCR2 
expression was seen on a small number of macrophages in endometrial 
adenocarcinoma, and although there is some evidence suggesting CXCL1 can 
chemoattract monocytes, this is primarily mediated by promoting their adhesion to 
the endothelium (Weber et al. 1999; Traves et al. 2004; Smith et al. 2005). Therefore 
the CXCL1 regulated by PGF2α-FP signalling in endometrial adenocarcinoma is 
unlikely to play a major role in their chemoattraction into the tumour, however 
CXCL1 expression which was demonstrated in the vascular endothelium may affect 
this. 
 
By immunohistochemical analysis, no significant difference was found between T 
cell infiltration in normal endometrium and endometrial cancer. However there was a 
trend towards increased numbers of CD4+ and CD8+ T cells in human endometrial 
adenocarcinoma. Previous studies have also described increased T cell infiltration in 
endometrial adenocarcinoma as compared to normal endometrium (Hachisuga et al. 
1997).  
 
Most evidence points towards a cytotoxic role for T cells in cancer. CD4+ T cells can 
recognise tumour antigen and with the aid of CD8+ T cells have been demonstrated 
to eradicate tumours from mouse models though production of cytokines (Nishimura 
et al. 1999). The cytokine profile produced by CD4+ cells however appears to be 
dependent on the environment of the tumour and cancer model used (Ellyard et al. 
2007). CD4+ T cells can  initiate the CD8+ T cell cytotoxic response and play a 
central role in maintaining it, however through the production of cytokines may also 
recruit other cells of the innate immune system such as macrophages (Badoual et al. 
2006). The plasticity and complexity of immune cell responses to tumours is 
demonstrated by CD4+ T cells, as a subset of these are known as regulatory T cells, 
as indicated by the specific expression of the cell surface antigen forkhead box p3 
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(FOXP3) which drives the development of this cell type. These cells have a distinct 
phenotype which can suppress T cell population expansion and cytotoxicity, and are 
associated with increased microvascular density and angiogenic factors including 
VEGF in endometrial adenocarcinoma (Giatromanolaki et al. 2008) 
 
The infiltration of CD8+ T cells into endometrial cancer has previously been 
inversely correlated with high COX-2 expression (Ohno et al. 2005). This low 
infiltration was associated with poor prognosis, further demonstrating that a high 
CD8+ infiltration may be destructive to the tumour. Additionally, a high CD8+ cell 
infiltration in endometrial adenocarcinoma has been correlated with an increased 
survival rate (Kondratiev et al. 2004). Beyond the expression of CD4 and CD8, the 
phenotype of T cells was not investigated in this chapter. However the non-
significant increase in infiltration in endometrial cancer as compared to normal 
endometrium may suggest that an inefficient cytotoxic response is being mounted. 
 
B cells were identified by CD20 staining. No significant difference was found 
between normal endometrium and endometrial adenocarcinoma, however similarly 
to T cells there was a trend towards increased numbers in cancer tissue. Previously in 
endometrial adenocarcinoma, B cells have been shown to be significantly increased 
(Hachisuga et al. 1997). As described earlier in this chapter, a popular model of 
immune cell infiltration suggests that adaptive immune cells such as B cells are 
recruited to the tumour and can destroy cancerous cells through mechanisms 
including antibody-induced complement-mediated lysis. However, evidence also 
suggests that the serum proteins secreted by B cells which chemoattract innate 
immune cells may promote chronic inflammation and therefore tumour progression 
(de Visser et al. 2006). Indeed, elimination of B and T cells in a mouse model 
reduced innate immune cell infiltration into developing tumours and levels of 
tumourigenic factors including VEGF and MMP9. This caused a decrease in tumour 
growth. Re-introduction of B cells restored the infiltration of innate immune cells 
and angiogenesis to control levels (de Visser et al. 2005). The function of B cells 
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seen in human endometrial adenocarcinomas is therefore unclear, as both tumour 
promoting and destructive properties are possible. 
 
The population of uterine NK cells fluctuates in the endometrium throughout the 
menstrual cycle, and they are most abundant during the secretory phase (King et al. 
1989). By examining CD56 expression, NK cells were found to be significantly 
decreased in endometrial adenocarcinoma as compared to normal endometrium, 
agreeing with previously published data (Ferguson et al. 1985). NK cells are 
specialised lymphocytes which can recognise MHC class I molecules. The frequent 
lack of MHC class I molecules on cancer cells means that NK cells can identify and 
lyse tumour cells (Zamai et al. 2007). However a subset of NK cells indiscriminately 
secrete cytokines to kill infected or transformed cells, for example IFN-γ and TNF-α, 
and therefore NK cells are seen as bridging the innate and adaptive immune systems 
(Caligiuri 2008). In a subcutaneous tumour mouse model decreased NK cell 
infiltration is also observed. This is due to secreted factors including granulocyte 
macrophage colony-stimulating factor (GM-CSF), IL-3 and IL-6 from the tumour 
impairing the maturation of NK cells (Richards et al. 2008). The cause of decreased 
NK infiltration into endometrial tumours as compared to normal tissue remains to be 
elucidated, however the low number of NK cells seen in endometrial 
adenocarcinoma suggests these tumours may be evading recognition by NK cells. 
 
Dendritic cells are the primary antigen-presenting cells which can activate T and B 
cell responses and also tolerance. By immunohistochemistry, dendritic cells were 
shown to be significantly increased in endometrial adenocarcinoma as compared to 
normal endometrium. The marker CD11c was used, which is expressed highly on 
immature dendritic cells that are unable to present antigen. Tumours often contain 
high numbers of these cells as they are recruited by factors secreted by the cancer, 
including VEGF and other C-C and C-X-C chemokines (Murdoch et al. 2008). A 
high number of immature dendritic cells can promote immune tolerance to tumours, 
as has been demonstrated in a mouse model of colon cancer (Bonnotte et al. 2004). 
Recently, a role for dendritic cells in angiogenesis has been demonstrated. Dendritic 
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cells have been observed producing VEGF adjacent to vasculature in models of both 
endometriosis and cancer (Fainaru et al. 2008). These same immature dendritic cells 
could also increase endothelial cell migration in vitro, demonstrating their potential 
to influence angiogenesis (Fainaru et al. 2008). Finally, in a study by Coneja-Garcia 
et al (Conejo-Garcia et al. 2005), cells with a dendritic cell phenotype expressing 
CD11c were able to differentiate into cells expressing endothelial markers and 
assemble into blood vessels in vivo. The increased numbers of immature dendritic 
cells present in endometrial adenocarcinoma could therefore be promoting both 
evasion of the adaptive immune system by the tumour and tissue remodelling via 
production of VEGF. 
  
Neutrophils were significantly increased in human endometrial adenocarcinoma as 
compared to normal endometrium from the proliferative phase of the cycle, as 
demonstrated by immunohistochemistry. As neutrophils were the main cell type 
expressing CXCR2, the ability of PGF2α-regulated CXCL1 to chemoattract 
neutrophils was investigated. CXCL1 was strongly chemotactic to neutrophils as 
conditioned media from PGF2α-stimulated FPS cells induced chemotaxis of 
peripheral human neutrophils. This chemotaxis was significantly reduced by CXCL1 
immunoneutralisation and CXCR2 inhibition using a specific antagonist. To 
determine a role for CXCL1 induced by PGF2α-FP interaction in vivo, nude mice 
were inoculated with FPS and WT cells. By flow cytometry, it was demonstrated that 
the increased neutrophils in the resulting FPS tumours compared with WT were 
significantly reduced by injection of CXCL1 neutralizing antibodies, demonstrating 
that PGF2α signalling via CXCL1 is influencing neutrophil infiltrate in endometrial 
adenocarcinomas. Neutrophil infiltration into tumours has also been shown to be 
dependent on CXC chemokine-CXCR2 signalling in a model of melanoma in a 
CXCR2 null nude mouse (Singh et al. 2009). 
 
A chemokine-mediated influx of neutrophils is seen in the late secretory phase of the 
normal endometrium (Critchley et al. 1994). Their role may be dependent on the 
activating agents and cytokines present, but they are thought to be involved in the 
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breakdown and repair at menstruation by degranulation and the release of proteases 
which degrade the extracellular matrix (Kaitu'u-Lino et al. 2007). They have also 
been implicated in angiogenesis, as neutrophils found close to or associated with 
endothelial microvessels express VEGF during or coincident with angiogenesis 
(Gargett et al. 2001).  
 
The role of neutrophils in endometrial adenocarcinoma is unclear, and in our 
xenograft model, similarly to other reports (Tazawa et al. 2003; Shojaei et al. 2008) 
neutrophil influx did not affect tumour size (R. Catalano, personal communication). 
However, considering their profound tissue-remodelling capabilities, which have 
been shown in a number of animal models of other cancer types, it is possible that 
they play a similar role in endometrial cancer. For example, neutrophils have been 
shown to uniquely produce a tissue inhibitor of metalloproteinase (TIMP)–free 
MMP-9, a key protease involved in extracellular matrix degradation, which may 
affect the tumour microenvironment by tissue remodelling (Ardi et al. 2007). In 
addition, the depletion of neutrophils in a mouse model prevented metastasis of 
fibrosarcoma cells from the primary tumour, suggesting a role for neutrophils in the 
switch to a metastatic phenotype (Tazawa et al. 2003). In a nude mouse model of 
breast cancer, over-expression of interleukin-8, a chemokine related to CXCL1, 
caused an infiltration of neutrophils which increased invasiveness of the tumour, 
likely due to an increase in protease production (Yao et al. 2007). Similarly, the 
decrease in neutrophil infiltration caused by an inhibition of CXCL1 expression in a 
nude mouse model of colon cancer significantly decreased metastasis in these 
animals (Yamamoto et al. 2008).  
 
Neutrophils may also promote tumourigenesis through means other than tissue 
remodelling. In an in vitro model of colon cancer, neutrophils promote cellular stress 
by inducing transient errors in DNA replication in epithelial cells (Campregher et al. 
2008), which could ultimately lead to carcinogenesis. Neutrophils from ovarian 
cancer patients released higher levels of reactive oxygen species, which could 
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potentially lead to cellular changes that support tumour progression (Klink et al. 
2008). 
 
As discussed in Chapter 3, as well as being chemotactic for neutrophils CXCL1 is an 
angiogenic chemokine. Despite this and evidence that neutrophils can contribute to 
angiogenesis, no difference in microvascular density was observed between WT, 
FPS or CXCL1-immunoneutralised xenografts. The reasons for this are unclear. 
However in the xenograft tissue, although significantly different rates of neutrophil 
infiltration are observed between groups, immunohistochemical staining of Gr-1 
reveals that the infiltration is lower than that seen in human tissue. It is possible that 
this nude mouse model does not replicate closely enough the situation seen in human 
tumours, and therefore the extent to which neutrophils could be affecting tissue 
remodelling within the tumour. Furthermore, only microvascular density was closely 
examined. Blood vessel size and arrangement in FPS xenograft tumours appeared 
different to that of WT xenografts or FPS xenografts from mice injected with 
CXCL1 (R. Catalano, personal communication), indicating that alterations in 
vasculature were occurring which were not purely based on blood vessel number. 
Other aspects of blood vessel development therefore need to be more closely 
examined in this model to determine the effects of CXCL1 on angiogenesis. 
 
This chapter provides evidence for a novel PGF2α –FP pathway that can regulate the 
inflammatory microenvironment in endometrial adenocarcinoma via CXCL1-
induced neutrophil chemotaxis. The presence of high numbers of other types of 
immune cells which do not express CXCR2 suggests other cytokines may play a role 
in their chemoattraction into the tumour. The role of these immune cells in 
endometrial adenocarcinoma is unclear, yet their incidence in endometrial tumours 
reflects the published literature on other cancer types describing the presence of both 
an infiltration of adaptive, cytotoxic immune cells and a higher infiltration of innate 
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5  PGF2α-F-prostanoid receptor regulation of chemokine 
(C-C) motif ligand 20 expression in endometrial 
adenocarcinoma  
5.1 Introduction 
As described in Chapter 3, chemokines are a group of small molecular weight 
proteins which are members of the cytokine family. They are characterised by their 
ability to induce chemotaxis and activation of haematopoietic cells at sites of 
inflammation. Novel actions of chemokines on other cell types including epithelial 
and endothelial cells have recently been discovered, including promotion of 
angiogenesis, invasion and proliferation (Slettenaar et al. 2006). 
 
The chemokine (C-C motif) ligand 20 (CCL20; also known as macrophage 
inflammatory protein-3α) belongs to the CC-family of chemokines, so named for the 
position of two cysteine molecules at the amino terminal of the proteins. CCL20 
binds to the CC-receptor 6 (CCR6), a G-protein coupled receptor that is expressed on 
dendritic cells, B and T lymphocytes, and tissues including spleen, lymph nodes, 
appendix and pancreas. Coupling of chemokines to receptors is generally 
promiscuous between members of the same family, however CCL20 is the only 
chemokine known to interact with the CCR6 receptor (Schutyser et al. 2003). 
 
CCL20 signalling plays an important role in the chemoattraction of immature 
dendritic cells to sites of inflammation. Dendritic cells are the main antigen 
presenting cells of the immune system, which infiltrate tissues as immature cells. 
Upon the uptake of antigen and in response to inflammatory stimuli they differentiate 
into mature dendritic cells capable of activating lymphocytes (Schutyser et al. 2003). 
Upon differentiation, CCR6 expression on dendritic cells and responsiveness to 
CCL20 decreases (Dieu et al. 1998). 
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Like many other chemokines, the expression of CCL20 and CCR6 has also been 
described in several different types of cancer. CCL20 is over-expressed in cancers of 
the colon (Brand et al. 2006) liver (Rubie et al. 2006), pancreas (Campbell et al. 
2005), prostate (Ghadjar et al. 2008) and Hodgkins lymphoma (Baumforth et al. 
2008). CCR6 is also upregulated in colon (Brand et al. 2006), liver (Dellacasagrande 
et al. 2003) and prostate cancer (Ghadjar et al. 2008). Within these cancer types, 
CCL20-CCR6 signalling has been proposed to influence neoplastic epithelial cell 
migration or metastasis (Dellacasagrande et al. 2003; Campbell et al. 2005; Rubie et 
al. 2006) and proliferation (Brand et al. 2006; Beider et al. 2009). Additionally, the 
influx of immature dendritic cells mediated by CCL20 signalling has been implicated 
in the promotion of immune tolerance to cancer and therefore tumour growth 
(Bonnotte et al. 2004; Wang et al. 2008). 
 
The expression of CCL20 has been described in the HHUA endometrial epithelial 
cell line and more recently primary endometrial epithelial cells (Ghosh et al. 2009), 
as well as primary endometrial stromal cells (Sun et al. 2002). Its expression in 
endometrial adenocarcinoma has been identified by a gene array comparing normal 
endometrium with adenocarcinoma samples (Wong et al. 2007); however protein 
localisation and physiological effects of CCL20 in endometrial cancer have not 
previously been examined.  
 
Chapters 3 and 4 of this thesis described a cytokine pathway in endometrial 
adenocarcinoma promoted by PGF2α-FP signalling. A gene array carried out in our 
laboratory on FPS cells used as an endometrial adenocarcinoma cell model has 
identified the chemokine CCL20 as a target gene of PGF2α-FP signalling. This 
chapter therefore investigated the expression and localisation of CCL20 and CCR6 in 
endometrial adenocarcinoma. The role of PGF2α-FP signalling in the regulation of 
CCL20 and potential physiological effects of CCL20 expression in endometrial 
adenocarcinoma were also examined.  
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5.2 Materials and Methods 
5.2.1 Tissue collection 
Normal endometrium and endometrial adenocarcinoma tissue were collected as 
described in sections 2.1.1 and 2.1.2, for use in RT-PCR and immunohistochemical 
analysis. Normal endometrial tissue was collected from women undergoing surgery 
for minor gynaecological procedures with no underlying endometrial pathology and 
endometrial adenocarcinoma tissue was obtained from women undergoing 
hysterectomy after diagnosis of adenocarcinoma of the uterus. Stage of cycle and 
grade of cancer was assessed by a pathologist. Written informed consent was 
collected from all patients before surgery and ethical approval was obtained from 
Lothian Research Ethics Committee. 
5.2.2 Cell Culture 
Ishikawa FPS cells were maintained as described in section 2.2.1. Primary tissue 
explants were maintained as described in section 2.2.2. 
5.2.2.1 Cell and tissue treatments 
To determine the pattern of CCL20 expression in response to PGF2α, FPS cells were 
serum starved in media containing 3 µg/ml indomethacin for at least 18 hours prior 
to stimulation for 2, 4, 6, 8, 12, 18, 24, 48 and 72 hours with fresh serum-free media 
containing indomethacin and vehicle or 100 nM PGF2α (n=5). Carcinoma tissue was 
serum starved in media containing 3 µg/ml indomethacin for at least 18 hours prior 
to treatment for 2, 4, 6, 8, and 24 hours with fresh serum-free media containing 
indomethacin and vehicle or 100 nM PGF2α (n=8). 
 
To determine signalling pathways leading to CCL20 expression regulated by PGF2α, 
FPS cells or carcinoma tissue were serum starved in media containing 3 µg/ml 
indomethacin for at least 18 hours and treated for 8 or 24 hours respectively with 
vehicle, inhibitor alone, 100 nM PGF2α alone or 100 nM PGF2α and a panel of 
chemical inhibitors indicated in the figure legends (n=7). 
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5.2.3 Polymerase chain reaction 
5.2.3.1 RNA extraction and reverse transcriptase PCR 
RNA from cells was extracted as described in section 2.4.1. Briefly, 1 ml TRI-
reagent was added to experimental wells and RNA extracted using the phenol 
method.  
 
RNA from tissue was extracted as described in section 2.4.1 using the Qiagen minikit 
protocol. Pieces of tissue, in 2 ml microcentrifuge tubes containing a stainless steel 
ball, were homogenised in 600 µl RLT lysis buffer using a tissue lyser (Qiagen, 
Crawley, West Sussex, UK) for 2 x 2 minutes at 25 Hz. RNA was then extracted 
following manufacturers guidelines (Qiagen). cDNA was prepared as described in 
section 2.4.2. 
5.2.3.2 Taqman quantitative RT-PCR 
CCL20 and CCR6 mRNA expression in cells and tissues was examined using 
Taqman quantitative PCR as described in section 2.4.3.2. Briefly, primer and probe 
sequences were designed to amplify CCL20 and CCR6 (sequences given in Table 
2.3). A master mix was made up containing 18S primers and probes and 200ng 
cDNA added to each sample. Samples were added in duplicate to a 96 well 
MicroAmp fast optical reaction PCR plate and analysed using an ABI Prism 7900 
HT Fast Real Time PCR machine. Expression of analyzed genes was normalised to 
RNA loading for each sample using the 18S ribosomal RNA as an internal standard. 
Results are expressed as fold increase above vehicle treated cells or relative to a 
normal endometrium control. 
5.2.4 Adenoviral and lentiviral constructs 
5.2.4.1 FP adenovirus 
A short hairpin adenovirus to knock down expression of FP was kindly prepared by 
Dr Pamela Brown (Biomolecular Core Facility, MRC Human Reproductive Sciences 
Unit, Edinburgh, UK). FP cDNA (ORIGENE, Rockville, MD) was excised with 
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EcoRI and SMA1 and fused to the pDC316 vector to create pDC316-FP. HEK-293 
cells were seeded in 6-well plates in nutrient mixture F-12 with Glutamax-1 and 
pyridoxine supplemented with 10% FCS and 1% penicillin-streptomycin (500 IU/ml 
penicillin and 500 µg/ml streptomycin). Once at 50% confluency, cells were co-
transfected with 0.75 µg pDC316-FP and 2.25 µg pBGH10 ΔE1,3 Cre adenoviral 
backbone in Optimem Reduced Serum Media (Invitrogen) using Trans-IT-293 
transfection reagent (Mirus Bio Corp, Madison, WI) as per the manufacturer‟s 
instructions. Cells were incubated for approximately 2 weeks with regular changes of 
media until evidence of cytopathic effect (CPE) was seen, which was defined as a 
rounded appearance to cells and when approximately 70% of cells had lifted from the 
plate surface. Adenovirus was then harvested and virus released from the cells by 3 
freeze-thaw cycles. Serial dilutions of the virus were performed and used to re-infect 
HEK-293 cells at 75-85% confluence. Wells were overlaid with 0.5% SeaPlaque 
Agarose (FMC Corp, Rockland, ME) to ensure homogenous plaques were obtained. 
Plaques were visible within 4-5 days and were picked using a P1000 tip. Plaques 
were freeze-thawed 3 further times and used to re-infect a further T75 flask which 
was incubated until CPE was observed. The virus from this flask was harvested and 
termed the first seed. The adenovirus was then expanded by inoculation of further 
flasks with the first seed. Adenovirus was purified and concentrated using the 
Vivapure AdenoPACK 100 purification kit (Sartorius AG, Goettingen, Germany) as 
per manufacturer‟s instructions. Virus titres were determined using the AdenoX 
Rapid titre kit (Clontech, France) as per manufacturer‟s instructions. 
 
FPS cells were seeded in 6-well plates and incubated for 24 hours. Cells were then 
infected with 5 viruses / cell in complete medium. After 24 hour incubation, cells 
were starved in media containing 3 µg/ml indomethacin for 18 hours before 
treatment with 100 nM PGF2α or vehicle for 8 hours (n=4). 
5.2.4.2 RCAN1-4 adenovirus 
An adenoviral construct was used to over-express RCAN-1-4, and was kindly 
prepared by Dr Pamela Brown. cDNA of RCAN-1-4 was prepared as previously 
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described (Maldonado-Perez et al. 2009) and fused to the pDC316 shuttle vector 
(Microbix Biopharmaceuticals, Toronto, Canada) to create pDC316-RCAN-1-4. The 
virus was then propagated and purified as described for the FP adenovirus in section 
5.2.4.3. Efficacy of RCAN1-4 over-expression has been previously described 
(Maldonado-Perez et al. 2009). 
 
FPS cells were seeded in 6-well plates and incubated for 24 hours. Cells were then 
infected with 5 viruses / cell in complete medium. After 24 hour incubation, cells 
were starved in media containing 3 µg/ml indomethacin for 18 hours before 
treatment with 100 nM PGF2α or vehicle for 8 hours (n=4). 
5.2.4.3 RCAN1-4 lentivirus 
A short hairpin RNA lentivirus was used to knock down expression of RCAN-1-4 as 
previously described (Bush et al. 2007), and was the kind gift of Professor Aubrey 
Thompson (Mayo Clinic, Florida, USA). FPS cells were seeded in 6-well plates and 
incubated for 24 hours. Cells were then infected with 5 viruses / cell in complete 
medium. After 24 hour incubation, cells were starved in media containing 3 µg/ml 
indomethacin for 18 hours before treatment with 100 nM PGF2α (n=4).  
 
5.2.5 Immunohistochemistry 
5.2.5.1 DAB immunohistochemistry 
3,3- diaminobenzidine tetrahydrochlorine (DAB) immunohistochemistry to localise 
CCL20 and CCR6 was performed as described in section 2.5.2 (for 
immunolocalisation of CCL20: proliferative phase endometrium n=7, early secretory 
phase endometrium n=3, mid secretory phase endometrium n=4, late secretory phase 
endometrium n=5, well differentiated adenocarcinoma n=7, moderately 
differentiated adenocarcinoma n=5, poorly differentiated adenocarcinoma n=3. For 
immunolocalisation of CCR6: proliferative phase endometrium n=7, early secretory 
phase endometrium n=3, mid secretory phase endometrium n=4, late secretory phase 
endometrium n=5, well differentiated adenocarcinoma n=7, moderately 
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differentiated adenocarcinoma n=5, poorly differentiated adenocarcinoma n=3). 
Tissue sections (5 µm) were dewaxed in xylene then rehydrated through graded 
ethanols and water. Antigen retrieval in citrate buffer (0.01M, pH 6) was performed, 
followed by blocking for endogenous peroxidise activity by washing sections in 3% 
hydrogen peroxidise in methanol. Sections were then blocked in normal serum of 
rabbit followed by overnight incubation with primary antibody at the concentrations 
indicated in Table 2.4. Control sections were included with non-immune IgG. 
Sections were then incubated in rabbit anti-goat biotinylated secondary antibody and 
subsequently streptavidin-HRP. Sections were then incubated with DAB for 1-5 
minutes until positive staining was identified by a brown colour under x10 
magnification. 
5.2.5.2 Dual immunofluorescence microscopy 
To colocalise CCR6 with CD11c, sections (5 µm; well differentiated 
adenocarcinoma n=3, moderately differentiated adenocarcinoma n=3, poorly 
differentiated adenocarcinoma n=3) were dewaxed in xylene then rehydrated through 
graded ethanols and water. Antigen retrieval in citrate buffer (0.01M, pH 6) was 
performed and sections were blocked in 5% normal rabbit serum diluted in PBS with 
5% BSA. Sections were then incubated with goat anti-CCR6 (1:50) overnight at 4ºC. 
Rabbit anti-goat biotinylated antibody was then added, diluted in PBS at 1:200 for 30 
minutes. Streptavidin AlexaFluor 546 (Molecular Probes) diluted 1:200 in PBS was 
then added for 30 minutes at room temperature. Sections were then re-blocked in 
normal goat serum and rabbit anti-CD11c (1:75) overnight at 4°C. Tissues were then 
incubated with a fluorophore-conjugated antibody diluted 1:200 in PBS (AlexaFluor 
488, Molecular Probes, UK) for 1 hour. Nuclei were counterstained in To Pro 
(Molecular Probes, UK) and then coverslipped and visualised as described in Section 
2.5.3 and 2.5.4 
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5.2.6 CCL20 ELISA 
CCL20 protein released into the culture media from treatments described in section 
5.2.2.1 was assayed by Human CCL20/MIP-3 alpha DuoSet ELISA (R& D Systems, 
Abingdon, UK) as described in section 2.6.2. 
5.2.7 Chemotaxis assay 
FPS cells were serum starved for at least 18 hours prior to harvesting with HyQtase 
cell detachment solution (Thermo Scientific, Leicestershire, UK). Cells were then 
seeded (2.5 x 10
4
) in 96-well Transwell inserts (8 µm pore, Corning Costar, 
Leicestershire, UK). A standard curve of cells was seeded to act as an internal 
control for random chemotaxis. Either serum free media, complete media containing 
fetal calf serum (FCS), or serum free media with recombinant CCL20 at 
concentrations of 10, 100, 200 and 300 ng / ml was added to the bottom chamber. 
Cells were cultured for 24 hours. Chemotaxis was then assayed by dissociating cells 
from the underside of the transwell insert using enzyme-free cell dissociation 
solution (Millipore, Herts, UK) with the addition of calcein acetoxymethylester (AM; 
BD Biosciences, Oxford, UK). Calcein AM is a non-fluorescent cell permeable 
compound which is metabolised into the fluoresecent anion calcein in viable cells, 
and thus can be used for the detection of cells in chemotaxis assays. Fluorescence 
was subsequently measured on a FLUOstar OPTIMA fluorescent plate reader (BMG 
Labtech, Aylesbury, UK) at 485 and 520 nm. Data are expressed as fold increase in 
chemotaxis above vehicle treated control (n=4). 
5.2.8 Proliferation assay 
FPS cells were seeded in complete medium in 96 well plates at 5 x 10
3
 cells per well. 
Cells were serum starved for at least 18 hours prior to stimulation for 24 hours with 
fresh media containing 1% serum and vehicle or recombinant CCL20 at a 
concentration of 10, 100, 200 or 300 ng/ml. 
 
Viable cells were then measured 24 hours later by CellTiter 96 AQueous One 
Solution Cell Proliferation Assay (Promega, Southampton, UK). This assay involves 
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the addition of the tertrazolium compound MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) and an electron coupling 
agent, PES (phenazine ethosulfate). When added to cells, MTS is bioreduced in the 
mitochondria of cells to form a soluble coloured formazan product. The quantity of 
formazan product can be measured optically at 490 nm and is directly proportional to 
the number of viable cells in culture, and therefore is a measure of proliferation. 
Results are expressed as fold difference in proliferation of cells treated with CCL20 
as compared to vehicle treated cells (n=4). 
5.2.9 Statistical analysis 
Where appropriate, data were analysed by Students t-test and one way ANOVA 
using GraphPad Prism (GraphPad Software. San Diego, California, USA). Data are 




5.3.1 Expression of CCL20 mRNA in normal endometrium across the 
menstrual cycle and endometrial adenocarcinoma 
The up-regulation of CCL20 mRNA expression induced by PGF2α treatment was 
demonstrated in a gene array study carried out in our laboratory (unpublished 
results). CCL20 mRNA expression was then examined in normal endometrium 
(n=29) and endometrial adenocarcinoma tissue (n=29) by quantitative PCR (Figure 
5.1). In normal endometrial tissue, CCL20 expression was significantly increased in 
the mid-late secretory phases as compared to early secretory and proliferative phase 
endometrium (p<0.05; Figure 5.1A). There was no significant difference in CCL20 
mRNA expression between different grades of cancer studied, hence data were 
pooled. CCL20 mRNA expression was significantly increased in endometrial 
adenocarcinoma by 45.4 ± 11.9 fold as compared to normal endometrium (p<0.01; 
Figure 5.1C). 
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Figure 5.1 Expression of CCL20 mRNA in normal endometrium and endometrial 
adenocarcinoma. A: CCL20 mRNA was examined by quantitative RT-PCR in proliferative 
(n=9), early secretory (n=10) and mid-late secretory (n=10) phase endometrium. Expression 
was significantly increased in the mid-late secretory phase as compared to other stages of 
the cycle. B: CCL20 mRNA expression was examined by quantitative RT-PCR in well (n=9), 
moderately (n=8) and poorly (n=10) differentiated cancers. No significant difference was 
demonstrated. C: CCL20 mRNA expression was examined by quantitative RT-PCR and 
found to be significantly increased in pooled endometrial adenocarcinoma tissue as 
compared to pooled normal endometrial tissue from all stages of the cycle. *denotes p<0.05, 
** denotes p<0.01, data are expressed relative to a normal endometrium control and are 
presented as mean ± SEM. 
 
5.3.2 Expression of CCR6 mRNA in normal endometrium and 
endometrial adenocarcinoma 
The expression of the receptor for CCL20, CCR6, was then examined in normal 
endometrium (n=30) and endometrial adenocarcinoma (n=28) by quantitative RT-
PCR (Figure 5.2). CCR6 mRNA expression did not significantly vary throughout the 
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menstrual cycle (Figure 5.2A) or between different grades of cancer (Figure 5.2B). 
Data were therefore pooled, and CCR6 mRNA expression was found to be 
significantly increased by 3.4 ± 1.3 fold in cancer as compared to normal 




Figure 5.2 Expression of CCR6 mRNA in normal endometrium and endometrial 
adenocarcinoma. A: CCR6 mRNA was examined by quantitative RT-PCR in proliferative 
(n=10), early secretory (n=10), and mid to late secretory (n=10) phase endometrium. There 
was no difference in levels of CCR6 expression at different stages of the menstrual cycle. B: 
CCR6 mRNA was examined by quantitative RT-PCR in well (n=10), moderately (n=10) and 
poorly (n=8) differentiated cancers. No significant difference was demonstrated between 
different grades of cancer. C: CCR6 mRNA expression was examined by quantitative RT-
PCR in pooled normal endometrial tissue from all stages of the cycle and pooled endometrial 
adenocarcinoma tissue, and demonstrated to be significantly increased in carcinoma tissue. 
** denotes p<0.01, data are expressed relative to a normal endometrium control and are 
presented as mean ± SEM. 
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5.3.3 Expression and localisation of CCL20 in normal endometrium 
and endometrial adenocarcinoma  
As mRNA expression of CCL20 had been demonstrated in endometrial tissue, the 
protein expression was then examined by immunohistochemistry in normal 
endometrial tissue from all stages of the cycle (proliferative phase endometrium n=7, 
early secretory phase endometrium n=3, mid secretory phase endometrium n=4, late 
secretory phase endometrium n=5). There was little to no immunoreactivity observed 
in endometrium from the proliferative phase of the menstrual cycle, with some 
staining seen in stromal cells (S; Figure 5.3A). In early secretory phase endometrium, 
positive CCL20 staining was observed in the cytoplasm of glandular epithelial cells 
(GE; Figure 5.3B).  This glandular epithelial staining was also observed in mid and 
late secretory phase endometrium (Figure 5.3C, D). Negative controls were 
incubated with non-immune IgG in place of primary antibody and displayed no 
immunoreactivity (inset; Figure 5.3D). 
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Figure 5.3 Localisation of CCL20 protein in normal endometrium by 
immunohistochemistry. Representative images demonstrating that A: CCL20 localises to 
the stroma in proliferative phase endometrium (S; left image is x200 magnification, right 
image is x400). B: In early secretory phase endometrium, weak CCL20 immunoreactivity 
can be seen in the glandular epithelium (GE; left image is x200 magnification, right image is 
x400). C: In mid secretory phase endometrium, CCL20 can be localised to glandular 
epithelium (left image is x200 magnification, right image is x400). D: In late secretory phase 
endometrium, CCL20 can be localised to glandular epithelium (left image is x200 
magnification, right image is x400).  Negative control (inset) is incubated with non-immune 






Chapter 5                                                           PGF2α regulation of CCL20 expression  
170 
CCL20 expression was then examined in all grades of endometrial adenocarcinoma 
by immunohistochemistry (well differentiated n=7, moderately differentiated n=5, 
poorly differentiated n=3). Staining of neoplastic epithelial cells (E) was observed in 
all grades of cancer (Figure 5.4A-C). Stromal cells (S) were also observed displaying 
immunoreactivity in all grades of cancer, and this is demonstrated in Figure 5.4B. 
Very weak staining of some vascular endothelial cells was observed, as demonstrated 
in Figure 5.4C (VE). Negative controls were incubated with primary antibody pre-
absorbed with blocking peptide (inset; Figure 5.4A). 
 
Figure 5.4 Localisation of CCL20 protein in endometrial adenocarcinoma by 
immunohistochemistry. Representative images demonstrating that CCL20 localises to the 
epithelium (E) and stroma (S) in A: Well differentiated carcinoma (left image is x200 
magnification, right image is x400). Negative control (inset) is incubated with primary 
antibody pre-absorbed with blocking peptide. B: Moderately differentiated carcinoma (left 
image is x200 magnification, right image is x400). C: Poorly differentiated carcinoma (left 
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5.3.4 Expression and localisation of CCR6 in normal endometrium and 
endometrial adenocarcinoma  
Expression of mRNA of the receptor for CCL20, CCR6, was also demonstrated in 
normal endometrium and endometrial adenocarcinoma (Figure 5.2). The expression 
and localisation of the protein was then examined by immunohistochemistry in 
normal endometrium (proliferative phase endometrium n=7, early secretory phase 
endometrium n=3, mid secretory phase endometrium n=4, late secretory phase 
endometrium n=5). Little or no CCR6 immunoreactivity could be seen in the 
glandular epithelial cells of normal endometrium at all stages of the cycle (Figure 
5.5A-C). CCR6 expression was observed in rare cells dispersed throughout the 
stroma in all stages of the cycle, demonstrated here in late secretory phase 
endometrium (Figure 5.5C). CCR6 expression was not demonstrated on vascular 
endothelium, demonstrated here in proliferative phase endometrium (VE; Figure 
5.2A). Negative control is incubated with non-immune goat IgG in place of primary 
antibody (inset, Figure 5.5A). 
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Figure 5.5 Localisation of CCR6 protein in normal endometrium by 
immunohistochemistry. Representative images demonstrating A: Weak immunoreactivity 
to CCR6 in the glandular epithelium of proliferative phase endometrium (GE; left image is 
x200 magnification, right image is x400). B: In early secretory phase endometrium, no CCR6 
immunoreactivity can be seen (left image is x200 magnification, right image is x400). C: In 
late secretory phase endometrium, CCR6 can be localised to some stromal cells (S;left 
image is x200 magnification, right image is x400). Negative control (inset) is incubated with 
non-immune goat IgG in place of primary antibody. All scale bars represent 100 µm. 
 
The expression of CCR6 in endometrial adenocarcinoma was then examined by 
immunohistochemistry (well differentiated n=7, moderately differentiated n=5, 
poorly differentiated n=3). Expression of CCR6 in neoplastic epithelial cells was 
observed in every grade of cancer examined (Figure 5.6A-C). No expression was 
seen in vascular endothelial cells in endometrial adenocarcinoma, as demonstrated in 
Figure 5.6B and C (VE). Stromal expression was also observed in rare cells in all 
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carcinoma (S; Figure 5.6B). Negative control is incubated with non-immune goat 
IgG in place of primary antibody (inset, Figure 5.6A). 
 
 
Figure 5.6 Localisation of CCR6 protein in endometrial adenocarcinoma by 
immunohistochemistry. Representative images demonstrating that CCR6 localises to the 
epithelium (E) and stroma (S) but not vascular endothelium (VE) in A: Well differentiated 
carcinoma (left image is x200 magnification, right image is x400). Negative control (inset) is 
incubated with non-immune goat IgG in place of primary antibody. B: Moderately 
differentiated carcinoma (left image is x200 magnification, right image is x400). C: Poorly 
differentiated carcinoma (left image is x200 magnification, right image is x400). All scale bars 
represent 100 µm. 
 
 
CCR6 is expressed on dendritic cells (Murdoch et al. 2008). To examine if CCR6 
positive cells throughout the stroma were dendritic cells, dual immunofluorescence 
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n=3, moderately differentiated n=3, poorly differentiated n=3). Expression of CD11c 
(Figure 5.7A) was observed in the stroma alongside expression of CCR6-positive 
neoplastic epithelial cells in well differentiated adenocarcinoma (Figure 5.7B), 
however no colocalisation of CCR6 and CD11c was observed in all grades of 
endometrial adenocarcinoma examined (Figure 5.7C). Negative control (inset) was 
incubated with non-immune IgG in place of primary antibody. 
 
 
Figure 5.7 Expression of CD11c and CCR6 in endometrial adenocarcinoma by 
dual immunofluorescence microscopy.  CD11c, a dendritic cell marker, (A) and CCR6 (B) 
were expressed in endometrial adenocarcinoma but did not colocalise (C). Negative control 
(inset) was incubated with non-immune IgG in place of primary antibody, scale bar 
represents 10 µm. 
 
5.3.5 Localisation of CCL20 and CCR6 to the same cells as the FP 
receptor in endometrial adenocarcinoma  
To further support a role for FP in the regulation of CCL20, immunohistochemistry 
for both proteins was carried out on serial sections of endometrial adenocarcinoma 
(well differentiated n=2, moderately differentiated n=2, poorly differentiated n=2). 
Immunohistochemistry for the receptor CCR6 was also carried out on serial sections. 
In all grades of cancer, FP could be localised to a number of the same epithelial cells 
as CCL20 and CCR6. Shown are representative images from a moderately 
differentiated cancer (Figure 5.8). Localisation of FP, CCL20 and CCR6 can be 
demonstrated in the same epithelial cells and is indicated by arrowheads. FP negative 
controls were incubated with non-immune IgG, CCL20 and CCR6 negative controls 
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Figure 5.8 CCL20 and CCR6 can be localised to the same cells as the FP receptor 
by immunohistochemistry of serial sections. Representative images demonstrating that 
FP, CCL20 and CCR6 can be colocalised to neoplastic epithelium (E; inicated by 
arrowheads) in moderately differentiated endometrial adenocarcinoma (x 200 magnification. 
All scale bars represent 100 µm. 
 
5.3.6 CCL20 mRNA expression is regulated by PGF2α in Ishikawa FPS 
cells  
As the regulation of CCL20 by PGF2α had been suggested by gene array, the 
temporal regulation of CCL20 in FPS cells was investigated by quantitative RT-PCR 
and ELISA. Cells were treated for 2-72 hours with vehicle or PGF2α (Figure 5.9). 
After 12 hours of PGF2α treatment, CCL20 mRNA was significantly elevated 609.1 ± 
94.7 fold as compared to vehicle treated cells, and was then decreased until 72 hours 
(p<0.01; Figure 5.9A). CCL20 protein was then measured in medium of FPS cells 
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present in the media from 24 hours of PGF2α treatment, and was significantly 
increased compared to vehicle treated cells by 55.7 ± 14.6 fold at 48 hours, and 
remained significantly elevated 93.3 ± 16.4 fold above vehicle treated control at  72 
hours (p<0.01, Figure 5.9B). 
 
 
Figure 5.9 Regulation of CCL20 by PGF2α in FPS cells. A: CCL20 mRNA expression 
in FPS cells was measured by quantitative RT-PCR after stimulation with vehicle or 100 nM 
PGF2α over a period of 2 to 72 hours. Data are expressed as fold increase over vehicle 
treated control. B: CCL20 protein secreted into media by FPS cells after stimulation with 
vehicle or 100 nM PGF2α over a period of 24 to 72 hours was measured by ELISA. CCL20 
protein production was significantly elevated above vehicle treated control cells after 
treatment with PGF2α for 48 hours. Data are expressed as fold increase over vehicle treated 
control cells. All data are presented as mean ± SEM. ** denotes p< 0.01, *** denotes 
p<0.001. 
 
5.3.7 CCL20 mRNA expression is regulated by PGF2α in endometrial 
adenocarcinoma explants 
To confirm that PGF2α also regulates CCL20 expression in carcinoma tissue, human 
endometrial adenocarcinoma explants were used (n=5). Tissue was treated for 2, 4, 6, 
8, and 24 hours with vehicle or 100 nM PGF2α and CCL20 mRNA expression 
measured by quantitative RT-PCR. After 24 hours PGF2α treatment, CCL20 mRNA 
expression was significantly increased in carcinoma explants 2.5 ± 0.8 fold as 
compared to vehicle treated control explants (Figure 5.10). 
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Figure 5.10 PGF2α regulates CCL20 expression in endometrial adenocarcinoma 
explants. Endometrial adenocarcinoma explants (n=5) were treated for 2 - 24 hours with 
vehicle or 100 nM PGF2α and CCL20 mRNA was measured by quantitative RT-PCR. CCL20 
mRNA was significantly increased after 24 hours of PGF2α treatment. Data are expressed as 
fold over vehicle treated control cells and are presented as mean ± SEM. ** denotes p<0.01. 
 
5.3.8 Intracellular pathways mediating PGF2α regulation of CCL20 
expression in FPS cells 
In chapter 3, the activation of intracellular signalling pathways by the FP receptor 
was discussed. The same panel of chemical inhibitors was used to examine signalling 
pathways regulating CCL20 production. FPS cells were treated with vehicle, 100 nM 
PGF2α alone or 100 nM PGF2α and a panel of chemical inhibitors (n=7; Figure 5.11). 
Treatment of FPS cells with PGF2α for 8 hours induced a 341.2 ± 75.2 fold increase 
in CCL20 mRNA compared to vehicle treated cells. This increase in mRNA 
expression was abolished by treatment of cells with a selective inhibitor of Gq 
(YM254890; p<0.01) and significantly inhibited with the FP receptor antagonist 
AL8810 (p<0.05) and inhibitors of epidermal growth factor receptor (EGFR, 
AG1478; p<0.01), mitogen activated protein kinase kinase (MEK; PD98059, 
p<0.05), calcineurin (CsA; p<0.05) and calcium (EGTA, p<0.05). An inhibitor of 
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protein kinase A (PKA; 43CMQ) did not significantly inhibit PGF2α induced CCL20 
mRNA expression.   
 
 
Figure 5.11 PGF2α regulated CCL20 expression is decreased by selected chemical 
inhibitors. FPS cells were treated for 8 hours in the presence or absence of vehicle or 100 
nM PGF2α and chemical inhibitors of Gq, FP, EGFR, MEK, calcineurin, calcium and PKA 
(n=7). PGF2α regulated CCL20 mRNA expression was examined by quantitative RT-PCR 
and found to be significantly inhibited by inhibitors of Gq, FP, EGFR, MEK, calcineurin and 
calcium. Data are expressed as fold over vehicle treated control. * denotes p<0.05, ** 
denotes p<0.01, *** denotes p<0.001. 
 
Adenovirus-mediated delivery of short hairpin mRNA directed against the FP 
receptor (sh FP) or a scrambled sequence as a control (sh scrambled) was used to 
confirm the role of the FP receptor in CCL20 regulation by PGF2α (n=4). Twenty-
four hours after infection, FPS cells were treated for 8 hours with 100 nM PGF2α or 
vehicle. Relative CCL20 mRNA expression with the addition of scrambled shRNA 
was increased 207.3 ± 131.3 fold over vehicle treated cells. This increase was 
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reduced with the addition of shRNA targeted against the FP receptor to 41 ± 16.4 
fold; however this reduction did not reach statistical significance. 
 
 
Figure 5.12 PGF2α regulated CCL20 mRNA expression is decreased with shRNA 
directed against the FP receptor. FPS cells were infected with adenovirus containing 
scrambled sequence shRNA (sh scrambled) or shRNA directed against the FP receptor 
(shFP) and treated for 8 hours with vehicle or 100 nM PGF2α (n=4). CCL20 expression was 
decreased in cells infected with shRNA directed against the FP receptor as compared to 
scrambled sequence shRNA. Data are expressed as fold over vehicle treated control and 
are presented as mean ± SEM. 
 
To further confirm the involvement of components of the NFAT signalling pathway 
in the regulation of CCL20, the role of the protein regulator of calcineurin1-4 
(RCAN1-4) was examined. RCAN1-4 binds to calcineurin to inhibit downstream 
NFAT activity (Maldonado-Perez et al. 2009). RCAN1-4 was overexpressed in FPS 
cells by adenoviral delivery, and 24 hours after infection, FPS cells were treated for 8 
hours with vehicle or PGF2α (n=4). A significant reduction in PGF2α-induced CCL20 
mRNA expression was seen in cells over-expressing RCAN1-4, as compared to FPS 
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cells infected with a control adenovirus (p<0.05, Figure 5.13A). In order to further 
demonstrate the role of this signalling pathway in CCL20 production, a shRNA 
lentiviral construct targeting RCAN1-4 was transfected into FPS cells (n=4). 
Twenty-four hours after infection, FPS cells were treated with PGF2α for 8 hours, and 
inhibition of RCAN1-4 caused a significant increase in CCL20 mRNA expression as 
compared to cells transfected with the control lentivirus (p<0.05, Figure 5.13B). 
 
 
Figure 5.13 RCAN1-4 is involved in the signalling pathway mediating PGF2α 
regulation of CCL20. A: FPS cells were infected with control empty adenovirus or RCAN1-4 
adenovirus and  treated for 8 hours with vehicle or PGF2α (n=4). CCL20 expression was 
significantly decreased in cells treated with the RCAN1-4 adenovirus. B: FPS cells were 
treated for 8 hours with vehicle or PGF2α and lentivirus containing scrambled sequence 
shRNA or shRNA against RCAN1-4 (n=4). CCL20 expression was significantly increased in 
cells infected with RCAN1-4 shRNA as compared to scambled sequence shRNA. Data are 
expressed as fold over vehicle treated control and are presented as mean ± SEM, * denotes 
p<0.05. 
 
5.3.9 Expression of CCR6 in FPS cells 
CCR6 expression was detected in endometrial adenocarcinoma epithelial cells by 
immunohistochemistry (Figure 5.6). As autocrine signalling was therefore possible, 
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CCR6 expression in FPS cells was then examined by quantitative RT-PCR. CCR6 
mRNA expression was detected in FPS cells, however at significantly lower levels 
than in cancer tissue (p<0.001, Figure 5.14). 
 
 
Figure 5.14 Expression of CCR6 mRNA in FPS cells. FPS cells, normal endometrium 
and endometrial adenocarcinoma tissue was examined by quantitative RT-PCR for CCR6 
mRNA expression. CCR6 mRNA expression was significantly higher in endometrial 
adenocarcinoma tissue. Data are expressed as mean ± SEM, *** denotes p<0.001.  
 
5.3.10 CCL20 does not significantly affect chemotaxis of FPS cells 
CCL20 promotes cell migration in several cancer types (Kimsey et al. 2004; Brand et 
al. 2006; Rubie et al. 2006). To examine the physiological effects of CCL20 in 
endometrial adenocarcinoma, chemotaxis of FPS cells towards recombinant CCL20 
was assessed by transwell assay after 24 hours (n=4). The chemotaxis of FPS cells 
towards the positive control of complete medium containing fetal calf serum was 
significantly increased as compared to a negative control of serum-free medium 
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(FCS, p<0.05; Figure 5.15). However the addition of recombinant CCL20 from 
concentrations of 10 ng/ml to 300 ng/ml did not significantly affect FPS cell 
chemotaxis.  
 
Figure 5.15 CCL20 does not increase migration of FPS cells.  Chemotaxis of FPS 
cells towards recombinant CCL20 after 24 hours was assessed by transwell assay (n=4). 
Chemotaxis towards complete media containing fetal calf serum (FCS) was significantly 
increased as compared to serum free (SF) medium. No significant chemotaxis toward 
recombinant CCL20 was observed. *denotes p<0.05.  
5.3.11  CCL20 promotes proliferation of FPS cells 
CCL20 has also been demonstrated to promote proliferation of colorectal cancer cells 
(Brand et al. 2006) and leukaemia cells (Beider et al. 2009). To examine if similar 
events are occurring in endometrial adenocarcinoma, proliferation of FPS cells was 
examined after treatment with vehicle or recombinant CCL20 (n=5). FPS cells were 
treated in 1% serum media with vehicle or CCL20 at doses between 10 – 300 ng / ml 
and proliferation examined by Cell Titer One Solution Assay (Promega). CCL20 
treatment resulted in significant increases in proliferation of 1.39 ± 0.07 fold at 10 ng 
/ ml (p<0.01), 1.45 ± 0.07 fold at 100 ng / ml (p<0.01), 1.40 ± 0.08 fold at 200 ng / 
ml (p<0.01) and 1.36 ± 0.1 fold at 300 ng / ml (p<0.05; Figure 5.16). 
Chapter 5                                                           PGF2α regulation of CCL20 expression  
183 
 
Figure 5.16 CCL20 induces FPS cell proliferation. FPS cells were treated with 
recombinant CCL20 protein at 10, 100, 200 and 300 ng / ml and proliferation measured 
using Cell Titer One Solution assay (n=5). FPS cell proliferation was significantly increased 
with the addition of CCL20 as compared to vehicle treated cells. Data are expressed as 
mean ± SEM, * denotes p<0.05, ** denotes p<0.01. 
 
5.4 Discussion  
A gene array carried out by our laboratory first identified CCL20 as a target of 
PGF2α-FP signalling (unpublished observations). This chapter confirmed the 
regulation of CCL20 by PGF2α in FPS cells and endometrial adenocarcinoma tissue 
explants, and the signalling pathways involved in its production. The localisation of 
CCL20 protein in endometrial tissue was described, and a role for CCL20-CCR6 
signalling in the promotion of epithelial cell proliferation was identified.  
 
The expression of CCL20 mRNA in endometrial tissue was significantly increased in 
the mid-late secretory phase of the menstrual cycle. A number of cytokines are 
upregulated at this stage of the cycle in preparation for implantation in order to 
facilitate complex interactions between the implanting embryo, uterus and other cells 
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including immune cells, and CCL20 may play a role in one of these processes 
(Guzeloglu-Kayisli et al. 2009). The expression of CCL20 in glandular epithelial 
cells in normal endometrium is in agreement with previous studies showing its 
expression in an endometrial epithelial cell line (Sun et al. 2002) and in primary 
endometrial epithelial cells (Ghosh et al. 2009). CCL20 mRNA expression has been 
previously demonstrated in a gene array of endometrial adenocarcinoma (Wong et al. 
2007), however no further literature exists describing its localisation or function in 
endometrial cancer.  
 
CCR6 expression did not significantly vary throughout the stages of the menstrual 
cycle, however its expression was significantly increased in endometrial 
adenocarcinoma. CCR6 expression in the human endometrium and endometrial 
adenocarcinoma has not previously been described. The expression of CCR6 in 
normal endometrium as demonstrated by immunohistochemistry was present only in 
rare cells throughout the stroma and was weakly localised to glandular epithelial 
cells in proliferative phase endometrium. In endometrial adenocarcinoma, CCR6 
expression was demonstrated in the neoplastic epithelial cells. This implied potential 
for autocrine signalling, as CCL20 expression was also present in the neoplastic 
epithelium in endometrial adenocarcinoma.  
 
A role for PGF2α-FP signalling in CCL20 production was confirmed by the 
demonstration of increased CCL20 mRNA and protein expression in FPS cells. The 
signalling pathways mediating expression of CCL20 expression were therefore 
investigated. In Chapter 3, PGF2α-FP regulation of the chemokine CXCL1 by an 
EGFR-Ras-ERK1/2 pathway was described, and therefore components of this 
MAPK pathway were investigated. CCL20 has been previously demonstrated to be 
regulated by the nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB) (Harant et al. 2001) and the related NFAT family of transcription factors 
(Pietila et al. 2007). As it has been previously demonstrated in our laboratory that 
NFκB signalling is not activated by PGF2α-FP interaction in FPS cells (K Sales, 
unpublished observations), only the MAPK and NFAT signalling pathways were 
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investigated. Inhibitors of FP, Gq, EGFR, MEK, calcineurin and calcium 
significantly decreased CCL20 mRNA expression. A chemical inhibitor of PKA did 
not decrease CCL20 mRNA. These findings correspond with previous data where 
CCL20 has been induced via an ERK signalling pathway (Sandri et al. 2008; Kanda 
et al. 2009), and a calcineurin-mediated NFAT signalling pathway (Pietila et al. 
2007).  
 
To further confirm the involvement of the NFAT signalling pathway in the 
regulation of CCL20, over-expression and knockdown of the calcineurin-binding 
protein RCAN1-4 was performed using adenoviral and lentiviral constructs. The 
efficacy of these constructs have been previously demonstrated (Maldonado-Perez et 
al. 2009). RCAN1-4 binds to calcineurin, preventing the dephosphorylation and 
activation of NFAT. NFAT translocation to the nucleus is prevented, and therefore 
NFAT-dependent gene transcription is inhibited. Over-expression of RCAN1-4 
caused a significant decrease in CCL20 mRNA, implying NFAT activation is crucial 
in CCL20 regulation. RCAN1-4 knockdown caused a significant increase in CCL20 
mRNA expression indicating that increased availability of calcineurin, and therefore 
increased translocation of NFAT to the nucleus, led to increased CCL20 mRNA 
expression. The crosstalk between the ERK and NFAT signalling pathways leading 
to production of CCL20 is unclear. ERK signalling can activate the DNA binding 
protein activating-protein complex-1 (AP-1), which is made up of a dimer of the Jun 
and Fos proteins.  AP-1 can act synergistically with NFAT to regulate gene 
transcription (Macian et al. 2001). A role for AP-1 in CCL20 induction has been 
previously demonstrated in human keratinocyte cells (Kanda et al. 2009), and 
therefore this may be occurring in FPS cells. Furthermore, RCAN1-4 can also be 
directly phosphorylated by MEK, demonstrating a further degree of cross talk that 
could be acting between these two pathways. Whether the function of this 
phosphorylation is to inhibit or increase calcineurin binding is unclear (Harris et al. 
2005). The interaction occurring between these pathways after PGF2α signalling is 
therefore unclear but both appear central in regulation of CCL20 expression. The 
potential signalling pathways leading to CCL20 expression in FP cells is illustrated 
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in Figure 5.17, with components of the signalling pathways investigated in this 

















Figure 5.17 PGF2α stimulates CCL20 production in FPS cells via FP-Gq-EGFR-MEK 
and FP-Gq-calcium-calcineurin-NFAT dependent pathways. Use of shRNA constructs 
and chemical inhibitors of cell signalling (highlighted in red) demonstrated that CCL20 
production by PGF2α-FP signalling is dependent on FP-Gq-EGFR-MEK and FP-Gq-calcium-
calcineurin-NFAT signalling pathways. Mechanisms of crosstalk between the pathways are 
unknown. 
 
In addition to regulation at the mRNA level by the signalling pathways described, 
CCL20 is also likely to be regulated post-transcriptionally. CCL20 mRNA contains 
the destabilisation motif AUUUA, which is associated with rapid mRNA degradation 
(Harant et al. 2001). 
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CCL20-CCR6 signalling has an established role in dendritic cell and lymphocyte 
migration (Schutyser et al. 2003), and has recently been shown to be important in 
epithelial cell migration. In pancreatic cancer tissue, CCL20 and CCR6 were co-
localised to the same cells, and in a pancreatic cancer cell line this autocrine 
signalling caused a significant increase in cell invasion (Kimsey et al. 2004). This 
was discovered to be dependent on an upregulation of MMP-9 by CCL20-CCR6 
signalling (Campbell et al. 2005). Increased migration was also demonstrated in 
colorectal cancer cells after autocrine CCL20-CCR6 signalling (Brand et al. 2006). 
Increased invasiveness and metastasis were also associated with CCL20 or CCR6 
expression in nasopharyngeal cancer (Chang et al. 2008), prostate cancer (Ghadjar et 
al. 2008) and liver cancer (Rubie et al. 2006). 
 
Interestingly, an increase in CCR6 expression can influence metastasis in some 
cancer types. Increased CCR6 expression in plasmacytoma cells in a mouse model 
led to increased liver metastasis. This was found to be due to the high levels of 
CCL20 production by the liver causing migration of cancer cells towards this 
chemokine gradient, in a similar mechanism to chemoattraction of immune cells 
(Dellacasagrande et al. 2003). This mechanism has also been proposed as the reason 
for the high number of patients with colorectal cancer presenting with liver 
metastasis (Ghadjar et al. 2006). This evidence indicates that CCL20-CCR6 
interactions may influence cell migration in endometrial adenocarcinoma. 
 
In this chapter, however, significantly increased proliferation rather than migration 
was demonstrated after addition of CCL20 to CCR6-expressing endometrial 
adenocarcinoma cells. Proliferation was significantly increased but not dose-
dependently after the addition of recombinant CCL20 from concentrations between 
10 – 300 ng / ml, potentially as a result of desensitisation or internalisation of the 
CCR6 receptor at high chemokine concentrations (Beider et al. 2009). An increase in 
proliferation with similar concentrations of CCL20 has also been demonstrated in 
colorectal cancer cells (Brand et al. 2006). In a further study, CCL20 expression was 
upregulated by signalling at another chemokine receptor, CXCR4. This increase in 
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CCL20 expression caused an increase in proliferation of prostate, colon and 
promyelocytic leukaemia cancer cell lines (Beider et al. 2009). Proliferation was 
shown to be dependent on the ERK and c-Jun N-terminal kinase (JNK; a further 
mitogen activated protein kinase) signalling pathways in colorectal cancer (Brand et 
al. 2006). Further work is required in endometrial adenocarcinoma cells to determine 
the signalling pathways leading to increased cell proliferation. Levels of CCR6 
mRNA expression in FPS cells were demonstrated to be significantly lower than 
those seen in cancer tissue. Therefore effects of CCL20 on FPS cell functions may be 
more pronounced if expression of CCR6 at similar levels to cancer in FPS cells was 
achieved. 
 
CCL20 has also previously been demonstrated to contribute to tumour growth by 
promoting a tumour microenvironment which induces immune tolerance to tumour 
cells. As described in Chapter 4, dendritic cells present antigen to activate T and B 
lymphocytes which participate in cell-mediated cytotoxicity. In a previous study in 
colorectal cancer cells, CCL20 signalling induced chemotaxis of immature dendritic 
cells. These were defective in tumour antigen presenting and therefore a means to 
escape immune surveillance (Wang et al. 2008). Increased tumour growth was also 
demonstrated in a colon cancer cell line stably transfected with CCL20 which 
displayed increased immature dendritic cell infiltration (Bonnotte et al. 2004). 
However, further demonstrating the complexity of the role of immune cells within 
cancer, a similar mouse model of lung cancer led to an increase in infiltrating 
immature dendritic cells yet a decrease in tumour growth (Zhu et al. 2006). In 
Chapter 4, significantly increased numbers of dendritic cells as measured by CD11c 
expression were described in endometrial adenocarcinoma as compared to normal 
endometrium. Co-localisation of CD11c and CCR6 was not observed in cancer 
sections studied in this chapter; therefore CCL20 signalling may not play a large role 
in any induction of immune tolerance in endometrial adenocarcinoma.  
 
This chapter has described a further chemokine regulated by PGF2α in an endometrial 
adenocarcinoma cell line and endometrial adenocarcinoma explants. The expression 
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of the chemokine CCL20 and its receptor CCR6 was identified and localised in 
normal endometrium and endometrial adenocarcinoma tissue, and CCL20 expression 
induced by PGF2α was found to be regulated by ERK and NFAT dependent 
signalling pathways. Finally, CCL20 was found to promote proliferation of 
endometrial adenocarcinoma cells. This chapter therefore highlights a function of the 
chemokine CCL20 in endometrial adenocarcinoma extending beyond its traditional 
role as a dendritic cell attractant. 
 
Chapter 6 
Interactions between the 
lysophosphatidic acid (LPA) and 
PGF2α signalling pathways 
Chapter 6                                                                           LPA and PGF2α interactions  
191 
6 Interactions between the lysophosphatidic acid (LPA) 
and PGF2α signalling pathways 
6.1 Introduction 
The previous chapters in this thesis have examined the signalling pathways and the 
downstream effects resulting from PGF2α-FP receptor signalling in endometrial 
adenocarcinoma. However, in a physiological setting, the net effect of cell signalling 
is not only determined by single signalling pathways but also by the integrative effect 
of all the pathways activated.  
 
Similarly to PGF2α, lysophosphatidic acid (LPA) is a membrane derived lipid 
mediator. The formation of LPA has been reported by different metabolic pathways 
dependent on the cell type examined; commonly the choline group from 
lysophosphatidylcholine is removed by the enzyme autotaxin (ATX) or 
phospholipids are cleaved extracellularly by phospholipase D into phosphatidic 
acids. A subsequent hydrolysis step by phospholipase A1 and A2 then forms LPA 
(Ye 2008). LPA acts through G-protein coupled receptors, of which seven have now 
been identified and named LPAR1-7 (Murph et al. 2008). LPAR1-3 are widely 
expressed in the body, while LPAR4-7 have limited expression and as yet unknown 
functions (Murph et al. 2006). Activation of LPAR1-3 leads to several downstream 
phenotypic effects including increased cell proliferation and migration, yet despite 
numerous studies, signalling cascades resulting from their activation are still unclear 
(Ye 2008).  
 
LPA receptors 1-3 (also known as endothelial differentiation genes 2, 4, and 7) share 
high sequence homology with each other but less than 20% homology with LPAR4-7 
(Murph et al. 2008). They have been reported to couple to Gi, Gq or G12/13 dependent 
on the cell type and model used (Ishii et al. 2004). In the female reproductive tract, 
LPA signalling plays a key role in fertilisation, implantation, decidualisation and 
parturition (Ye 2008), and has been shown to induce oocyte maturation in vitro 
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(Komatsu et al. 2006). While knock out of LPAR1 and 2 showed no adverse affects 
on reproduction, LPAR3-knock out mice have impaired implantation and embryo 
spacing, resulting in embryo death and small litter sizes (Ye et al. 2005). LPAR3 
expression in the murine uterus is also upregulated by progesterone and 
downregulated by oestrogen, further implicating LPA signalling in implantation 
(Hama et al. 2006). Throughout pregnancy, LPA expression is increased in serum 
(Tokumura et al. 2002) and expression of LPAR 2 and 3 in the human and mouse 
placenta has been reported (Ye 2008). 
 
In cancer, LPA signalling can promote cell migration, cell proliferation and tissue 
remodelling through production of proteases and stimulation of angiogenesis (Murph 
et al. 2006). Elevated LPA concentrations have been found in the ascites and serum 
of patients with ovarian (Shen et al. 1998) and endometrial (Tokumura et al. 2007) 
cancer. Expression of LPAR1-3 has been documented in numerous cancers including 
breast (Kitayama et al. 2004), colon (Yun et al. 2005), prostate (Guo et al. 2006), 
gastrointestinal (Shin et al. 2009), and ovarian (Jeong et al. 2008; Yu et al. 2008). 
The expression of LPAR2 has also been demonstrated in an endometrial 
adenocarcinoma cell line (Hope et al. 2009). LPA signalling may promote tumour 
growth through the regulation of other signalling molecules, including angiogenic 
factors and cytokines. LPA promotes expression of CXCL1 in ovarian cancer via 
LPAR2 (Lee et al. 2006) as well as the related chemokine IL-8 in endometrial 
stromal cells via a Gi-MAPK-NFκB pathway (Chen et al. 2008). 
 
The convergence of the COX-2 and LPA signalling pathways has been previously 
demonstrated, as LPA signalling via LPAR1-3 upregulates COX-2 expression and 
therefore prostaglandin production (Ye et al. 2005; Liszewska et al. 2009; 
Woclawek-Potocka et al. 2009; Woclawek-Potocka et al. 2009). Additionally, the 
LPAR3 knock out mouse displays a similar reproductive phenotype to the COX-2 
knock out mouse and mice treated with an inhibitor of prostaglandin formation (Shah 
et al. 2005; Ye et al. 2005). The phenotype of the LPAR3 knockout mouse can be 
partly reversed by exogenous prostaglandin treatment, further indicating possible 
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feedback between these signalling molecules (Ye et al. 2005). This chapter examined 
a further interaction between the two pathways. As the FP receptor is known to 
localise to neoplastic epithelial cells in endometrial adenocarcinoma, the localisation 
of the LPA receptors 1-3 was investigated in endometrial adenocarcinoma to 
determine if potential cross talk could occur. The effects of LPA signalling on FP 
receptor expression and on the expression of genes demonstrated to be regulated by 
FP previously in this thesis were then examined.  
 
 
6.2 Materials and methods 
6.2.1 Tissue collection 
Normal endometrium and endometrial adenocarcinoma tissue was collected as 
described in sections 2.1.1 and 2.1.2. Normal endometrial tissue was collected from 
women undergoing surgery for minor gynaecological procedures with no underlying 
endometrial pathology, and endometrial adenocarcinoma tissue was obtained from 
women undergoing hysterectomy after diagnosis of adenocarcinoma of the uterus. 
Stage of cycle and grade of cancer was assessed by a pathologist. Written informed 
consent was collected from all patients before surgery and ethical approval was 
obtained from Lothian Research Ethics Committee. 
6.2.2 Cell culture  
Ishikawa FPS cells were maintained as described in section 2.2.1.  
6.2.3 Cell treatments 
To determine the pattern of FP, CXCL1, CCL20, COX-2 and PGF2α expression in 
response to LPA, FPS cells were serum starved for at least 18 hours prior to 
stimulation for 2, 4, 6, 8, 12, 18, 24, 48 and 72 hours with fresh serum-free media 
containing vehicle or 10 µM LPA (n=5).  
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To determine if target gene expression occurred independently of activation of the 
FP receptor, FPS cells were serum starved for at least 18 hours and treated for 4 
hours with vehicle, AL8810 alone, 10 µM LPA or 10 µM LPA and AL8810 (n=4). 
6.2.4 Polymerase chain reaction 
6.2.4.1 RNA extraction and reverse-transcriptase PCR 
RNA from cells was extracted as described in section 2.4.1. Briefly, 1 ml TRI-
reagent was added to experimental wells and RNA extracted using the phenol 
method.  
 
RNA from tissue was extracted as described in section 2.4.1 using the Qiagen minikit 
protocol. Pieces of tissue, in 2 ml microcentrifuge tubes containing a stainless steel 
ball, were homogenised in 600 µl RLT lysis buffer using a tissue lyser (Qiagen, 
Crawley, West Sussex, UK) for 2 x 2 minutes at 25 Hz.  RNA was then extracted 
following manufacturers guidelines (Qiagen). cDNA was prepared as described in 
section 2.4.2. 
6.2.4.2 Taqman quantitative RT-PCR 
FP, CXCL1, CCL20, COX-2, LPAR1, LPAR2 and LPAR3 mRNA expression in 
FPS cells (n=6), normal endometrium (n=29) and endometrial adenocarcinoma tissue 
(n=29) was examined using Taqman quantitative PCR as described in section 
2.4.3.2. Briefly, primer and probe sequences were designed to amplify the above 
genes (sequences given in Table 2.3). A master mix was made up containing 18S 
primers and probes and 200 ng cDNA was added to each sample. Samples were 
added in duplicate to a 96 well MicroAmp fast optical reaction PCR plate and 
analysed using an ABI Prism 7900 HT Fast Real Time PCR machine. Expression of 
analyzed genes was normalised to RNA loading for each sample using the 18S 
ribosomal RNA as an internal standard. Results are expressed as fold increase above 
vehicle treated cells or relative to a normal endometrium control. 
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6.2.5 Immunohistochemistry 
3,3- diaminobenzidine tetrahydrochlorine (DAB) immunohistochemistry to localise 
LPAR1, LPAR2 and LPAR3 was performed as described in section 2.5.2 (normal 
endometrium: proliferative phase n=4, early secretory phase n=3, mid secretory 
phase n=3, late secretory phase n=4; endometrial adenocarcinoma: well 
differentiated n=4, moderately differentiated n=3, poorly differentiated n=3). Tissue 
sections (5 µm) were dewaxed in xylene then rehydrated through graded ethanols 
and water. Antigen retrieval in citrate buffer (0.01M, pH 6) was performed, followed 
by blocking for endogenous peroxidase activity by washing sections in 3% hydrogen 
peroxidase in methanol. Sections were then blocked in normal serum of goat 
followed by overnight incubation with primary antibody at the concentrations 
indicated in Table 2.4. Control sections were included with non-immune IgG. 
Sections were then incubated in goat anti-rabbit biotinylated secondary antibody and 
subsequently streptavidin-HRP. Sections were then incubated with DAB for 1-5 
minutes until positive staining was identified by a brown colour under x10 
magnification. 
6.2.6 PGF2α assay 
PGF2α released into the culture medium from treatments described in section 6.2.3 
was measured using an assay developed in our laboratory. 96-well plates were coated 
with donkey anti-rabbit serum diluted 1:200 in PBS overnight. After removal of this, 
wells were blocked with Dry Coat solution (2% polyvinyl pyrollidine, 1% BSA, 
0.05% sodium azide, 5mM EDTA in Tris-buffered saline) for 1 hour and washed in 
wash buffer (0.05% Tween in PBS, pH 7.2-7.4). A volume of 50 µl of rabbit 
antiserum, 50 µl of biotin-labelled prostaglandin link and 100 µl of sample or 
standards were then added to each well. The PGF2α assay works by competitive 
binding. Any PGF2α present in the sample will displace binding of the link, and 
therefore at the addition of streptavidin peroxidase and substrate color detection step, 
a stronger colour indicates a low concentration of PGF2α. The link was prepared by 
ether extraction and purified by reverse phase chromatography using 20mg of 
synthetic PGF2α, 320µL of dry dimethylformamide, 3µl butylchlororomate and 
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0.05nM biocytin. The link and antisera were diluted 1:1 million and 1:50000 in assay 
buffer (150 mM NaCl, 100 mM Tris-HCl, 50 mM phenol red 1 mM 2-
methylisothiaolone, 1 mM bromonitrodioxane, 2 mM EDTA, 2 mg/ml BSA to a final 
pH of 7.2) respectively. A control was included containing no antiserum. After 
overnight incubation at 4 °C plates were washed in wash buffer 4 times. Streptavidin 
peroxidase (Roche, UK) diluted 1:2000 in assay buffer was added for 20 minutes. 
Colour change was detected by addition of substrate solution (1:1 mix in 100mM 
sodium acetate buffer, pH 6, of: 5mg/ml hydrogen peroxide in sodium acetate buffer, 
pH 6: tetramethylbenzidine 3mg/ml in dimethyl formamide) and the reaction was 
stopped by addition of 2N sulphuric acid. Optical density of wells was read at 
450nM. 
6.2.7 Statistical analysis 
Where appropriate, statistical analysis was carried out using GraphPad Prism 




6.3 Results  
6.3.1 Expression of the LPA receptors in normal endometrium and 
endometrial adenocarcinoma 
The mRNA expression of three of the receptors for LPA was examined in normal 
endometrium and endometrial adenocarcinoma. 
6.3.1.1 Expression of LPAR1 mRNA in normal endometrium and 
endometrial adenocarcinoma 
The expression of LPAR1 was examined in normal endometrium (n=29) and 
endometrial adenocarcinoma (n=29) by quantitative RT-PCR. LPAR1 mRNA 
expression was significantly lower in the mid secretory phase of the menstrual cycle 
as compared to the early secretory phase (p<0.01; Figure 6.1A). LPAR1 mRNA 
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expression did not significantly differ between different grades of endometrial 
adenocarcinoma (Figure 6.1B) and did not significantly differ between pooled 




Figure 6.1 Expression of LPAR1 mRNA in normal endometrium and endometrial 
adenocarcinoma. A: LPAR1 mRNA was examined by quantitative RT-PCR in endometrium 
from the proliferative (n=11), early secretory (n=7), mid secretory (n=6) and late secretory 
(n=5) phases of the menstrual cycle. Expression in the early secretory phase was 
significantly lower than the mid secretory phase. B: LPAR1 mRNA was examined by 
quantitative RT-PCR in well (n=9), moderately (n=10) and poorly (n=10) differentiated 
endometrial adenocarcinoma. No significant difference was demonstrated. C: LPAR1 mRNA 
expression was examined by quantitative RT-PCR in pooled normal endometrial and 
endometrial adenocarcinoma tissue. There was no significant difference between normal 
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endometrium and cancer. ** denotes p<0.01, data are expressed relative to a normal 
endometrium control and are presented as mean ± SEM. 
6.3.1.2 Expression of LPAR2 mRNA in normal endometrium and 
endometrial adenocarcinoma 
Expression of LPAR2 mRNA was also examined in normal endometrium (n=30) and 
endometrial adenocarcinoma (n=30) by quantitative RT-PCR. LPAR2 mRNA 
expression was significantly increased in the early secretory phase of the menstrual 
cycle (p<0.01; Figure 6.2A). No significant difference in LPAR2 mRNA expression 
was observed between different grades of endometrial cancer (Figure 6.2B), however 
mRNA expression was significantly higher by 10.9 ± 0.29 fold in pooled endometrial 
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Figure 6.2 Expression of LPAR2 mRNA in normal endometrium and endometrial 
adenocarcinoma. A: LPAR2 mRNA was examined by quantitative RT-PCR in endometrium 
from the proliferative (n=11), early secretory (n=7), mid secretory (n=6) and late secretory 
(n=6) phases of the menstrual cycle. Expression in the early secretory phase was 
significantly higher as compared to all other stages of the cycle. B: LPAR2 mRNA was 
examined by quantitative RT-PCR in well (n=10), moderately (n=10) and poorly (n=10) 
differentiated endometrial adenocarcinoma. No significant difference was demonstrated. C: 
LPAR2 mRNA expression was examined by quantitative RT-PCR and found to be 
significantly higher in pooled endometrial adenocarcinoma tissue as compared to pooled 
normal endometrial tissue. *** denotes p<0.001, data are expressed relative to a normal 
endometrium control and are presented as mean ± SEM. 
6.3.1.3 Expression of LPAR3 mRNA in normal endometrium and 
endometrial adenocarcinoma 
Expression of LPAR3 mRNA was also examined in normal endometrium (n=30) and 
endometrial adenocarcinoma (n=28) by quantitative RT-PCR. LPAR3 mRNA 
expression was significantly higher in the early secretory phase of the menstrual 
cycle (p<0.001; Figure 6.3A). No significant difference in LPAR3 mRNA expression 
was observed between different grades of endometrial cancer (Figure 6.3B). LPAR3 
mRNA expression was also significantly higher by 3.2 ± 2.1 fold in pooled 
endometrial adenocarcinoma as compared to pooled normal endometrium (p<0.05; 
Figure 6.3C). 
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Figure 6.3 Expression of LPAR3 mRNA in normal endometrium and endometrial 
adenocarcinoma. A: LPAR3 mRNA was examined by quantitative RT-PCR in endometrium 
from the proliferative (n=11), early secretory (n=7), mid secretory (n=6) and late secretory 
(n=6) phase of the menstrual cycle. Expression in the early secretory phase was significantly 
higher as compared to all other stages of the cycle. B: LPAR3 mRNA was examined by 
quantitative RT-PCR in well (n=10), moderately (n=10) and poorly (n=8) differentiated 
endometrial adenocarcinoma. No significant difference was demonstrated. C: LPAR3 mRNA 
expression was examined by quantitative RT-PCR and found to be significantly higher in 
pooled endometrial adenocarcinoma tissue as compared to pooled normal endometrial 
tissue. *denotes p<0.05, *** denotes p<0.001, data are expressed relative to a normal 
endometrium control and are presented as mean ± SEM. 
6.3.2 Localisation and expression of LPA receptors in normal 
endometrium and endometrial adenocarcinoma 
Expression of the LPA receptors 1, 2 and 3 was then examined by 
immunohistochemistry in normal endometrium and endometrial adenocarcinoma. 
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6.3.2.1 Localisation and expression of LPAR1 in normal endometrium 
and endometrial adenocarcinoma 
LPAR1 expression has been previously demonstrated by immunohistochemistry in 
epithelial, stromal and vascular endothelial cells in normal endometrial tissue (Chen 
et al. 2008). Expression has also been previously shown in bovine endometrium 
(Woclawek-Potocka et al. 2009). Normal endometrial tissue from all phases of the 
menstrual cycle (proliferative n=3, early secretory n =3, mid secretory n=3, late 
secretory n=4) was examined by immunohistochemistry for LPAR1 protein 
expression. At all stages of the cycle, LPAR1 expression was present in glandular 
epithelium, stroma and some vascular endothelial cells (GE, S, VE; Figure 6.4). In 
the proliferative phase, strong expression can be seen in glandular epithelium and 
vascular endothelial cells (Figure 6.4A). This expression in glandular epithelium and 
stroma can also be seen in the early, mid and late secretory phases (Figure 6.4 B, C, 
D). Negative controls included were incubated with non-immune IgG in place of 
primary antibody (Figure 6.4D, inset). 
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Figure 6.4 Localisation of LPAR1 protein in normal endometrium by 
immunohistochemistry. Representative images demonstrating that LPAR1 localises to the 
glandular epithelium, stroma and vascular endothelium in normal endometrium. A: LPAR1 
localises to the glandular epithelium (GE), stroma (S) and vascular endothelium (VE) in 
proliferative phase endometrium (left image is x200 magnification, right image is x400). B: In 
early secretory phase endometrium, LPAR1 immunoreactivity can be seen in the glandular 
epithelium, stroma and vascular endothelial cells (left image is x200 magnification, right 
image is x400). C: In mid secretory phase endometrium, LPAR1 can be localised to 
glandular epithelium and stroma (left image is x200 magnification, right image is x400). D: 
LPAR1 also localises to glandular epithelium in late secretory phase endometrium. Negative 
control (inset) is incubated with non-immune IgG in place of primary antibody.  All scale bars 
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Expression of LPAR1 was also examined in all grades of endometrial 
adenocarcinoma by immunohistochemistry (well differentiated n=4, moderately 
differentiated n=4, poorly differentiated n=4). LPAR1 was localised to epithelial 
cells (E), stroma (S) and vascular endothelial cells (VE) in all grades of cancer 
examined. Representative images are shown in Figure 6.5. Negative controls 




Figure 6.5 Localisation of LPAR1 protein in endometrial adenocarcinoma by 
immunohistochemistry. Representative images demonstrating that LPAR1 localises to the 
neoplastic epithelium (E), vascular endothelium (VE) and stroma (S) in A: Well differentiated 
carcinoma (left image is x200 magnification, right image is x400). Negative control (inset) is 
incubated with non-immune IgG in place of primary antibody. B: Moderately differentiated 
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carcinoma (left image is x200 magnification, right image is x400). All scale bars represent 
100 µm. 
6.3.2.2 Localisation and expression of LPAR2 in normal endometrium 
and endometrial adenocarcinoma 
The localisation of LPAR2 was then examined by immunohistochemistry in 
endometrial tissue. Endometrial tissue from all stages of the menstrual cycle was 
examined (proliferative n=3, early secretory n =3, mid secretory n=3, late secretory 
n=4).  In the proliferative phase of the cycle, LPAR2 expression was found to be 
weakly localised to glandular epithelial cells (GE) and strongly to cells throughout 
the stroma (S; Figure 6.6A). Immunoreactivity in the glandular epithelium was 
increased in the early and mid secretory phases, with decreased stromal expression 
(Figure 6.6 B, C). In the late secretory phase, epithelial and stromal expression was 
decreased (Figure 6.6C). Negative controls included were incubated with non-
immune IgG in place of primary antibody (inset; Figure 6.6A) 
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Figure 6.6 Localisation of LPAR2 protein in normal endometrium by 
immunohistochemistry. Representative images demonstrating that LPAR2 localises to the 
glandular epithelium and stroma in normal endometrium. A: LPAR2 localises weakly to the 
glandular epithelium (GE) and more strongly in the stroma (S) of proliferative phase 
endometrium (left image is x200 magnification, right image is x400). B: In early secretory 
phase endometrium, LPAR2 immunoreactivity can be seen in the glandular epithelium (left 
image is x200 magnification, right image is x400). C: In mid secretory phase endometrium, 
LPAR2 can be localised to glandular epithelium and stroma (left image is x200 magnification, 
right image is x400). D: LPAR2 localises weakly to glandular epithelium in late secretory 
phase endometrium. Negative control (inset) is incubated with non-immune IgG in place of 
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Expression of LPAR2 was also examined in all grades of endometrial 
adenocarcinoma by immunohistochemistry (well differentiated n=4, moderately 
differentiated n=4, poorly differentiated n=4). LPAR2 was localised weakly to 
epithelial cells (E) and stroma (S) in all grades of cancer examined. LPAR2 did not 
localise to vascular endothelial cells. Representative images are shown in Figure 6.8. 
Negative controls included were incubated with non-immune IgG in place of primary 
antibody (inset; Figure 6.7A) 
 
 
Figure 6.7 Localisation of LPAR2 protein in endometrial adenocarcinoma by 
immunohistochemistry. Representative images demonstrating that LPAR2 localises to the 
neoplastic epithelium (E) and stroma (S) in A: Well differentiated carcinoma (left image is 
x200 magnification, right image is x400). Negative control (inset) is incubated with non-
immune IgG in place of primary antibody. B: Moderately differentiated carcinoma (left image 
is x200 magnification, right image is x400). C: Poorly differentiated carcinoma (left image is 
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6.3.2.3 Localisation and expression of LPAR3 in normal endometrium 
and endometrial adenocarcinoma 
LPAR3 expression has been demonstrated in the luminal and glandular epithelium of 
the porcine endometrium (Seo et al. 2008). LPAR3 expression was localised by 
immunohistochemistry in endometrial tissue from all phases of the menstrual cycle 
(proliferative n=3, early secretory n =3, mid secretory n=3, late secretory n=4).  In 
the all phases of the cycle, LPAR3 expression was demonstrated in glandular 
epithelial cells (GE) and cells throughout the stroma (S; Figure 6.8). Strong 
immunoreactivity was seen in the glandular epithelium in the proliferative phase of 
the cycle (Figure 6.8A), and immunoreactivity in the stroma was increased in the mid 
secretory phase (Figure 6.8C). Expression was not seen in vascular endothelial cells 
at any stage of the menstrual cycle. Negative controls included were incubated with 
non-immune IgG in place of primary antibody (inset; Figure 6.8D) 
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Figure 6.8 Localisation of LPAR3 protein in normal endometrium by 
immunohistochemistry. Representative images demonstrating that LPAR3 localises to the 
glandular epithelium and stroma in normal endometrium. A: LPAR3 localises to the glandular 
epithelium (GE) and the stroma (S) of proliferative phase endometrium (left image is x200 
magnification, right image is x400). B: In early secretory phase endometrium, LPAR3 
immunoreactivity can be seen in the glandular epithelium and stroma (left image is x200 
magnification, right image is x400). C: In mid secretory phase endometrium, LPAR3 can be 
localised to glandular epithelium and expression is increased in the stroma (left image is 
x200 magnification, right image is x400). D: LPAR3 localises to glandular epithelium and 
stroma in late secretory phase endometrium. Negative control (inset) is incubated with non-
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Expression of LPAR3 was also examined in all grades of endometrial 
adenocarcinoma by immunohistochemistry (well differentiated n=4, moderately 
differentiated n=4, poorly differentiated n=4). LPAR3 was localised to epithelial 
cells (E), stroma (S) and vascular endothelial cells (VE) in all grades of cancer 
examined. In well differentiated cancer, LPAR3 expression was present in some but 
not all neoplastic epithelial cells, in cells throughout the stroma and in some 
endothelial cells (Figure 6.9A). A similar pattern of expression was demonstrated in 
moderately differentiated cancer and poorly differentiated cancer (Figure 6.9B,C). 
Negative controls included were incubated with non-immune IgG in place of primary 
antibody (inset; Figure 6.9A) 
 
 
Figure 6.9 Localisation of LPAR3 protein in endometrial adenocarcinoma by 
immunohistochemistry. Representative images demonstrating that LPAR3 localises to the 
neoplastic epithelium (E), vascular endothelium (VE) and stroma (S) in A: Well differentiated 
carcinoma (left image is x200 magnification, right image is x400). Negative control (inset) is 
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carcinoma (left image is x200 magnification, right image is x400). C: Poorly differentiated 
carcinoma (left image is x200 magnification, right image is x400). All scale bars represent 
100 µm. 
 
6.3.3 Expression of target genes mediated by LPA signalling in FPS 
cells 
Crosstalk between the LPA and prostaglandin signalling pathways has been 
previously demonstrated. The localisation of LPAR1-3 to the neoplastic epithelium 
in endometrial adenocarcinoma (Figures 6.5, 6.7 and 6.9) indicated that LPA 
signalling could interact with the FP receptor signalling pathway, as FP is also 
expressed on neoplastic epithelial cells. To examine this, the expression of FP, COX-
2 and target genes previously demonstrated to be regulated by the FP receptor in this 
thesis, CXCL1 and CCL20, were examined by RT-PCR. Gene expression was 
measured in FPS cells which were treated for 2-72 hours with vehicle or 10 µm LPA. 
After 8 hours of LPA treatment, FP receptor mRNA was significantly elevated 8.6 ± 
4.1 fold as compared to vehicle treated cells (p<0.05). FP receptor mRNA expression 
then decreased until 72 hours (Figure 6.10A). COX-2 mRNA expression was slightly 
but non-significantly increased after 2 hours of LPA treatment to 1.6 ± 0.3 fold over 
vehicle treated cells (Figure 6.10B). After 4 hours of LPA treatment, CXCL1 mRNA 
was significantly increased 6.3 ± 2.3 fold above vehicle treated cells (p<0.05; Figure 
6.10C). CCL20 mRNA expression was also significantly increased after 4 hours of 
LPA treatment to 9.2 ± 2.5 fold after 4 hours LPA treatment (p<0.05; Figure 6.10D). 
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Figure 6.10 Regulation of FP, COX-2, CXCL1 and CCL20 mRNA expression in FPS 
cells by LPA. A: FP mRNA expression in FPS cells was measured by quantitative RT-PCR 
after stimulation with vehicle or 10 µM LPA over a period of 2 to 72 hours, and was 
significantly increased at 8 hours. B: COX-2 mRNA expression in FPS cells was measured 
by quantitative RT-PCR after stimulation with vehicle or 10 µM LPA over a period of 2 to 72 
hours. C: CXCL1 mRNA expression in FPS cells was measured by quantitative RT-PCR 
after stimulation with vehicle or 10 µM LPA over a period of 2 to 72 hours, and was 
significantly increased at 4 hours. D: CCL20 mRNA expression in FPS cells was measured 
by quantitative RT-PCR after stimulation with vehicle or 10 µM LPA over a period of 2 to 72 
hours, and was significantly increased at 4 hours. All data are expressed as fold increase 
over vehicle treated control and are presented as mean ± SEM. * denotes p< 0.05. 
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6.3.4 Regulation of target genes by LPA is independent of PGF2α  
LPA signaling has been previously shown to upregulate COX-2 and prostaglandin 
expression (Jeong et al. 2008; Woclawek-Potocka et al. 2009; Woclawek-Potocka et 
al. 2009) and a small increase in COX-2 was shown after LPA treatment of FPS cells 
(Figure 6.10B). To confirm that the upregulation of target genes shown in Figure 
6.10 was mediated by LPA independently of PGF2α, PGF2α synthesis was measured 
by prostaglandin assay. After 2 hours LPA treatment, PGF2α synthesis was slightly 
but non-significantly increased (Figure 6.11A). FPS cells were also treated with 10 
µm LPA and the specific FP antagonist AL8810 for 4 hours. LPA treatment resulted 
in increases in FP, CXCL1 and CCL20 mRNA expression. Addition of the FP 
antagonist AL8810 made no significant difference to LPA induced FP, CXCL1 and 
CCL20 mRNA expression (Figure 6.11 B, C, D). 
 
 
Figure 6.11 Increased FP, CXCL1 and CCL20 mRNA expression is independent of 
PGF2α – FP signaling. A: PGF2α secretion into the media was measured by prostaglandin 
after treatment of FPS cells with 10 µm LPA for 2-72 hours. No significant increase over 
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vehicle treated cells was shown. B:  FP mRNA expression in FPS cells was measured by 
quantitative RT-PCR after treatment with vehicle control, 10 µM LPA or 10 µM LPA and 
AL8810 for 4 hours. No significant difference was demonstrated between treatments. C: 
CXCL1 mRNA expression in FPS cells was measured by quantitative RT-PCR after 
treatment with vehicle control, 10 µM LPA or 10 µM LPA and AL8810 for 4 hours. No 
significant difference was demonstrated between treatments D: CCL20 mRNA expression in 
FPS cells was measured by quantitative RT-PCR after treatment with vehicle control, 10 µM 
LPA or 10 µM LPA and AL8810 for 4 hours. No significant difference was demonstrated 
between treatments. All data are expressed as fold increase over vehicle treated control and 




Over-expression of the LPA receptors in cancer has been associated with increased 
cell proliferation, migration and neovascularisation (Murph et al. 2006). This chapter 
identified the temporal expression and localisation of LPAR1-3 in normal 
endometrium, and the increased expression of LPAR2 and 3 in endometrial 
adenocarcinoma. Crosstalk between the LPA and PGF2α signalling pathways was 
then identified in endometrial adenocarcinoma cells.  
 
LPAR1 expression varied little throughout the normal menstrual cycle however was 
significantly lower in the early secretory phase. It could be localised to the glandular 
epithelium and stromal cells, in agreement with a previous study describing LPAR1 
localisation in late secretory phase endometrium (Chen et al. 2008). LPAR1 
signalling has been proposed to play a role in angiogenesis in the normal 
endometrium, as endometrial stromal cells stimulated with LPA produced the 
angiogenic chemokine IL-8 via a LPAR1 and NFκB pathway (Chen et al. 2008). 
Increased expression of LPAR1 has also been described in the bovine endometrium 
during the estrous cycle, however in this animal model it is thought to contribute to 
PGF2α induced luteolysis (Woclawek-Potocka et al. 2009). Nonetheless knock-down 
of LPAR1 in a mouse model shows no adverse effects on reproduction (Ye et al. 
2005), and as its expression did not vary a large amount between stages of the 
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menstrual cycle, it is possible that it plays a largely redundant role in the normal 
endometrium. 
 
 As expression of LPAR1,2 and 3 has been documented in many different cancer 
types including breast and ovarian (Nakamoto et al. 2005; Chen et al. 2007; Yu et al. 
2008), the expression of these LPA receptors was examined in endometrial 
adenocarcinoma. No difference in LPAR1 expression was detected between normal 
endometrium and endometrial adenocarcinoma. In endometrial adenocarcinoma, 
LPAR1 expression could be localised to the neoplastic epithelial cells, in the stroma 
and to what appears to be endothelial cells. LPAR1 expression has been previously 
demonstrated on cultured vascular endothelial cells (Lee et al. 2000). In the stroma, 
the cell types expressing LPAR1 are unclear however expression of the receptor has 
been documented on a number of cell types which make up the stroma of 
endometrial adenocarcinoma including macrophages, neutrophils and lymphocytes 
(Zheng et al. 2000; Hornuss et al. 2001; Graler et al. 2002; Tou et al. 2005). LPAR1 
expression in other cancer types promotes a variety of effects contributing toward 
tumour progression. In gastrointestinal cancer, LPAR1 was shown to be the main 
LPA receptor involved in mediating LPA-induced cell migration via an ERK 1/2 
signalling pathway (Shin et al. 2009). In prostate cancer, LPAR1 over-expression 
resulted in increased cell proliferation in vitro and increased tumour growth in vivo. 
This occurred independently of ERK 1/2 signalling, demonstrating the complex 
downstream signalling of LPA receptors (Guo et al. 2006). In breast cancer cell lines, 
LPA treatment can also increase migration through LPAR1 (Chen et al. 2007).  
 
Expression of LPAR2 and LPAR3 in normal endometrium was significantly 
increased in the early secretory phase of the menstrual cycle, just before the window 
of implantation at the mid-secretory phase of the cycle. Immunohistochemical 
analysis of LPAR2 also reflected the mRNA data. The involvement of LPAR3 in 
implantation has been previously suggested as it is upregulated by progesterone and 
down-regulated by oestrogen in the mouse (Hama et al. 2006), and the deletion of 
LPAR3 in mice led to aberrant embryo implantation (Ye et al. 2005).  
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In endometrial adenocarcinoma, LPAR2 expression was predominantly expressed in 
the stroma, with weak localisation to the epithelial cells. LPAR2 mRNA has been 
previously found to be increased in endometrial cancer tissue (Yun et al. 2005), and 
in a moderately differentiated endometrial adenocarcinoma cell line (Hope et al. 
2009). This supports the finding in this chapter that LPAR2 mRNA is increased in 
moderately differentiated cancer as compared to well or poorly differentiated cancer, 
although this difference was not statistically significant. In the study by Hope et al 
(Hope et al. 2009), LPA signalling through LPAR2 significantly increased 
endometrial adenocarcinoma cell invasion, which was dependent on an up-regulation 
of matrix metalloprotease (MMP)-2 and MMP-7 expression (Hope et al. 2009). In 
other cancer types, LPAR2 has been shown to promote tumour progression through 
other mechanisms. In colon cancer for example, over-expression of LPAR2 
increased in ERK1/2 phosphorylation, leading to an up-regulation of the angiogenic 
chemokine IL-8 (Yun et al. 2005). 
 
Localisation of LPAR3 in endometrial adenocarcinoma followed a similar expression 
pattern to that of LPAR1 and 2, with strong expression seen in the neoplastic 
epithelial cells, stroma and endothelial cells. One of the cancer types studied 
extensively in relation to LPA signalling is ovarian cancer, due to the high 
concentration of LPA found in the ascites of ovarian cancer patients (Shen et al. 
1998). LPAR2 and LPAR3 both display increased expression in ovarian cancer 
(Nakamoto et al. 2005; Jeong et al. 2008). LPA treatment increased ovarian cancer 
cell line migration and invasion, an effect that could be abolished with siRNA 
against LPAR2 (Jeong et al. 2008). LPA signalling also promotes VEGF expression 
in ovarian cancer cells (Hu et al. 2001). The knockdown of LPAR2 or LPAR3 in 
ovarian cancer cells has also been reported to decrease LPA-induced expression of 
angiogenic factors including VEGF, and over-expression of these same two receptors 
increased invasiveness of ovarian cancer xenografts in mice (Yu et al. 2008). 
Interestingly, a link between LPA signalling and CXCL1 expression has been 
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previously described in this cancer type, as LPA signalling via LPAR2 increased 
CXCL1 expression in ovarian cancer cell lines (Lee et al. 2006).  
 
Collectively, LPAR1-3 mediate effects in cancer ranging from promotion of cell 
proliferation and migration to production of angiogenic factors. However the LPA 
receptors which are over-expressed and mediate LPA signalling differ dependent on 
the cancer type. A significant increase in LPAR2 and 3 mRNA expression was seen 
in endometrial adenocarcinoma. Therefore these receptors may play a role in LPA 
signalling in this cancer type. Enzymes in the LPA-producing pathway, including 
ATX, are elevated in the ascites of patients with endometrial cancer (Tokumura et al. 
2007), and have been shown to promote tumour progression in other models of 
cancer (Nam et al. 2001). Therefore this indicates that the availability of LPA in 
endometrial adenocarcinoma may lead to increased signalling, and the up-regulation 
of genes targeted by LPA. 
 
In our Ishikawa endometrial adenocarcinoma cell line model (FPS cells), LPA 
treatment upregulated FP receptor mRNA expression. LPA signalling has been 
previously demonstrated to promote COX-2 upregulation and prostaglandin 
synthesis (Ye et al. 2005; Jeong et al. 2008; Liszewska et al. 2009; Woclawek-
Potocka et al. 2009; Woclawek-Potocka et al. 2009). However a direct effect of LPA 
signalling on prostaglandin receptor expression has not previously been described. It 
remains to be determined if an up-regulation in FP receptor protein is seen in this cell 
type after LPA treatment. In addition, treatment with LPA resulted in a significant 
increase in CXCL1 and CCL20 expression. However, no significant increase in 
COX-2 or PGF2α synthesis was observed in response to LPA treatment. This 
suggests that in our cell line model LPA induction of FP receptor, CXCL1 and 
CCL20 expression was independent of PGF2α secretion or FP receptor activation. 
Indeed, cells treated with LPA and the FP antagonist AL8810 did not alter LPA 
mediated gene expression.  
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Therefore, in a physiological or pathological setting in vivo, LPA may increase 
expression of the FP receptor which can be activated by endogenous enhanced 
synthesis of PGF2α. Concomitant co-activation of the LPA and FP receptors (by LPA 
and PGF2α respectively) may enhance the expression of common chemokines such as 
CXCL1 and CCL20. LPAR1-3 activation leading to increased cytokine expression 
has been previously described for the chemokines IL-6, IL-8 and CXCL1 (Lee et al. 
2006; Chen et al. 2008). This would thereby lead to an exacerbated inflammatory 
phenotype. A schematic representation of this is shown in Figure 6.12, with 
pathways regulated by PGF2α displayed in blue and those regulated by LPA 










regulation of FP 
receptor
 
Figure 6.12 Schematic representation of possible PGF2α and LPA signalling 
interactions in endometrial adenocarcinoma. PGF2α signalling (shown in blue) activates 
the FP receptor to up-regulate expression of the chemokines CXCL1 and CCL20. LPA 
signalling (shown in green) activates the LPA receptors to also up-regulate expression of the 
chemokines CXCL1 and CCL20. LPA signalling additionally up-regulates expression of the 
FP receptor, further promoting inflammatory pathways in endometrial adenocarcinoma.  
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Data presented in this chapter have described a novel pathway mediated by LPA 
which may amplify PGF2α-FP receptor signalling in endometrial adenocarcinoma. 
LPAR1-3 are expressed in endometrial adenocarcinoma and both LPAR2 and 3 are 
upregulated as compared to normal endometrium. LPA may therefore stimulate 
tumour progression in endometrial adenocarcinoma by two mechanisms; firstly by an 
increase in FP mRNA expression which may increase FP signalling, and secondly by 
acting directly to up-regulate expression of the chemokines CXCL1 and CCL20, 
which have been previously discussed in this thesis. As both FP and LPA signalling 
pathways can converge on these chemokines, future studies are required to determine 
if a synergistic effect of these two lipid mediators can promote progression of 
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7 General Discussion 
Elevated expression of the prostaglandin-forming enzyme COX-2 has been 
demonstrated in several epithelial cell cancer types including breast, stomach, 
bladder and lung (Cha et al. 2007). It is also elevated in endometrial adenocarcinoma 
(Tong et al. 2000), as is expression of the FP receptor (Sales et al. 2004). A role for 
the FP receptor and prostaglandins in the progression of endometrial adenocarcinoma 
has been hypothesised, as PGF2α–FP receptor signalling up-regulates expression of 
angiogenic genes (Sales et al. 2005; Sales et al. 2007). It also promotes cell migration 
and proliferation (Milne et al. 2003; Sales et al. 2008). The work described in this 
thesis investigated the contribution of the FP receptor to inflammatory pathways in 
endometrial adenocarcinoma.  
 
Data from epidemiological studies propose that chronic inflammation pre-disposes to 
cancer development. For example inflammatory bowel disease has been associated 
with an increased risk of developing colorectal cancer (Flossmann et al. 2007), and 
persistent inflammation of the prostate has been associated with an increased risk of 
prostate cancer (Sandhu 2008). Chronic inflammation can therefore drive tumour 
initiation, and inflammation also promotes tumour progression through the up-
regulation of chemokines and the presence of leukocytes (Mantovani et al. 2008). 
Inflammatory conditions also lead to tissue remodelling within the tumour 
microenvironment. For instance a number of chemokines have angiogenic properties 
(Strieter et al. 2006), and leukocytes have been demonstrated to produce proteases 
which can increase cancer cell invasion and metastasis (Ardi et al. 2007; Yang et al. 
2007). 
 
Many of the risk factors for development of endometrial adenocarcinoma promote 
prolonged exposure of the endometrium to oestrogen, which is an established cause 
of endometrial adenocarcinoma (Modugno et al. 2005). However these risk factors 
are also known to be linked to inflammatory pathways. For example, obesity is one 
of the major risk factors for endometrial adenocarcinoma (Reeves et al. 2007), and 
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may increase likelihood of cancer development due to high rates of oestrogen 
formation in excess adipose tissue (Akhmedkhanov et al. 2001). Excess adipose 
tissue also leads to increased levels of pro-inflammatory cytokines such as IL-6 and 
TNFα (Bastard et al. 2000). These pro-inflammatory cytokines have been shown to 
activate signalling pathways mediating angiogenesis and invasion in endometrial 
adenocarcinoma (Seo et al. 2004; Choi et al. 2009), and elevated levels of these 
cytokines have been associated with a poor prognosis (Bellone et al. 2005). 
Therefore inflammatory signalling pathways may be acting in conjunction with 
oestrogen exposure to increase risk of endometrial adenocarcinoma. Non-steroidal 
anti-inflammatory drug (NSAID) intake in patients at risk of developing cancers 
significantly reduces cancer occurrence (Dannenberg et al. 2003). These drugs 
inhibit the cyclo-oxygenase (COX) enzymes, preventing prostaglandin synthesis and 
signalling. The role of the receptor for PGF2α, FP, in cancer has not previously been 
extensively studied. 
  
 In this chapter, the main findings of this thesis are summarised. Future research 
directions that could further investigate the mechanisms by which the PGF2α and 
LPA signalling pathways contribute to inflammation in endometrial adenocarcinoma 
are also considered. 
7.1 PGF2α regulates CXCL1 expression in endometrial 
adenocarcinoma 
A cytokine antibody array was used initially in this thesis to investigate cytokines up-
regulated by the PGF2α-FP receptor signalling pathway. The chemokine CXCL1 
displayed increased expression in an endometrial adenocarcinoma cell line model 
after PGF2α treatment, and this signalling pathway was confirmed in endometrial 
adenocarcinoma tissue explants. CXCL1 expression was also found to be elevated in 
endometrial adenocarcinoma as compared to normal endometrium. 
 
The elevation of CXCL1 expression in cancer as compared to normal tissue has also 
been demonstrated in melanoma, colorectal and prostate cancer (Haghnegahdar et al. 
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2000; Wang et al. 2006; Wen et al. 2006; Kawanishi et al. 2008; Rubie et al. 2008). 
CXCL1 expression was regulated via an ERK dependent signalling pathway. This is 
similar to a study of colorectal cancer demonstrating CXCL1 expression mediated by 
the prostaglandin PGE2 and ERK activation (Wang et al. 2006). Inhibition of 
components of the ERK signalling pathway is effective in reducing cancer growth in 
in vivo models of cancer (Iverson et al. 2009). Indeed, a specific inhibitor of MEK, 
the protein directly upstream of ERK, has entered clinical trials in late-stage cancer 
patients (Iverson et al. 2009). In endometrial adenocarcinoma, the receptor for 
CXCL1, CXCR2, was localised to neoplastic epithelial cells. Therefore autocrine 
signalling is possible. In colorectal cancer and melanoma, autocrine CXCL1-CXCR2 
signalling increases cell proliferation and migration (Li et al. 2004; Singh et al. 
2009). Thus investigating this further in endometrial adenocarcinoma could 
determine if this is one mechanism by which CXCL1 promotes tumour progression. 
7.1.1 Impact of CXCL1 expression in endometrial adenocarcinoma on 
angiogenesis 
The up-regulation of chemokines in cancer is believed to drive leukocyte influx and 
tissue remodelling. In other cancer types, CXCL1 has been shown to promote tissue 
remodelling by increasing angiogenesis. This is achieved by signalling directly to its 
receptor, CXCR2, which is expressed on endothelial cells. CXCL1 induced 
angiogenesis and increased tumour growth in mouse models of melanoma (Moore et 
al. 1999), lung cancer (Keane et al. 2004) and prostate cancer (Singh et al. 2009). In 
our study, CXCR2 expression was localised to endothelial cells in endometrial 
cancer. Therefore the effects of FP-mediated CXCL1 expression on angiogenesis 
were examined in this thesis by the measurement of microvascular density (MVD) in 
xenografts arising from the inoculation of nude mice with FPS cells. These were 
compared to xenografts arising from WT cells, or xenografts arising from FPS cells 
in mice treated with CXCL1 antibody. No significant difference in MVD was shown 
between the three groups. 
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Measurement of MVD in tumours is frequently used to investigate angiogenesis.  In 
numerous immunohistochemical studies of tumours, an increase in MVD has been 
associated with increased severity of disease (Weidner et al. 1993; Weidner 1995; 
Mentzel et al. 2001). However, evidence has shown that measuring MVD to establish 
the angiogenic capability of one tumour-derived factor is not effective (Hlatky et al. 
2002). This may be because tumour angiogenesis is the net product of the balance of 
pro and anti-angiogenic factors. For example, although VEGF and FGF are known to 
be key factors contributing to tumour angiogenesis, many studies have not found an 
association between expression levels of these proteins and MVD (Terris et al. 1998; 
Smith et al. 1999). A recent study found no association between VEGF expression 
and MVD in endometrial adenocarcinoma (Erdem et al. 2007). The vasculature 
present in tumours develops rapidly and is therefore frequently abnormal in structure, 
and can be ineffective in oxygen transportation and lead to hypoxia (Stefansson et al. 
2006). Therefore MVD may not always be an accurate measure of rates and efficacy 
of tumour angiogenesis. In endometrial adenocarcinoma, measurement of vascular 
proliferation was in fact shown to be more indicative of aggressiveness of tumour 
and adverse prognosis than assessment of MVD (Stefansson et al. 2006).  
 
In the xenograft study described in Chapter 4 of this thesis, the structure of vessels 
was altered between FPS, WT and CXCL1-neutralised groups (R Catalano, personal 
communication). Any alterations in vessel structure and integrity were not analysed 
within this thesis. Therefore future research should examine the impact of FP 
receptor expression on changes to the structure of blood vessels, which may be 
indicative of an alteration in angiogenesis. This could be examined by analysing the 
density of surrounding perivascular cells. A loose arrangement of perivascular cells 
is associated with rapid angiogenesis, and has also been described as indicative of 
integrity and maturity of vessels (Bergers et al. 2003). Vascular endothelial cell 
proliferation could also be measured as this has previously been correlated with both 
increased levels of angiogenic factors and a poor prognosis in endometrial 
adenocarcinoma (Hlatky et al. 2002; Stefansson et al. 2006). These studies would 
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assist in elucidation of the angiogenic activities of PGF2α induced CXCL1 in 
endometrial adenocarcinoma.   
7.1.2 Impact of CXCL1 and cytokine expression in endometrial 
adenocarcinoma on immune cell infiltration 
CXCL1 is a potent neutrophil chemoattractant (Moser et al. 1990). Studies presented 
in Chapter 4 of this thesis demonstrated that CXCL1 expression mediated by PGF2α-
FP receptor signalling increased neutrophil chemotaxis and infiltration into 
endometrial cancer xenografts. Neutrophils were also increased in human 
endometrial adenocarcinoma tissue as compared to normal endometrium. In cancer, 
the up-regulation of chemokine expression by neoplastic cells is proposed to 
chemoattract cells of the innate immune system (de Visser et al. 2006). These cells 
have been demonstrated to contribute to tumour progression. Neutrophils promote 
cancer growth by producing angiogenic factors such as VEGF and C-X-C 
chemokines (Scapini et al. 2004; Ai et al. 2007). They also secrete proteases which 
may aid tissue remodelling and metastasis (Ardi et al. 2007). Despite an increase of 
neutrophil infiltration into tumour xenografts mediated by FP receptor signalling, no 
significant difference in tumour size was observed between the different xenograft 
groups. Furthermore, in human endometrial adenocarcinoma tissue, increased 
neutrophil numbers did not correlate with grade of cancer. Thus, although the role of 
the FP receptor in mediating neutrophil infiltration has been demonstrated, it is 
impossible to tell from data presented within this thesis if neutrophils are performing 
pro or anti-tumourigenic functions in endometrial adenocarcinoma.  
 
Therefore, future research could be directed into understanding the role of 
neutrophils in endometrial adenocarcinoma. Neutrophils have been demonstrated to 
promote angiogenesis in normal tissues and pathologies, and the production of 
VEGF by neutrophils has been described in the normal endometrium (Gargett et al. 
2001). Increased neutrophil numbers have been correlated with increased vasculature 
and grade of tumour in myxofibrosarcoma (Mentzel et al. 2001), and a number of 
experimental in vitro models have also demonstrated the angiogenic capability of 
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neutrophils. For example, pro-inflammatory cytokines often elevated in cancers such 
as TNF-α and IL-6 induce VEGF release from neutrophils (McCourt et al. 1999). A 
more complex interaction has been described in breast cancer. Cytokines secreted by 
breast cancer cells have been demonstrated to induce production of the cytokine 
oncostatin M from neutrophils, which reciprocally induces VEGF expression by the 
neoplastic epithelial cells (Queen et al. 2005). Furthermore, the production of MMP-
9 by neutrophils is well described (Coussens et al. 2000; Ardi et al. 2007) and in the 
chick angiogenesis assay this MMP-9 was demonstrated to be crucial in the 
induction of angiogenesis (Ardi et al. 2007). 
 
 As discussed above, no difference in MVD was observed in our xenograft 
endometrial adenocarcinoma model, indicating that in this model neutrophils may 
not be contributing to angiogenesis. However, future research into the angiogenic 
properties of neutrophils in endometrial adenocarcinoma is warranted due to the 
body of evidence demonstrating neutrophil mediated angiogenesis in other cancer 
types. In the normal endometrium, an immunohistochemical study has correlated 
neutrophils expressing VEGF to areas of proliferating endothelial cells (Gargett et al. 
2001). Similar assessments of the physical relationship between neutrophils, VEGF 
expression and the vasculature in endometrial adenocarcinoma could indicate the 
contribution of neutrophils to angiogenesis. Subsequently, the functions of 
neutrophils in endometrial adenocarcinoma should be examined in vitro. To 
investigate this, flow cytometry could be used to isolate these cells from human 
endometrial tissue and analysis of gene and protein expression could then indicate if 
factors produced by neutrophils are pro or anti-angiogenic. It is also possible that 
interactions between the neoplastic epithelial cells and neutrophils could 
synergistically promote tumour growth, as has been demonstrated by interactions 
between macrophages and lung carcinoma cells (Kimura et al. 2007) and between 
neutrophils and breast cancer cells discussed previously (Queen et al. 2005). To 
investigate this, co-cultures of neutrophils with our endometrial adenocarcinoma cell 
line model could be used. 
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Neutrophils also influence tumour progression through the promotion of invasion 
and metastases. This has been demonstrated in in vivo models of cancer. The 
depletion of neutrophils in a mouse model of fibrosarcoma prevented metastasis of 
cells from the primary tumour, suggesting a role for neutrophils in the switch to a 
metastatic phenotype (Tazawa et al. 2003). Equally, an increase in invasion of breast 
cancer xenografts was associated with an increased infiltration of neutrophils 
mediated by IL-8 over-expression. Invasion was increased due to elevated protease 
production by neutrophils (Yao et al. 2007). Therefore, future research into the role 
of neutrophils in endometrial adenocarcinoma could also be directed toward their 
role in cancer cell migration. To investigate this, it would be valuable to use an 
alternative xenograft mouse model of endometrial adenocarcinoma in which 
metastases can be measured (Vollmer 2003). The metastatic ability of endometrial 
adenocarcinoma cells could then be investigated with the depletion of neutrophils 
from the mouse, for example, as described in the paper by Kaitu'u-Lino et al (2007). 
 
Several other cytokines were shown to be upregulated by the PGF2α-FP signalling 
pathway in the antibody array used in Chapter 1 of this thesis, including the 
chemokine IL-8. IL8 is an ELR+ C-X-C chemokine which acts as a potent neutrophil 
chemoattractant by binding to CXCR2 and the structurally related CXCR1. 
Therefore IL-8 may play a similar role in endometrial adenocarcinoma to that 
described in this thesis for CXCL1. In the normal endometrium, IL-8 is thought to 
recruit neutrophils during the menstrual cycle (Critchley et al. 1994). It has also been 
demonstrated to promote angiogenesis in breast cancer (Yao et al. 2007). Dependent 
on the cancer type, the relative role that different C-X-C chemokines play in tumour 
development differs (Moore et al. 1999). Therefore it would be interesting to 
determine if IL-8 is produced by a similar signalling mechanism to that of CXCL1 in 
endometrial cancer cells. As neutralisation of CXCL1 in FPS xenografts did not 
bring neutrophil infiltration down to the basal levels seen in the WT xenografts, it 
may be that this extra neutrophil infiltration was dependent on IL-8. Hence, studies 
with neutralisation of both CXCL1 and IL-8 may be informative about the 
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contribution of these two chemokines to the inflammatory environment in 
endometrial adenocarcinoma. 
 
Additional cytokines which were elevated after activation of the FP receptor in our 
endometrial adenocarcinoma cell line model were IL-6, IL-7, CXCL2, CXCL3 and 
leptin. These cytokines are also likely to play a role in inflammation in endometrial 
adenocarcinoma. For example, the receptor for IL-6 is expressed on macrophages 
and T cells. Activation of this receptor can cause cytokine secretion by these cells, 
which may be pro or anti-tumorigenic. IL-6 signalling can also promote apoptosis of 
cancer cells (Rose-John et al. 2007); however elevated expression has been linked 
with increased aggressiveness of endometrial adenocarcinoma (Bellone et al. 2005). 
Leptin has been shown to regulate expression of angiogenic factors including VEGF 
in endometrial adenocarcinoma cell lines, indicating it may contribute to tissue 
remodelling of the microenvironment (Carino et al. 2008). Therefore, the regulation 
of these cytokines by the PGF2α-FP signalling pathway warrants further 
investigation, to determine if all cytokines regulated by this pathway contribute to 
tumour progression. 
 
Furthermore, a result of this cytokine secretion may be increased immune cell influx, 
as de Visser et al (2006) described the influx of innate immune cells into a tumour to 
be driven by cytokine secretion. Immune cell infiltration into endometrial 
adenocarcinoma was examined in this thesis. In addition to neutrophils, significantly 
elevated numbers of macrophages and dendritic cells were observed. These innate 
immune cells have all been demonstrated to promote angiogenesis in different cancer 
types (Scapini et al. 2004; Lin et al. 2007; Fainaru et al. 2008), and therefore may be 
promoting tumour growth in endometrial adenocarcinoma. 
  
 NK cells were observed at significantly lower numbers in endometrial 
adenocarcinoma as compared to normal endometrium. These cells can secrete 
cytokines which lyse tumour cells (Zamai et al. 2007), therefore the low infiltration 
observed in endometrial adenocarcinoma may imply low levels of leukocyte-
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mediated tumour cell death.  No significant difference was observed in influx of 
CD4+ T cells, CD8+ T cells or B cells between normal and cancerous endometrial 
tissue. T cells have been frequently reported to be cytotoxic to tumour cells, as a high 
T cell infiltration has been associated with a good prognosis (Kondratiev et al. 2004). 
This is because T cells are able to recognise antigens present on cancer cells in order 
to destroy them (Nishimura et al. 1999). The role of B cells in cancer is unclear, as 
they have been demonstrated to lead to tumour cell destruction (de Visser et al. 2006) 
but also tumour promotion by the chemoattraction of innate immune cells such as 
macrophages and neutrophils (de Visser et al. 2005). The comparable levels of these 
cells in endometrial adenocarcinoma to normal endometrium suggest an ineffective 
cytotoxic immune response in endometrial adenocarcinoma. This would enable 
tumour growth. However, in this thesis these cells have been compared in 
endometrial cancer to endometrial tissue of a normal cycling uterus. Most patients 
with endometrial adenocarcinoma are post-menopausal. It would therefore be 
worthwhile examining immune cell numbers by flow cytometry in endometrial tissue 
adjacent to the tumour in the same patient, to determine more accurately the levels of 
immune cells in normal and cancerous tissue. In this situation, after isolation these 
immune cells could be cultured in vitro to investigate cell function, to determine pro 
or anti-tumourigenic functions. Leukocytes can make up to 50% of the tumour 
microenvironment (Colotta et al. 2009). Therefore determining their function in 
endometrial adenocarcinoma would be valuable to investigate downstream 
consequences of inhibiting inflammatory cytokine pathways mediated by FP. 
7.2 PGF2α regulates CCL20 expression in endometrial 
adenocarcinoma 
The roles of chemokines in cancer beyond their ability to chemoattract immune cells 
has been expanded with evidence that they promote tissue remodelling by 
influencing cell proliferation and migration (Slettenaar et al. 2006). In this thesis, the 
regulation of expression of the chemokine CCL20 by PGF2α–FP receptor signalling 
was described in an endometrial adenocarcinoma cell line and confirmed in 
endometrial adenocarcinoma explants. The elevated expression of CCL20 and its 
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receptor CCR6 in endometrial adenocarcinoma as compared to normal endometrium 
was described, and activation of the CCR6 receptor on endometrial epithelial cells 
was found to promote cell proliferation. 
 
CCL20 signalling plays an important role in the chemoattraction of immature 
dendritic cells to sites of inflammation (Schutyser et al. 2003). However, as CCR6 
expression was not demonstrated on dendritic cells in endometrial adenocarcinoma 
the chemoattraction of dendritic cells by CCL20 may not be impacting on tumour 
growth. Like many other chemokines, the expression of CCL20 and CCR6 has also 
been described in several different types of cancer. CCL20 is over-expressed in 
cancers of the colon (Brand et al. 2006) liver (Rubie et al. 2006), pancreas (Campbell 
et al. 2005), prostate (Ghadjar et al. 2008) and Hodgkins lymphoma (Baumforth et al. 
2008). CCR6 is also upregulated in colon (Brand et al. 2006), liver (Dellacasagrande 
et al. 2003) and prostate cancer (Ghadjar et al. 2008). In these cancer types, CCL20 
expression promotes both cell migration (Dellacasagrande et al. 2003; Campbell et 
al. 2005; Rubie et al. 2006) and proliferation (Brand et al. 2006; Beider et al. 2009). 
CCL20 caused a significant increase in proliferation of endometrial adenocarcinoma 
cells. This is similar to published literature describing autocrine CCL20-CCR6 
signalling of colorectal and prostate cancer cell lines which promoted cell 
proliferation (Brand et al. 2006; Beider et al. 2009). Cell migration was not affected 
in endometrial adenocarcinoma cells by CCR6 activation.  
 
These data demonstrate the pleiotropic nature of chemokines in tumour progression, 
as CXCL1 increased immune cell infiltration while CCL20 is able to signal directly 
to neoplastic epithelial cells to promote proliferation. The regulation of CCL20 by 
PGF2α was also mediated through an ERK dependent signalling pathway, similarly to 
CXCL1. Therefore, the effects of inhibiting FP activation may impact on many 
facets of inflammation. In addition to an inhibition of chemokine expression and 
leukocyte infiltration, a decrease in tissue remodelling mediated by angiogenesis and 
cell proliferation may be observed with decreased PGF2α-FP signalling. 
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7.3 The role of LPA signalling in endometrial adenocarcinoma 
Data presented in this thesis describes the signalling pathways activated by PGF2α-FP 
receptor interactions, and their downstream consequences in endometrial 
adenocarcinoma. In a physiological setting, activation of other signalling cascades 
will influence the overall signalling outcome in a cell. LPA is a membrane derived 
lipid mediator, which has been proposed to play an important role in implantation in 
the normal endometrium (Ye et al. 2005). It has also been demonstrated to contribute 
to tumour progression in numerous cancers including breast (Kitayama et al. 2004), 
colon (Yun et al. 2005) and ovarian (Yu et al. 2008). In Chapter six, it was 
demonstrated that the receptors for LPA, LPAR1, 2 and 3, are expressed at all stages 
of the menstrual cycle in the endometrium. The expression of LPAR2 and LPAR3 
was elevated in endometrial adenocarcinoma as compared to normal endometrium. 
LPA signalling increased expression of the chemokines CXCL1 and CCL20 in 
endometrial adenocarcinoma cells. An elevation of FP receptor mRNA expression 
was also mediated by LPA signalling, independently of PGF2α signalling. These data 
demonstrate a convergence of the PGF2α and LPA signalling pathways. 
 
LPA signalling contributes to cancer progression. Activation of the LPA receptors 
promotes cell proliferation in ovarian, prostate and breast cancer (Shida et al. 2005; 
Guo et al. 2006; Yu et al. 2008), and migration in gastrointestinal and ovarian cancer 
(Jeong et al. 2008; Shin et al. 2009). In addition to tissue remodelling of the tumour 
microenvironment, a number of factors regulated by LPA signalling are 
inflammatory. For example, LPA signalling promotes the release of chemokines 
including IL-8 (Chen et al. 2008) and CXCL1 in ovarian cancer (Lee et al. 2006). 
LPA signalling also interacts with the COX inflammatory pathway by elevating 
prostaglandin and COX-2 synthesis (Liszewska et al. 2009; Woclawek-Potocka et al. 
2009; Woclawek-Potocka et al. 2009).  
 
The preliminary study of LPA signalling in endometrial adenocarcinoma presented 
in this thesis therefore brings up numerous questions. Firstly, the receptor type 
mediating LPA signalling in endometrial adenocarcinoma cells is unclear. LPAR3 
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signalling is important in reproduction (Ye et al. 2005), however mRNA and protein 
expression of all three receptors was found in endometrial adenocarcinoma. 
Expression of both LPAR2 and 3 was significantly increased in endometrial 
adenocarcinoma as compared to normal tissue, indicating that these receptors may be 
involved in mediating signalling pathways activated by LPA. The receptor which 
mediates the effects of LPA may determine the functional outcome. For example 
LPAR3 does not couple to the G-protein G12/13, which mediates movement of cells 
through activation of the protein Rho. Thus LPA mediated promotion of migration is 
achieved through activation of LPAR1 or 2 (Ishii et al. 2000). Invasion of 
endometrial cancer cells was previously shown to be increased by LPAR2 activation 
(Hope et al. 2009); therefore it is likely this receptor plays an important role in 
mediating the effects of LPA signalling in endometrial cancer. Future research into 
the role of LPA in endometrial adenocarcinoma should examine the importance of 
each of the LPA receptors in LPA signalling. To achieve this, silencing of each 
receptor independently would need to be achieved. Some LPAR antagonists exist, 
including pan-LPAR antagonists (Jan et al. 2003; Ohta et al. 2003) and some newly 
discovered antagonists selective for LPAR2 and LPAR3 (Fischer et al. 2001; Beck et 
al. 2008; Fells et al. 2008).  
 
The outcome of LPA signalling is mediated by diverse signalling pathways 
downstream of receptor activation. For example, NFκB activation was essential for 
LPA-mediated IL-8 production in endometrial stromal cells (Chen et al. 2008), and 
in ovarian cancer cells ERK signalling was essential for LPA-driven COX-2 
production and cell migration (Jeong et al. 2008). In this thesis, LPA signalling was 
demonstrated to up-regulate expression of the chemokines CXCL1 and CCL20. 
Further research could therefore determine if the regulation of these chemokines 
converges on the same signalling pathways as those mediated by the FP receptor. 
This could be achieved by use of chemical inhibitors to identify other components of 
the signalling pathway. If LPA and PGF2α signal via the same pathway in 
endometrial adenocarcinoma cells, it would be valuable to determine if PGF2α and 
LPA signalling display an additive effect on chemokine production. Inhibition of 
Chapter 7                                                                                        General Discussion 
232 
both of these pathways may be required to significantly decrease inflammation in 
endometrial adenocarcinoma. 
 
Furthermore, the downstream consequences of LPA signalling in endometrial 
adenocarcinoma should be investigated. As discussed in Chapter 6, LPA signalling 
inreases cell proliferation and migration in many cancer types. In addition to in vitro 
studies on endometrial adenocarcinoma cell lines, the nude mouse xenograft model 
used in this thesis could be employed to examine tumour growth regulated by LPA 
signalling. By xenografting cells with depleted LPA receptors the downstream 
consequences of signalling through each receptor may be ascertained. Interactions 
with the FP receptor signalling pathway could be further investigated by 
simultaneously silencing FP receptor expression. Finally, immunohistochemistry 
identified expression of LPAR on stromal cells which may be leukocytes. Previous 
evidence suggests that LPA signalling to its receptor on leukocytes causes release of 
inflammatory mediators rather than the chemoattraction of leukocytes (Zheng et al. 
2000; Hornuss et al. 2001; Tou et al. 2005). Therefore this could be another 
mechanism by which LPA promotes inflammation in endometrial cancer, and 
warrants further investigation. 
7.4 Conclusions: The FP receptor and inflammation in endometrial 
adenocarcinoma 
Evidence presented in this thesis suggests that signalling via the FP receptor in 
endometrial adenocarcinoma promotes inflammation by the increase of chemokine 
expression, the infiltration of immune cells, and tissue remodelling in the form of cell 
proliferation. The up-regulation of FP receptor mRNA expression mediated by LPA 
and the effects of LPA signalling on chemokine expression serve to demonstrate that 
other factors may amplify these signalling pathways in endometrial adenocarcinoma, 
further contributing to an inflammatory environment. 
 
As described in Chapter 1, inflammation in cancer is proposed to function by two 
pathways (Colotta et al. 2009). In the extrinsic pathway, local inflammation 
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promotes malignant transformation of the tissue (Flossmann et al. 2007; Sandhu 
2008). In the intrinsic pathway, genetic changes give rise to cancerous cells which 
leads to the up-regulation of inflammatory pathways promoting tumour progression 
and growth. In the endometrium, the insertion of contraceptive intra-uterine devices 
promotes a local environment of inflammation, with an infiltration of leukocytes and 
increase in prostaglandin expression (Srivastava et al. 1989). However, users of this 
contraceptive method do not display a higher incidence of endometrial 
adenocarcinoma (Beining et al. 2008). Additionally, prospective studies have now 
been carried out examining the effects of NSAID use on development of endometrial 
adenocarcinoma. In general, these have shown that use of NSAIDs does not 
significantly influence risk of developing endometrial adenocarcinoma (Viswanathan 
et al. 2008; Danforth et al. 2009) except in some small subgroups of very obese 
women (Viswanathan et al. 2008; Fortuny et al. 2009). A retrospective study also 
displayed these results (Moysich et al. 2005).  
 
These epidemiological data suggest that in endometrial cancer, it may generally be 
the intrinsic pathway which is important in initiation of tumour development. This 
implies that cancer development is initiated by genetic mutations, possibly in stem 
cells (Rutella et al. 2009), causing uncontrolled proliferation and subsequently 
cellular changes such as elevated FP receptor expression. These genetic changes may 
be a result of increased proliferation driven by an increased oestrogen to 
progesterone ratio in endometrial adenocarcinoma (Jazaeri et al. 2001). In further 
support of the intrinsic pathway, a number of genetic mutations such as those of 
PTEN and K-Ras have been associated with the development of endometrial 
adenocarcinoma (Enomoto et al. 1990; Tashiro et al. 1997). The deletion of PTEN in 
the endometrium of a mouse model rapidly leads to endometrial adenocarcinoma 
development. In the initial stages of hyperplasia and tumour development in this 
model, COX-2 was highly upregulated, implicating this pathway in enhancing 
tumour growth (Daikoku et al. 2008). Therefore cancer will develop by mutation, 
and the COX-2 signalling pathway, and those described in this thesis driven by the 
FP receptor will enhance and promote inflammation. This further facilitates cancer 
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growth and the acquisition of more hallmarks of cancer by the cells. This is 
consistent with the theory that low level chronic inflammation, or “smouldering” 
inflammation, can promote tumour growth more than acute “polarised” inflammation 
which may be self-limiting (Balkwill et al. 2005). 
 
Endometrial adenocarcinoma at advanced stages has a poor prognosis (Fleming et al. 
2004). By reducing inflammation, it is possible that late-stage tumour growth or 
further metastases may be prevented. The use of specific COX-2 inhibitors in cancer 
trials has been halted since the discovery of cardiovascular side effects after repeated 
intake (Cha et al. 2007). Therefore there has been increased interest in inhibiting 
other targets in the COX-2-prostaglandin signalling pathway by targeting the 
prostaglandin receptors (Rocca 2006). Currently, it is thought that cancer treatment 
will necessitate targeting numerous pathways in the tumour, to treat all the hallmarks 
of cancer (Hanahan et al. 2000). Therefore, antagonists of the FP receptor may be a 
further target to reduce inflammation and consequent processes driving tumour 
progression in endometrial adenocarcinoma.  
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